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Abstract 
Metastatic breast cancer, or breast cancer which has spread from the primary 
tumour to distal secondary sites, remains a major killer of women today. Researchers 
have observed that the relationship between tumour cells and its surrounding 
environment plays an important role in cancer progression. One such interaction is 
between the Insulin-like growth factor (IGF) system and the integrin system, which 
has been demonstrated to be involved in cancer cell metabolic activity and migration. 
Therefore, the aim of this project was to translate this knowledge into the generation 
of bispecific antibody fragments (BsAb) targeting both systems, in order to disrupt 
their roles in cancer growth and metastasis. To screen for IGF-1R and αv integrin 
binding ScFv, a phage display enrichment procedure using the Tomlinson ScFv 
libraries was conducted. After the panning cycles, 192 clones were screened for 
binding using ELISA, of which 16 were selected for sequencing. Analysis of the 
results revealed 1 IGF-R and 3 αv integrin unique binding ScFv, which were all 
subsequently expressed in a bacterial expression system. The ScFv were purified to a 
high degree using Ni-NTA and protein-L agarose affinity chromatography and were 
further assessed using size exclusion chromatography to detect the presence of any 
ScFv aggregates. Functional characterisation studies using MCF-7 breast cancer cells 
indicated that the IGF-1R targeting ScFv was able to inhibit both IGF-I and VN 
dependent metabolic activity and migration. Cell-based assays were also used to 
characterise the anti-αv integrin ScFv, however, no inhibition of cell attachment or 
migration was observed. Investigation into possible reasons for the inability to inhibit 
cell processes revealed the original αv integrin sample used for panning may not have 
been fit for purpose. Thus, while the anti-IGF-1R ScFv shows potential, the lack of a 
functional anti-αv integrin ScFv made the generation of a bi-specific antibody 
fragment unachievable within this project. In light of these results, further 
characterisation should be conducted to assess the potential therapeutic treatment of 
breast cancer using the generated ScFv.  
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1.1 BREAST CANCER 
Breast cancer is a major burden globally, with the probability of 1 in 8 females 
developing the disease. Furthermore, breast cancer is the second most common cause 
of cancer related death in Australian women (Australian Institute of Health and 
Welfare, 2014). In 2012, close to a third of all new cancer cases in women were 
attributed to breast cancer (Siegel, Ma, Zou, & Jemal, 2014). Being a heterogeneous 
disease, breast cancer presents with variable clinical diagnosis and progression, and 
the selection of treatments proves very difficult (Bertucci, 2008). The Tumour, Node 
and Metastases (TNM) classification system is a 5 point scale which defines the 
progression of breast cancer, from the pre-invasive stage 0 to metastasised stage 4 
(National Cancer Institute, 2011). As the name suggests, the algorithm used to 
calculate the TNM score is based on the three parameters of tumour size, lymph node 
status and metastatic state (National Breast and Ovarian Cancer Centre, 2010). The 
tumour component, scored from 1-4, factors in the size and depth of the tumour. The 
node component incorporates the presence of cancerous cells found in sentinel and 
surrounding lymph nodes and is scored from 1-3 in severity. The metastases score is 
based on the detection of secondary tumours which have spread from the primary site. 
Upon dissemination from the primary tumour to secondary organs, predominantly 
bone and lung, the term metastatic breast cancer (MBC) is used (Minn et al., 2005; 
Solomayer, Diel, Meyberg, Gollan, & Bastert, 2000). Despite advances in treatments, 
translating into an average five-year survival rate of 99% and 84% for localised and 
regional breast cancer respectively, MBC remains incurable, with an average five year 
survival rate of 24% (Siegel, et al., 2014). Given the poor prognosis of MBC compared 
to localised breast cancer, therapies that disrupt the metastatic process would likely 
improve patient prognosis and survival. 
 
Traditional breast cancer treatments can be divided into four main categories: 
surgery, chemotherapy, radiation, and hormone therapies, combinations of which may 
be used depending on disease progression (National Cancer Institute, 2011). The 
limitations of current treatments include their invasive nature, undesirable side effects, 
prohibitive costs, and potential drug resistance. Surgery is a common treatment option 
in Australia with close to 32,000 breast cancer related surgical procedures performed 
in hospitals during 2006-2007 (Cancer Australia and Cancer Council Australia, 2010). 
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Two main surgical procedures are performed, depending on the stage of breast cancer. 
Breast-conserving surgery (lumpectomy) removes the tumour and surrounding 
margin, whereas the more invasive mastectomy aims to remove the whole breast and 
associated lymph nodes. For early stage breast cancer (where the tumour can be 
removed surgically in its entirety) no survival difference was found between breast 
conserving surgery followed by radiotherapy compared to full mastectomy (Early 
Breast Cancer Triallists’ Collaborative Group, 1995). The inherent invasiveness of 
surgery can cause physical and psychological stress, with 82% of patients reporting 
swelling, weakness and pain in their arms (Maunsell, Brisson, & Deschenes, 1993). In 
addition to surgical interventions, chemotherapy is often prescribed as an adjuvant to 
the primary surgical treatments. The two main classes of chemotherapy drugs most 
commonly administered are the taxanes and anthracyclines. The taxanes target the 
microtubule network, leading to the disruption of mitosis. Another class of 
chemotherapy drugs, anthracyclines disrupts DNA repair and replication (Bilardi, 
Kimura, Phillips, & Cutts, 2012). The use of cytotoxic drugs can have severe side 
effects, including hair loss, nausea, fatigue, and emotional stress (Love, Leventhal, 
Easterling, & Nerenz, 1989). In particular, the use of anthracyclines has been linked 
with an increased frequency of heart failures (Volkova & Russell, 2011). Due to the 
current limitations associated with breast cancer treatments, there is a driven effort by 
researchers to develop novel targeted approaches to breast cancer therapy. 
 
1.2 TARGETED CANCER THERAPIES 
Recently, targeted cancer therapies have been developed that preferentially 
target tumour cells based on specific molecules on the surface of, or within the cell. A 
wide range of molecules expressed in tumour cells can be targeted, including growth 
factor receptors, adhesion molecules, and signalling pathways associated with cell 
proliferation and differentiation (Munagala, Aqil, & Gupta, 2011). One of the best-
known drugs to combat breast cancer is Trastuzumab (Herceptin), a monoclonal 
antibody targeting Human Epidermal Growth Factor Receptor 2 (HER2). It was 
approved in 1998 and has been shown to be effective in treating HER2+ breast cancers 
(Vogel et al., 2002). The use of monoclonal antibodies dominates the 
biopharmaceutical industry, indeed, six of the top ten selling products in 2013 were 
antibody based, with Humira (adalimumab) generating global sales of $USD 11 billion 
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(Walsh, 2014). The monoclonal antibody targeting HER2 in the treatment of breast 
cancer, Herceptin (trastuzumab), was ranked 7th with total sales of $USD 6.91 billion. 
The current monoclonal antibodies approved by the Food and Drug Administration 
(FDA) for the treatment of cancer are listed in Table 1-1. Given that one of the 
indicators of cancer is growth dysregulation, it is not surprising that a large proportion 
of the approved antibodies bind to growth factor receptors and their cognate ligands 
such as epidermal growth factor receptor (EGFR), Vascular endothelial growth factor 
receptor 2 (VEGFR2) and human epidermal growth factor receptor (HER2) in order 
to inhibit the growth of cancer cells. Another growth factor system which is an 
omission from the approved therapeutic table is the Insulin-like growth factor (IGF), 
which has been linked to various malignancies, including breast cancer 
(Christopoulos, Msaouel, & Koutsilieris, 2015). 
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Table 1-1: Monoclonal Cancer therapeutic antibodies approved in the United 
States 
Trade name  International 
nonproprietary 
name  
Target; Format  Indication first 
approved or reviewed  
Approval 
year  
Tecentriq atezolizumab PD-L1; Human 
IgG1 
Bladder cancer 2016 
Portrazza Necitumumab  EGFR; Human 
IgG1  
Non-small cell lung 
cancer  
2015  
Empliciti Elotuzumab SLAMF7; 
Humanized IgG1 
Multiple myeloma 2015 
Darzalex Daratumumab CD38; Human 
IgG1 
Multiple myeloma 2015 
Unituxin  Dinutuximab  GD2; Chimeric 
IgG1  
Neuroblastoma  2015  
Opdivo  Nivolumab  PD1; Human IgG4  Melanoma, non-small cell 
lung cancer  
2014  
Blincyto  Blinatumomab  CD19, CD3; 
Murine bispecific 
tandem scFv   
Acute lymphoblastic 
leukemia  
2014  
Keytruda  Pembrolizumab  PD1; Humanized 
IgG4  
Melanoma  2014  
Cyramza  Ramucirumab  VEGFR2; Human 
IgG1  
Gastric cancer  2014  
Gazyva  Obinutuzumab  CD20; Humanized 
IgG1;  
Chronic lymphocytic 
leukemia  
2013  
Kadcyla  Adotrastuzumab 
emtansine  
HER2; humanized 
IgG1;  
Breast cancer  2013  
Perjeta  Pertuzumab  HER2; humanized 
IgG1  
Breast Cancer  2012  
Adcetris  Brentuximab 
vedotin  
CD30; Chimeric 
IgG1;  
Hodgkin lymphoma, 
systemic anaplastic large 
cell lymphoma  
2011  
Yervoy  Ipilimumab  CTLA-4; Human 
IgG1  
Metastatic melanoma  2011  
Arzerra  Ofatumumab  CD20; Human 
IgG1  
Chronic lymphocytic 
leukemia  
2009  
Vectibix  Panitumumab  EGFR; Human 
IgG2  
Colorectal cancer  2006  
Avastin  Bevacizumab  VEGF; Humanized 
IgG1  
Colorectal cancer  2004  
Erbitux  Cetuximab  EGFR; Chimeric 
IgG1  
Colorectal cancer  2004  
Bexxar  Tositumomab- 
I131  
CD20; Murine 
IgG2a  
Non-Hodgkin lymphoma  2003 
Zevalin  Ibritumomab 
tiuxetan  
CD20; Murine 
IgG1  
Non-Hodgkin lymphoma  2002  
MabCampath,  
Campath-1H;  
Lemtrada  
Alemtuzumab  CD52; Humanized 
IgG1  
Chronic myeloid 
leukemia; multiple 
sclerosis  
2001 
  
Mylotarg  Gemtuzumab 
ozogamicin  
CD33; Humanized 
IgG4  
Acute myeloid leukemia  2000 
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Herceptin  Trastuzumab  HER2; Humanized 
IgG1  
Breast cancer  1998  
MabThera, 
Rituxan  
Rituximab  CD20; Chimeric 
IgG1  
Non-Hodgkin lymphoma  1997  
Source: Modified from Janice M. Reichert, Reichert Biotechnology Consulting LLC 
(May 26, 2015) with information from FDA, New Molecular Entity and New 
Therapeutic Biological Product Approvals for 2015, 2016. Last accessed 3/10/16 
 
1.3 INSULIN-LIKE GROWTH FACTOR SYSTEM 
The insulin-like growth factor (IGF) system consists of ligands (IGF-I and IGF-
II), receptors (IGF-1R, IGF-2R) and IGF binding proteins (IGFBP 1-6) (Denley, 
Cosgrove, Booker, Wallace, & Forbes, 2005). Upon the binding of IGF-I, the tyrosine 
kinase receptor (IGF-1R) autophosphorylates at tyrosine residues 1131, 1135 and 
1136, resulting in the activation of two main signalling pathways (Riedemann & 
Macaulay, 2006). The first pathway is mediated by the recruitment and 
phosphorylation of insulin receptor substrate 1 (IRS-1), followed by activation of 
phosphoinositide 3-kinase (PI3K) and eventual AKT stimulation (Denduluri et al., 
2015). The activation of PI3K/AKT pathway confers a potent anti-apoptotic effect 
(Kennedy et al., 1997). The second signalling pathway resulting from IGF-1R 
stimulation is the Ras/Mitogen-activated protein kinases (MAPK) pathway, which 
through the actions of mediators such as Raf induces an increase in mitogenicity, 
motogenicity and anti-apoptotic effects in cells (Dhillon, Hagan, Rath, & Kolch, 
2007).  
 
Research has shown that the IGF system plays an intimate role in somatic and 
cancer cell survival, proliferation and migration/metastasis (Samani, Yakar, LeRoith, 
& Brodt, 2007). Studies have demonstrated that IGF-1R is over expressed in many 
different cancer tissues, including breast, gastrointestinal, stromal, multiple myeloma 
and cervical cancers (Chng, Gualberto, & Fonseca, 2005; Papa et al., 1993; Resnik, 
Reichart, Huey, Webster, & Seely, 1998; Steller, Delgado, Bartels, Woodworth, & 
Zou, 1996; Tarn et al., 2008). The alteration in the expression of IGF-1R can be 
explained by investigating genomic and molecular changes of IGF related genes in 
breast cancer samples. Analysis of The Cancer Genome Atlas (TCGA) dataset 
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(Ciriello et al., 2015) using cBioPortal (http://www.cbioportal.org/) was conducted on 
the IGF system’s related genes (IGF1R, IGF2R, IGF-I, IGF-II, IGFBP 1-6). The 
resulting genomic and expression data shown in Figure 1-1 revealed that 38% of 
TCGA breast cancer samples (n= 367/971) contained molecular alteration in at least 
one member of the IGF system. Of particular interest is IGF-1R, which was amplified, 
deleted, overexpressed and/or mutated in 9 % of tumours. The genomic alteration of 
IGF-1R related genes in breast cancer commonly result in IGF-1R overexpression. A 
study conducted on 930 primary breast cancer samples using tumour microarrays 
demonstrated that IGF-1R was overexpressed in 87% of all cases tested (Nielsen et al., 
2004). In a follow up study, it was demonstrated that phosphorylated IGF-1R/insulin 
receptor was detected in all breast cancer subtypes, including the difficult to treat triple 
negative breast cancers (Law et al., 2008).  
 
 
Figure 1-1: Genomic and transcriptomic alteration of IGF system genes in breast 
cancer samples 
Data from the 2015 TCGA dataset analysed using cBioPortal 
(http://www.cbioportal.org/) for disruption to IGF system related genes. Included for 
analysis are the genes encoding for Insulin-like growth factor ligands I and II (IGF-I, 
IGF-II), their cognate receptors (IGF1R, IGF2R) and Insulin-like growth factor 
binding proteins (IGFBP 1-6). Each row represents a different gene and the percentage 
of alteration among the tested samples. Each grey box represents an individual tumour 
sample. Genetic alteration includes amplification and deletion of the indicated gene 
(filled in red and blue boxes respectively), mRNA upregulation and downregulation 
(red and blue outline respectively) and somatic base pair mutation (green dot). 
Tumours without any alteration in the IGF related genes were removed for 
visualisation.  
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1.4 INTEGRINS 
Integrins are cell surface receptors which interact with the ECM and influence 
many cellular functions, including growth, migration and adhesion (Jin & Varner, 
2004). In humans, the integrin family consists of eighteen α subunits (α1-11, αIIb, αD, 
αE, αL, αM, αx, and αv) and eight β subunits (β1-β8) forming heterodimers consisting 
of one α and one β subunit. The αv subfamily, consisting of 5β binding partners (β1, 
β3, β5, β6, β8), is termed αv because of its ability to bind to the ECM protein 
vitronectin (VN) (Hynes, 2002). VN binding integrins, in particular αvβ3 and αvβ5, 
have been the major focus of investigations to determine the roles of αv-integrins in 
cancer biology. Table 1-2 outlines the expression of αvβ3 and αvβ5 in various types 
of cancer. In a similar manner to the IGF analysis, αv integrin related genes, encoding 
for the alpha chain (ITGAV) and beta chains (ITGB1, ITGB3, ITGB5, ITGB6, ITGB8) 
were submitted for analysis on the TCGA dataset using the cBioPortal. The resulting 
genomic and expression data shown in Figure 1-2 demonstrate that 28% of TCGA 
breast cancer (n= 271/971) contained molecular alteration in at least one member of 
the αv integrin family.  
 
Table 1-2: Expression of αvβ3 and αvβ5 in various cancers and cancer 
Adapted from (Desgrosellier & Cheresh, 2010; Meyer, Marshall, & Hart, 1998) 
Tumour Type Integrins expressed 
Melanoma αvβ3 
Breast αvβ3, αvβ5 
Prostate αvβ3 
Pancreatic αvβ3 
Ovarian αvβ3 
Cervical αvβ3,  
Glioblastoma αvβ3, αvβ5 
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Figure 1-2: Genomic and transcriptomic alteration of αv integrin genes in breast 
cancer samples 
Data are from the 2015 TCGA dataset and analysed using cBioPortal 
(http://www.cbioportal.org/) analysed for disruption to αv integrin related genes. 
Included for analysis are the genes encoding for the alpha chain (ITGAV) and five beta 
chains (ITGB1, ITGB3, ITGB5, ITGB6, ITGB8). Each row represents a different gene 
and the percentage of alteration among the tested samples. Each grey box represents 
an individual tumour sample. Genetic alteration includes amplification and deletion of 
the indicated gene (filled in red and blue boxes), mRNA upregulation (red outline), 
somatic base pair missense and truncating mutation (green and grey dot). Tumours 
without any alteration in the αv integrin genes were removed for visualisation. 
 
The expression of αvβ3 has been associated with an increased metastatic 
potential in breast, osteosarcoma and prostate cancers (Cooper, Chay, & Pienta, 2002; 
Duan et al., 2005; Zhao et al., 2007). In addition, both αvβ3 and αvβ5 interaction with 
the ECM has been found to be critical in tumour induced angiogenesis (Brooks, Clark, 
& Cheresh, 1994; Hodivala-Dilke, Reynolds, & Reynolds, 2003). Furthermore, αvβ3 
integrin has been detected on the leading edge of migrating tumour cells, supporting 
its role in cancer metastasis (Gladson & Cheresh, 1991). Moreover, it has been 
demonstrated in that study on primary breast tumours that αvβ5 expression was 
detected in nearly all the samples studied (97.6%) (Vogetseder et al., 2013). Given this 
association, the integrin system may provide a potential target for cancer therapies 
intended to disrupt not only tumour growth, but more specifically the detachment, 
migration and re-attachment metastasis process.  
 
1.5 IGF-1R AND αV INTEGRIN SIGNALLING PATHWAY 
INTERACTION 
While the IGF and αv integrin systems both show independent influences on 
cancer cell biology, studies have also demonstrated there are collaborative 
mechanisms between the two systems. IGF-I was demonstrated to bind directly to 
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αvβ3 integrin and have a direct influence on IGF-I signalling (Saegusa et al., 2009). 
The mechanism involved is still under investigation, however the current “ligand 
occupancy” modelling suggests that the binding of integrins such as αvβ3 to ECM 
proteins (vitronectin) serves to enhance IGF-1R signalling (Clemmons, 2007). In 
addition, research from our group has shown that there is cross talk between VN-
binding integrins and IGF-I activated signalling pathways (Hollier, Kricker, Van 
Lonkhuyzen, Leavesley, & Upton, 2008; Kashyap et al., 2011; Van Lonkhuyzen, 
Hollier, Shooter, Leavesley, & Upton, 2007). We have shown that the increase in 
cancer cell responses, including cell migration and survival, stimulated by VN+IGF-I 
complexes is associated with synergistic increases in intracellular signalling mediated 
via the co-activation of the IGF-1R and VN-binding αv integrins (Hollier, et al., 2008; 
Kashyap, et al., 2011; Van Lonkhuyzen, et al., 2007). In addition, monoclonal antibody 
treatments against αv integrins, IGF-1R and a combination of both have demonstrated 
that the stimulatory effect of the VN+IGF-I complex can be abrogated by inhibition of 
these receptors (Hollier, et al., 2008; Van Lonkhuyzen, et al., 2007). Furthermore, in 
cell migration studies, dual antibody inhibition of both αv integrins and IGF-1R 
produced a significantly greater decrease in migration of cancer cells as compared to 
individual antibody treatment (Hollier, et al., 2008). This is consistent with other 
studies which concluded that activation of both the IGF-1R and αv integrins is required 
for maximal cellular response (Doerr & Jones, 1996). The breast cancer cell line MCF-
7 used in previous studies within our group expresses both IGF-1R and αv integrin, 
making it an ideal cell model for the investigation of IGF and αv integrin interactions.  
 
1.6 IGF-1R AND VN BINDING INTEGRIN TARGETING STRATEGIES 
As discussed in previous sections, both the IGF and VN-binding integrin systems 
play critical roles in breast cancer cell survival and metastasis. The cumulative data 
identify these systems as potential targets for cancer therapies. A review of recent 
literature has revealed several strategies that may be used to target the IGF or αv 
integrin systems ligand binding along with downstream signal transduction pathways 
(Figure 1-3).  
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Figure 1-3: Various IGF-1R and αv targeting strategies.  
Disruption of the IGF and integrin systems can be achieved by different strategies. The 
neutralisation of the ligands using antibodies or modified receptors can reduce 
circulating ligands. The receptor itself can be targeted with antibodies, preventing the 
ligand from binding. Finally, the signalling pathway could be inhibited using small 
molecule inhibitors. Because of the association of IGF-I and VN to form a trimeric 
complex, inhibiting peptides could also target complex formation.  Adapted from: 
(Askari, Buckley, Mould, & Humphries, 2009; Belfiore & Malaguarnera, 2011) 
 
There has been sustained research on the role of IGF-1R in cancer growth and 
metastasis (Surmacz, 2000). Indeed, over 30 novel IGF-1R targeting therapies are 
currently under investigation, the majority of which are IGF-1R targeting antibodies 
(n=29, Appendix 1) with a small subset consisting of IGF-1R tyrosine kinase 
inhibitors (TKIs) (Crudden, Girnita, & Girnita, 2015). A search of current clinical trials 
revealed 30 trials involving IGF-1R alone, or in combination therapies in the United 
States (U.S National Institude of Health, 2016). Despite the intense research focus on 
generating therapeutics against IGF-1R, clinical trial results have been less promising. 
An example of this is cixutumumab (IMC-A12), a monoclonal antibody against IGF-
1R. Preclinical data with MCF-7 breast cancer cells showed that it was able to inhibit 
IGF-I dependent signalling and demonstrated significant inhibition of tumour growth 
in breast, renal and pancreatic tumours using xenograft models (Burtrum et al., 2003). 
Phase I clinical trial data from cixutumumab as a treatment showed the antibody was 
well tolerated, with no major adverse events (Ma et al., 2013; Wilky et al., 2015). 
When phase II trials were conducted, it was concluded that cixutumumab exhibited 
limited clinical efficacy in treating breast (Gradishar, Yardley, et al., 2015) and 
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prostate cancers (Hussain et al., 2015). Several potential factors may explain the 
limited success of IGF-1R inhibitors in a clinical setting. In the case of the stage 2 
clinical trial for Ganitumab targeting IGF-1R, patient’s tumour IGF-1R expression 
status was not assessed during enrolment (Robertson et al., 2013). This could limit 
Ganitumab efficacy in patients having tumours with low IGF-1R expression. An 
alternative explanation is that by inhibiting IGF-1R signalling, other pathways such as 
Epidermal growth factor receptor (EGFR) are activated to compensate, with studies 
demonstrating their linked roles in drug resistance (Jin & Esteva, 2008; Lee, Wang, 
James, Jeong, & You, 2015; Wang et al., 2013). Given the involvement of IGF-1R in 
different pathways, combination therapies targeting multiple systems are being 
investigated.  
 
Another approach to inhibiting the IGF system is by the use of tyrosine kinase 
inhibitors (TKI) which block the signal transduction cascade upon ligand binding. 
Examples of candidates in development are Linsitinib (OSI-906) (Mulvihill et al., 
2009), BMS-754807 (Carboni et al., 2009), BVP 51004 (Girnita et al., 2004) and 
XL228 (Smith et al., 2009). Linsitinib, the leading candidate, is an oral TKI with IGF-
1R and IR targeting functionality. In a similar result to antibody based candidates 
against IGF-1R, Linsitinib showed promise in preclinical studies, however, results 
from a phase III study revealed that Linsitinib did not improve overall survival 
(Fassnacht et al., 2015). The authors suggested that there needs to be improved genetic 
classification of patients for which IGF-1R or IR targeting therapeutics can derive 
benefit. In addition, potential as a combination treatment should be explored.  
 
Furthermore, an alternative approach to target the IGF signalling pathway is for 
the IGF ligands (IGF-I, IGF-II) to be sequestered using antibodies or modified 
receptors in order to reduce their bioavailability (D'Ambrosio, Ferber, Resnicoff, & 
Baserga, 1996; Gao et al., 2011a; Wang et al., 2015). The ‘ligand trap’ approach has 
managed to reduce circulating TNF-α using a TNF-α receptor-FC, and is currently 
available for use as Enbrel® (etanercept) for the treatment of rheumatoid arthritis. A 
promising candidate of an IGF ligand trap is MEDI-573, an antibody which can bind 
to both IGF-I and IGF-II. It has demonstrated anti-tumour activities in preclinical 
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trials, and was well tolerated in a phase I trial in patients with advanced solid tumours 
(Haluska et al., 2014).  
 
Therapies targeting VN-binding integrins have also been investigated, due to its 
importance in metastasis as outlined above. These include: αv integrin targeting 
peptides (Witt et al., 2009), antibodies (Trikha et al., 2004), and RGD inhibitors (Russo 
et al., 2013). Currently, 14 antibody based therapeutic candidates targeting αv integrin 
are in various stages of development (Appendix 2). A promising candidate is 
Intetumumab (formerly CNTO 95), a fully humanised monoclonal antibody which 
binds to αv integrins (Trikha, et al., 2004). It has been evaluated in combination with 
docetaxel in phase I clinical trials in patients with metastatic prostate cancer (Chu et 
al., 2011). The results demonstrated Intetumumab’s safety profile and that at 10 mg/Kg 
has the potential to be therapeutic. The phase II clinical trial involved comparing the 
progression-free survival (PFS) of a combination of Intetumumab, docetaxel and 
prednisone in metastatic prostate cancer (Heidenreich et al., 2013). Unexpectedly, the 
results of the clinical trial showed that Intetumumab was unable to improve PFS, 
possibly due to the limited sample size.  
 
As discussed previously, synergistic cross-talk can be observed between the 
IGF-1R and αv integrin systems. Although therapeutic candidates targeting these 
pathways individually have not been successful, targeting both IGF and integrin 
systems simultaneously may increase potency by limiting the potential of 
compensation. This dual pathway targeting approach has been investigated by the 
addition of α-IGF-1R or αv integrin inhibitory antibodies either alone or as a dual 
combination treatment on the breast cancer cell line MCF-7 (Hollier, et al., 2008). 
When stimulated with IGF-I and VN in migration studies, reductions in migration of 
22.2% (αv) and 61.6% (IGF-1R) were observed. Importantly, the dual treatment 
showed increased potency by inhibiting migration by 85.7% (αv±IGF-1R) compared 
to the uninhibited control. Another approach of targeting both IGF and integrin 
pathways is by using an agonistic peptide against the formation of the VN-IGFBP-
IGF-I complex, therefore inhibiting the co-activation of the pathways (Kashyap et al., 
2016). Clearly, a therapy with the ability to inhibit activation of both the IGF-1R and 
αv integrin may have the potential to arrest tumour growth and metastasis. A possible 
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approach for targeting two separate molecules is the generation of bispecific antibodies 
(BsAb), which will be the platform investigated within this study.  
1.7 ANTIBODY STRUCTURE AND FRAGMENTATION 
Antibodies are glycoproteins which elicit various functions as part of the 
adaptive and innate immune system. There are five classes of antibody: IgA, IgD, IgE, 
IgG and IgM. Each class differs in structure, molecular weight, avidity, and 
localisation. The most abundant antibody subclass in serum, IgG, makes up ~85% of 
total serum antibodies (Manz, Hauser, Hiepe, & Radbruch, 2005). In addition to being 
abundant, IgG is also the most stable, with a serum half-life of 20 days, compared to 
5-8 days for IgM and IgA (Brekke & Sandlie, 2003), 2.8 days for IgD (Rogentine Jr, 
Rowe, Bradley, Waldmann, & Fahey, 1966) and 2 days for IgE (Stone, Prussin, & 
Metcalfe, 2010). Given its stability and relative abundance, IgG is the principal 
antibody class used for therapeutic and diagnostic purposes.  
 
IgG is made up of two heavy and two light polypeptide chains joined by 
disulphide bonds in the classical ‘Y’ arrangement. An IgG molecule can be further 
divided into the crystallisable fragment (Fc) and the antigen biding fragment (Fab) 
(Figure 1-4). The Fab contains the variable light (VL) and variable heavy (VH) 
domains, which determines antigen binding specificity. Because of the modular nature 
of IgG, it can be fragmented using reducing agents, enzymatic cleavage (using 
papain/pepsin) or recombinant production, with the resulting products retaining the 
VH and VL domains giving equal specificity as their full length parental antibody 
(Vlasak & Ionescu, 2011). 
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Figure 1-4: Examples of intact IgG and its fragments.  
Full length IgG molecules can be fragmented into Fab by enzymatic means (papain) 
or can be recombinantly generated by linking the VH and VL domains with a 
polypeptide linker to form a ScFv. The crystal structure representation of IgG (1IGT), 
Fab (4M43) and ScFv (1P4I) were obtained from the protein data bank 
(http://www.rcsb.org) and visualised using VMD 1.9.2.  
 
1.8 BISPECIFIC ANTIBODIES 
A novel means to increase the functionality of conventional monospecific 
antibodies is to develop bispecific antibodies, also known as dual targeting antibodies. 
Bispecific antibodies are designed to have dual modes of action which can include: 1) 
Neutralising two ligands, 2) Inhibiting two receptors, 3) Cross-linking of two 
receptors, or 4) the recruitment of cytotoxic immune cells (Kontermann, 2011). They 
were initially generated by chemically cross-linking two different targeting antibody 
fragments. In this approach, Fab’ fragments were generated from the enzymatic 
cleavage of the two parental IgG, and subsequently reduced to produce reactive SH 
groups. The SH groups of one Fab were alkylated yielding free maleimide groups. The 
two halves were combined which allowed the maleimide and SH groups to react, 
therefore facilitating the formation of a thioester-linked bispecific Fab (Glennie, 
McBride, Worth, & Stevenson, 1987). An alternative method of producing BsAb was 
to fuse two different antibody producing hybridoma to form a hybrid 
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hybridoma/quadroma, which would secrete various combinations of mono and 
bispecific species (Milstein & Cuello, 1983). Both methods have disadvantages 
including being labour intensive, low yield, high cost and producing heterogeneous 
BsAb species (Staerz & Bevan, 1986). Given the limitations, both techniques were 
mainly used as a research tool. With the refinement of molecular cloning and 
recombinant techniques, the interest in BsAb was reignited. Sequences encoding for 
Ab’s could be isolated and specifically manipulated to form novel BsAb structures 
relatively easily, at high yield, low cost and with inherent high specificity.  
 
There has been a growing interest in bispecific antibodies (BsAb) since this 
technology was first reported as a pharmacological strategy in the 1980s with the 
market totalling >$3.5 billion for the period 2009-2011 (Baeuerle, 2011; Frincke et al., 
1986). As of 2015, the number of bispecific antibodies in clinical trials stands at 14, 
with the majority of them in phase 1 and 2 (Sheridan, 2015). The first bispecific 
antibody to obtain market approval by the European Medicines Agency (EMA) was 
Removab (catumaxomab) in 2009. It binds to epithelial cell adhesion molecule 
(EpCAM)-expressing carcinoma cells, CD3 on T cells, and also to the accessory cells 
(macrophages, dendritic cells and natural killer cells) via the Fc receptor (Walsh, 
2010). As a result, the T-cells activate apoptotic and lytic pathways while the accessory 
cells act via the antibody-dependent cell-mediated cytotoxicity (ADCC) phagocytosis 
pathway to clear cancer cells (Seimetz, 2011).  
 
Recombinant BsAbs can be engineered into multiple formats, with more than 45 
different frameworks in development that can be classified into groups based on their 
key features (Kontermann, 2012). ScFv based BsAbs consist only of the variable 
fragment (Fv) of an antibody, the smallest unit of antigen recognition, for each target. 
As such, they are compact and capable of being expressed in both bacterial and 
eukaryotic expression systems (Pleass & Holder, 2005). The simplest form of ScFv 
based BsAb is the tandem single chain format, which is arranged as VH1-VL1-VH2-VL2 
and is linked by a polypeptide linker such as (Gly4Ser)n (Figure 1-5). This format was 
chosen for this project. However, while small antibodies such as the ScFv based format 
are compact (~60 kDa) and allow for deep tissue penetration, they have a much shorter 
serum half-life than the larger IgG based antibodies (150 kDa) (Kipriyanov et al., 
 Chapter 1: Literature Review 17 
1999). Due to its simplicity, the ScFv format has been used widely, including the 
creation of the promising Bi-specific T-Cell Engager (BiTE) format® as a potential 
cancer therapeutic (Nagorsen et al., 2009). A BiTE® antibody consists of two different 
targeting ScFv linked by a polypeptide linker. One ScFv would target the tumour 
specific antigen, and the other binds to a T cell specific receptor (T cell:ScFv-
ScFv:tumour cell). The mechanism of BiTE® acts firstly to recruit cytotoxic T cells 
to tumour cells, and upon close physical contact, activates the T cells for the lysis of 
the targeted cell. The first BiTE® antibody Blincyto® (Blinatumomab) was generated 
by isolating the VH and VL domains of α-CD3 and α-CD19 IgG and engineered as a 
single chain BsAb linked by a Gly4Ser linker sequence. Given the success of the phase 
II clinical trial, in which 43% (n= 81/189) of the treated patients with acute 
lymphoblastic leukaemia achieved complete remission (CR) or partial haematological 
recovery of peripheral blood counts (CRh), it was placed in the accelerated approval 
program and was the first FDA approved BsAb on the market in 2014 (Table 1-1) 
(Topp et al., 2015). Other tumour antigen markers are also being investigated for use 
in the BiTE® format, including Epithelial cell adhesion molecule (EpCAM) for use in 
pancreatic cancer and prostate-specific membrane antigen (PSMA) as a potential 
prostate cancer therapeutic (Cioffi, Dorado, Baeuerle, & Heeschen, 2012; Friedrich et 
al., 2012). These studies demonstrate the function of the BsAb arrangement in both in 
vitro and in vivo, thus such a format will be utilised in the current study.  
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Figure 1-5: Selected classes of bispecific antibodies and examples of their unique 
configurations. 
Orange and yellow VH and VL domains indicate different antigen specificity. 
Wildtype IgG molecule is made up of 2 identical heavy chains and 2 identical light 
chains. The heavy chain consists of one variable (VH) and three constant (CH1-CH3) 
domains. The light chain contains the VL and CL domains. The VH and VL domains 
determine antigen specificity and can be engineered to form fusion molecules via 
linkers. In the case of ScFv based bispecific antibodies, this linker is often based on a 
GlySer motif. Adapted from (Baeuerle, 2011) 
 
1.9 ANTIBODY GENERATION 
Antibodies against a particular target can be generated in a number of ways. 
Historically, it was by challenging an animal’s immune system with a purified antigen 
or hapten. Upon detection by the immune system, it would prompt the generation of a 
humoral response in which the secretion of antibodies is a component. Because 
different epitopes can be present in an antigen, the resulting antibody is polyclonal. 
The antibodies created can be isolated and purified from the host’s blood. Therefore, 
the choice of animal host is dependent on the total amount of antibody required. For 
small animals such as mouse and rat, their total blood volume is low; 2.5 mL and 30 
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mL respectively. If higher yield is required, a larger animal such as a goat (3000 mL) 
or sheep (4000 mL) can be used (Hanly, Artwohl, & Bennett, 1995).  
 
The development of the mouse hybridoma technology by Kohler and Milstein in 
1975 allowed for the continuous production of monoclonal antibodies, and to a large 
extent making the need to constantly harvest blood from an immunised animal 
redundant (Kohler & Milstein, 1975). This was achieved by isolating antibody 
producing B cells from a host such as a mouse, and fusing it with a cancerous myeloma 
cell. The resulting immortalised hybridoma can be implanted back into the mouse to 
form an antibody producing tumour or can be cultured for in vitro production. 
However, this approached for the generation of a human therapeutic was unsuccessful 
because the mouse antibody generated an adverse immune response in humans, termed 
human anti-mouse antibody (HAMA) (Tjandra, Ramadi, & McKenzie, 1990). 
Subsequently, techniques have been developed to ‘humanise’ murine antibodies in 
order to reduce immunogenicity (Kettleborough, Saldanha, Heath, Morrison, & 
Bendig, 1991; Roguska et al., 1994).  
 
The use of animals for scientific purposes requires careful ethical considerations 
for the welfare of the animals involved. The National Health and Medical Research 
Council (NHMRC) has set guidelines for the use of animals in monoclonal antibody 
production (National Health and Medical Research Council, 2008). It recommends that 
the use of mice will continue to be required, however, improved techniques which can 
minimise animal harm should be employed. Thus, there is an ever increasing 
stringency with respect to methods involving animals and it is foreseeable that such 
techniques will be phased out in time. Consequently, antibody production systems not 
requiring animals are of significant interest. One such method which by-passes the use 
of animals and also allows for the screening of fully human antibodies is phage display. 
 
1.10 PHAGE DISPLAY 
Phage display was first described by Smith in 1985 as a method to display exogenous 
protein fused to coat proteins of bacteriophage (Smith, 1985). It is a powerful 
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technique that has been used in many protein interaction studies, including: antibody 
epitope mapping (He et al., 2012), monoclonal antibody generation (Chu, et al., 2011), 
protein-DNA interactions (Choo & Klug, 1994) and molecule specific diagnostic 
applications (Deutscher, 2010). Phage display is the oldest and the most applied 
technique in the field of molecular display, with competing platforms such as bacterial 
and yeast, ribosome and mRNA display (Levin & Weiss, 2005). The key feature of 
phage display is the direct linkage between phenotype (function) of the displayed 
protein, and the genotype. This relationship allows for the screening of libraries 
encoding for millions of different protein variants and selection based on affinity 
interactions. One important application of this technology is the ability to screen 
human antibody encoding libraries against therapeutic targets. A selection of the 
antibody encoding libraries for phage display is shown in (Table 1-3). Phage display 
libraries can be broadly divided into 3 categories, depending on the source of the 
antibody encoding sequences and method of generating diversity: 1) Naïve libraries 
are produced by harvesting B-cells from human donors, isolating the mRNA and 
subsequent reverse transcription into cDNA. The variable domain genes are amplified 
using PCR and cloned into a suitable phage display vector such as pIT2 or pHEN. The 
resulting library’s diversity is a result of naturally reorganised immunoglobin encoding 
genes from the human donor/s (Pansri, Jaruseranee, Rangnoi, Kristensen, & 
Yamabhai, 2009a; Sheets et al., 1998). 2) To further increase a library diversity, the 
amplified variable domain genes from donors be mutated to form a semi-synthetic 
library (de Wildt, Mundy, Gorick, & Tomlinson, 2000) and 3) Fully synthetic libraries 
are diversified by rational design using artificially generated sequences (Knappik et 
al., 2000; Prassler et al., 2011; Rothe et al., 2008). An example of a phage display 
library which has been well characterised in the literature are the Tomlinson libraries 
(I+J), which has been used in many diverse applications, such as for generation of 
ScFv for diagnostics and imaging (de la Cruz et al., 2013; Kim, Wang, Wahlberg, & 
Edwards, 2014; Xu, Liu, Brown, Christian, & Hornby, 2012), and a screen for potential 
therapeutic candidates (Patil et al., 2015; ten Haaf et al., 2015). As a consequence of 
its popular usage, the libraries were readily obtainable to researchers. Taken together, 
the Tomlinson libraries was chosen for this project. The antibody libraries are encoded 
by phagemid vectors which are propagated within E. coli hosts. To produce functional 
phage molecules displaying the antibody fragment from antibody libraries, additional 
genetic information is required. Infecting the phage library containing E. coli with a 
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helper phage such as KM13 provides the necessary components for packaging the 
phagemid DNA into phage particles (Kristensen & Winter, 1998).  
 
Table 1-3: Select antibody encoding libraries for phage display 
All libraries encode for the Fab or ScFv format. The size of a library indicates the 
total number of unique antibody sequences contained within the library. 
Name of library Format Size of library Reference 
Dyax library Fab 3.5 × 1010 (Hoet et al., 2005) 
HuCAL® ScFv 2.0 × 109 (Knappik, et al., 2000) 
HuCAL Gold® Fab 1.0 × 1010 (Rothe, et al., 2008) 
HuCAL® PLATINUM® Fab 4.5 × 1010 (Prassler, et al., 2011) 
MedImmune  ScFv 1.4 × 1010 (Vaughan et al., 1996) 
Tomlinson I + J ScFv 2.8 × 108 (de Wildt, et al., 2000) 
 
1.10.1 KM13 phage physiology and structure 
KM13 is an E. coli specific filamentous bacteriophage that is ~1 μm in length and ~6 
nm in diameter (Marvin, Hale, Nave, & Citterich, 1994). Unlike other bacteriophage 
such as lamda or T4, M13 is non-lytic in its life cycle. This is important in a phage 
display context as it simplifies phage recovery and purification by reducing 
contaminating bacterial proteins. Phage particles are composed of supercoiled single 
stranded DNA (ssDNA) surrounded by 2700 copies of the major coat protein (pVIII), 
and 5 copies each of the minor coat proteins (pIII, pVI, pVII, pIX) (Figure 1-6). All 5 
coat proteins have been used in phage display systems, with fusion to pIII being the 
most common (Sidhu, 2001).  
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Figure 1-6: Schematic of a KM13 phage particle 
M13 phage particles contain a ssDNA core surround by the major coat protein pVIII 
and minor coat proteins pIII, pVI, pVII, pIX. The pIII protein is essential for infection 
and contains three domains, N1, N2, and CT.  
 
1.10.2 Phage display selection 
Antibody fragments displayed on the surface of phage can be used to screen 
against immobilised targets. The antibody phage display enrichment procedure can be 
summarised as follows (Rouet et al., 2012): 
 
1. Phage generation. The first stage involves the generation of phage particles 
displaying the ScFv encoded by the phagemid vector housed and propagated in E. 
coli. The phagemid contained both the ScFv fused to pIII in addition to phage 
origin of replication. In order to produce phage displaying ScFv, additional genetic 
materials for phage packaging is provided upon infection with a helper phage. 
There are many different helper phage strains, in this case, the Tomlinson library 
system utilises the protease sensitive KM13 helper phage (Chasteen, Ayriss, 
Pavlik, & Bradbury, 2006; Kristensen & Winter, 1998).  
 
2. Immobilisation of target. In order to select displayed phage, the target of interest 
is immobilised onto a solid substrate. This step can be facilitated by passive 
adsorption of the target molecule onto polystyrene materials with different 
chemistries. For example, Thermo Fisher offers a variety of surfaces to provide 
optimal binding of the target (Esser, 2010). PolySorp® surface treatment has a 
high affinity to molecules of hydrophobic nature. Whereas MultiSorp™ surface 
pVIII 
pIII pVI pIX
pVII 
ssDNA CTN2 N1 
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treatment binds more efficiently to hydrophilic molecules. MaxiSorp™ surfaces 
enable immobilisation with high affinity for molecules with mixed 
hydrophilic/hydrophobic domains. In addition to passive absorption, the target can 
also be immobilised onto solid support by affinity systems. One example is by 
firstly biotinylating the target, followed by immobilisation onto streptavidin 
conjugated magnetics beads and using this as the matrix through which the phage 
preparation will be selected (Chames & Baty, 2010).  
 
3. Enrichment of binders. The selection and enrichment of binders requires the 
completion of step 1 and 2, that is, the generation of phage displaying the antibody 
fragment library, and the immobilisation of the target onto a solid substrate. To 
enrich for positive binders, the solid substrate containing the target is firstly 
incubated commonly with skim milk or BSA blocking agent to reduce non-specific 
binding. The phage is allowed to mix with the target and a wash step is performed 
to remove any non-binders. The population of binders will be low at the end of the 
first panning round, but will increase once the positive binders are allowed to re-
amplify by firstly infecting E. coli and additional incubation and wash steps.  
 
1.11 CONCLUSION AND KNOWLEDGE GAPS 
Breast cancer currently contributes close to a third of all new cancer cases in 
women (Siegel, et al., 2014). The treatment of metastatic breast cancer, or cancers 
which have spread to secondary sites, are limited in success, translating into a low five-
year survival rate (Siegel, et al., 2014). In addition, traditional cancer treatment such 
as surgery and chemotherapy can have severe side effects. This prompted researchers 
to investigate targeted approaches in treating tumour cells. Two systems have been 
identified as potential therapeutic targets. The IGF system plays an important role in 
normal cellular growth processes and has links to various cancers, where the growth 
checkpoints are dysregulated (Samani, et al., 2007). It has been demonstrated that IGF-
1R is overexpressed in breast cancer tissues and inhibiting the IGF system by blocking 
ligand binding decreased cancer cell growth (Farabaugh, Boone, & Lee, 2015; Gao et 
al., 2011b). The integrin system mediates various functions, including angiogenesis, 
migration, attachment and survival of cells (Avraamides, Garmy-Susini, & Varner, 
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2008; Kim, Turnbull, & Guimond, 2011). Like the IGF system, integrins have been 
linked to cancer progression, in particular metastatic dissemination (Desgrosellier & 
Cheresh, 2010). Our own research has shown synergism between the systems, and 
their additive effect on cell migration and proliferation upon co-simulation (Hollier, et 
al., 2008; Van Lonkhuyzen, et al., 2007). Despite demonstrating functional success in 
preclinical studies using a singular antibody targeting IGF-1R or αv integrin, results 
from clinical trials were less promising, potentially due to signalling pathway 
compensation. Given the roles of both the IGF and integrin systems in cancer 
progression, an agent which can inhibit both pathways has the potential to be a potent 
cancer therapeutic. To achieve this goal, the current project will attempt to generate 
independent function blocking ScFv toward IGF-1R and αv integrin, with the ultimate 
aim of combining them into a BsAb based on the tandem ScFv format with the 
potential to inhibit key cancer progression mechanisms.  
 
1.12 PROJECT OUTLINE 
1.12.1 Hypothesis 
The hypotheses explored in this PhD studies were: 
1) By using phage display technologies, ScFv which can bind to IGF-1R 
and αv integrin will be selected and recombinantly expressed.  
2) The generated ScFv will inhibit the migration and survival of breast 
cancer cells upon stimulation by IGF-I and VN; and 
3) The BsAb constructed from IGF-1R and αv integrin targeting ScFv 
would retain the functional activities of the parental ScFv. 
 
1.12.2 Aims 
To address the above mentioned hypothesese, the following aims were pursued: 
  
1) Selection of IGF-1R and αv integrin function blocking single chain 
variable fragments (ScFv). 
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2) Functional characterisation of the generated anti-IGF-1R and anti-αv 
integrin ScFv in cell based assays (Hollier, et al., 2008; Van Lonkhuyzen, 
et al., 2007). 
3) Selection of functional ScFv and recombinant bispecific antigen binding 
antibody based protein/s towards IGF-1R and αv integrin. 
4) Functional characterisation of the generated BsAb in cell based assays as 
per aim 2.  
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2.1 INTRODUCTION 
The materials and methods in the following results chapters are outlined within. 
Any deviations are stated in the respective chapters as required. 
 
2.2 MATERIALS 
All mammalian cell culture materials, including Dulbecco’s Modified Eagle 
Medium/F12 (DMEM/F12), penicillin-streptomycin, gentamicin, TrypLE™ Express, 
0.4% trypan Blue and Fetal bovine serum (FBS) were all purchased from Thermo 
Fisher Scientific/Life Technologies (Scoresby, Australia). The NuPage SDS-PAGE 
system, consisting of pre-casted 4-12% Bis-Tris Protein Gels, MES SDS running 
buffer, LDS sample buffer, and reducing agent were sourced from Thermo Fisher 
Scientific/Life Technologies (Scoresby, Australia). All oligonucleotides used in both 
PCRs and sequencing reactions were synthesised by Sigma-Aldrich (St Louis, US). 
OneTaq® Hot Start Quick-Load® 2X Master Mix and Q5® Hot Start High-Fidelity 
2X Master Mix were sourced from New England Biolabs (Massachusetts, US). 
Monoclonal antibody for phospho-IGF-1R β (Tyr1135/1136), IGF-1R, GAPDH 
(14C10) and Integrin αv were all sourced from Cell Signalling (Danvers, US). All 
primers were synthesised from Sigma-Aldrich. The naïve human ScFv libraries ‘I’ and 
‘J’ (Tomlinson I+J), KM13 helper phage, Escherichia coli (E. coli) TG1 and HB2151 
were purchased from Source Bioscience (Cambridge, UK). Immuno MaxiSorp® 5 mL 
tubes (cat: NUN444202) and MaxiSorp® 96 well plates (NUN442404) for phage 
panning were sourced from Thermo Fisher. All general reagents are of the highest 
quality and were purchased from Sigma-Aldrich unless otherwise stated. 
 
2.3 CLONING 
2.3.1 General PCR 
Reaction setup 
One Taq reaction setup for the routine non proof read applications, such as 
mycoplasma testing is given in Table 2-1.  
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Table 2-1: PCR reaction setup for One Taq master mix 
Reagent 20 μL Reaction (μL) Final 
concentration 
One Taq Master mix (2x) 10 1x 
DNA sample 1  
F primer (10 μM) 1 0.2 μM 
R primer (10 μM) 1 0.2 μM 
Water 7  
Total 20  
 
Setup for Q5 reactions used in high fidelity applications is given in Table 2-2.  
 
Table 2-2: PCR reaction setup for Q5 master mix 
  25 μl 
Reaction 
Final 
concentration 
Q5 Hot Start High-Fidelity 2X Master Mix 12.5 μL 1X 
10 μM Forward Primer 1.25 μL 0.5 μM 
10 μM Reverse Primer 1.25 μL 0.5 μM 
Template DNA (1-25 ng/ μL) 1 μL 1-25 ng 
Nuclease-free water 9.0 μL   
 
Annealing temperature calculations 
Primer annealing temperatures were calculated per primer set and for each 
polymerase using the NEB Tm calculator at http://tmcalculator.neb.com/ 
 
2.3.2 Mini-prep plasmid isolation 
Plasmids were isolated from E. coli clones which housed the pIT2 based vector 
using the QIAprep miniprep spin column kit (Qiagen) according to manufacturer’s 
high yield protocol. All the required buffers are supplied with the kit and all isolation 
procedures were conducted at room temperature. Briefly, 5 mL of 2YT medium (16 g 
bacto-tryptone, 10 g of yeast extract and 5 g of NaCl per litre) was inoculated overnight 
from either a single colony on an agarose plate or from a frozen glycerol stock. The 
culture was maintained with shaking at 200 RPM at 37 °C overnight. The cells were 
then pelleted by centrifugation at 3,200 g for 5 mins and the supernatant discarded. 
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The pelleted cells were resuspended in 250 μL of P1 buffer and transferred to a 1.5 
mL microcentrifuge tube. Cells were lysed by the addition of 250 μL of P2 into the 
microcentrifuge tube, after which the reaction was neutralised by the addition of 250 
μL of N3. The reaction was centrifuged at 18,000 g to remove chromosomal DNA 
contaminants. The supernatant was transferred into a spin column and centrifuged for 
1 min, at which point the flowthrough was discarded. The spin column was further 
washed with 500 μL of buffer PB, and 750 μL of buffer PE. The plasmid DNA were 
eluted from the spin column using ultrapure water and stored at 4 °C. The yield and 
quality of the isolated plasmid was assessed using spectrophotometry (Nanodrop ND-
1000).  
 
2.3.3 Sanger sequencing of plasmids 
Plasmids were submitted to the Australian Genome Research Facility (AGRF) 
for Sanger sequencing using the purified DNA (PD) service. Samples were submitted 
based on recommendations from AGRF. The sequencing primers used to sequence 
clones based on the pIT2 vector are listed in Table 2-3. 
 
Table 2-3: Sanger sequencing primers for the pIT2 vector 
 
 Primer name Sequence (5’ to 3’) Binding site 
Forward LMB3 CAG GAA ACA GCT ATG AC Upstream of 
RBS 
Reverse pHEN CTA TGC GGC CCC ATT CA Downstream 
of myc-tag 
 
In short, each sequencing reaction submitted consists of 600-1500 ng of plasmid, 
6.9 pmol of sequencing primer, and ultra-pure water to a final volume of 12 μL. The 
resulting sequencing chromatograms were organised, analysed and annotated using 
CLC Main Workbench version 7.6. From the DNA sequence, the protein sequence 
was translated using the standard translation tables as provided in the software. 
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2.4 MAMMALIAN CELL CULTURE 
2.4.1 Propagation of MCF-7 cell lines 
The human breast adenocarcinoma cell line MCF-7 (HTB-22) was cultured in 
growth medium (GM) consisting of Dulbecco’s Modified Eagle Medium/F12 
(DMEM/F12) supplemented with 10% fetal bovine serum (FBS), 0.1 mg/mL 
streptomycin, 50 units/mL penicillin and 1 μg/mL gentamicin. All cell lines were 
maintained in a humidified incubator at 37 °C with 95% air and 5% CO2. Media was 
changed every 3-4 days or upon 80% confluence, at which point cells were passaged 
at a ratio of 1:3. Cells were detached from the tissue culture flasks using TrypLE™ 
Express, a trypsin replacement dissociation agent. All functional assays were 
performed using serum free media (SFM), with the same supplements as the GM 
minus the FBS. The identities of the breast cancer cell line have been validated using 
short tandem repeat profiling (CellBank Australia, Sydney, NSW, Australia). 
 
2.4.2 Cell counting 
Cells were manually counted using a hemocytometer and the trypan blue 
exclusion method. Aliquots of the harvested cell suspension were added to 0.4% trypan 
blue solution 5 fold. The stained cells were loaded into the hemocytometer chamber 
and counted using a phase contrast microscope at a total magnification of 400x. The 
cell concentration was determined from the average of one square using the formula: 
 
     
  
=        	    	     	   	      	 ×         	       10  
 
2.4.3 Cryopreservation of cell lines 
Cells to be frozen were detached from cell culture flasks using TrypLE™ 
Express. The excess TrypLE™ was inactivated by the addition of GM and a cell count 
performed as per 2.4.2. The cell suspension was pelleted by centrifugation at 1000 
RPM on a Hettich Universal 320 and resuspended to 2x106 viable cells/mL/Cryovial 
using ice-cold freezing medium consisting of Growth Media with 5% (v/v) DMSO. 
The cryovials were cooled at a rate of -1 °C per minute to -80 °C in a freezer container 
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filled with isopropanol and subsequently transferred to liquid nitrogen for long term 
storage. 
 
2.4.4 Mycoplasma Testing 
Cell lines were tested for mycoplasma infection using nested polymerase chain 
reaction (Nested PCR) before freezing down of cells for stock. The PCR reaction was 
carried out using two sets of primers as listed in Table 2-4: 
 
Table 2-4: Nested PCR primers for Mycoplasma detection. Primers are listed 
from 5’ to 3’ direction. 
 Forward 5’ to 3’ Reverse 5’ to 3’ 
Mycoplasma PCR 1 ACACCATGGGAGCTGG
TAAT 
CTTCATCGACTTTCAGA
CCCA 
Mycoplasma PCR 2 GTTCTTTGAAAACTGA
AT 
GCATCCACGAAAAACT
CT 
 
 Two independent reactions with the amplicon from the first reaction used as the 
template for the second. The cycling conditions are listed below in Table 2-5. 
 
Table 2-5: Mycoplasma PCR cycling conditions 
STEP TEMP TIME 
Initial Denaturation 94 °C 300 seconds 
35 Cycles 94 °C 30 sec 
55 °C 60 sec 
72 °C 60 sec 
Hold 4-10 °C ∞ 
 
The resulting products were separated on a 1.5 % agarose gel run at 120 V. The 
banding patterns of the samples were compared to the Mycoplasma positive samples 
to assess infection status.  
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2.5 PROTEIN ISOLATION FROM ADHERENT CELL CULTURES 
2.5.1 Denaturing conditions 
Adherent MCF-7 cells were grown until 80% confluent in growth medium (GM) 
consisting of Dulbecco’s Modified Eagle Medium/F12 (DMEM/F12) supplemented 
with 10% fetal bovine serum (FBS), 0.1 mg/mL streptomycin, 50 units/mL penicillin 
and 1 μg/mL gentamicin. The cultures were maintained in a humidified incubator with 
5% CO2 and 95% atmospheric air at 37 °C. Prior to assays, the cells were serum starved 
for 4 hours by firstly removing the old media, washing once with PBS, then adding 
serum free DMEM/F12 (SFM) with 0.1 mg/mL streptomycin, 50 units/mL penicillin 
and 1 μg/mL gentamicin. The media was aspirated and washed twice with ice-cold 
PBS. Cell lysis was achieved by adding 0.4 mL of complete lysis buffer containing 
Radioimmunoprecipitation assay (RIPA) buffer, 20 mM Tris-HCl (pH 7.5), 150 mM 
NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM 
sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na3VO4, 1 µg/mL leupeptin, 
(Cell signalling) with the addition of Complete protease inhibitor (Roche) and 
phosphatase inhibitor (Thermo-Fisher Scientific). After 5 mins incubation with the 
lysis buffer, the cell lysates were harvested using a cell scraper and transferred into a 
pre-chilled centrifuge tube. The samples were then placed in a sonication water bath 
(Soniclean 120 TD) for 4 mins and were subsequently centrifuged for 15 mins at 
14,000 g to remove insoluble proteins. The supernatant was reserved and frozen at -80 
°C. The protein concentration was estimated using the BCA assay using the Pierce™ 
BCA protein assay kit according to the manufacturer’s instructions.  
 
2.5.2 Non-denaturing conditions 
To maintain the native conformation of cellular proteins, a non-denaturing lysis 
buffer was also used. After the 4 hour serum starve incubation, SFM was aspirated and 
2 mL of non-denaturing lysis buffer, consisting of 50 mM Tris (pH 7.4), 100 mM 
NaCl, 1% Triton X-100 and complete protease inhibitor (Roche), was added to each 
of the T-175 flasks. The cell lysates were harvested from the cell culture flasks using 
cell scrapers and transferred into pre-chilled low protein binding microfuge tubes. To 
assist with cell lysis, the samples were immersed in a sonication water bath at 4 °C for 
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5 mins. The samples were then centrifuged at 14,000 g for 20 mins and the supernatant 
was retained and stored at -80 °C for protein quantification and purification.  
 
2.6 PROTEIN QUANTIFICATION 
Protein concentration was estimated using the Bicinchoninic Acid (BCA) 
protein assay kit (Pierce) as per the manufacturer's instruction. BSA standards were 
diluted in either PBS or lysis buffer depending on the protein sample to form a range 
of concentrations from 2000 µg/mL to 125 μg/mL used as the protein concentration 
reference. The BCA reaction plate was read at 562 nm using the benchmark plus 
microplate spectrophotometer system. The resulting standards and unknown 
absorbance data were corrected for dilution factors and curve fitted using a quadratic 
formula using the Microplate Manager Software version 6.2 (Biorad) 
 
2.7 PROTEIN DETECTION 
2.7.1 SDS-PAGE and Chemiluminescence Western 
Protein samples were mixed with NuPage® LDS sample buffer and reducing 
agent to a final concentration of 141 mM Tris base, 2% LDS, 10% Glycerol, 0.51 mM 
EDTA, 0.22 mM SERVA Blue G, 0.175 mM Phenol Red, 50 mM DTT, pH 8.5 and 
heated at 70 °C for 10 mins. The protein samples were separated based on molecular 
weight on a precast NuPage® 4-12% SDS-PAGE with NuPage® MES-SDS running 
buffer. The electrophoresis proceeded at a constant 200 V for 35 mins. SDS-PAGE 
separated proteins were transferred onto a nitrocellulose membrane using the wet tank 
blotting system (Biorad) filled with Towbin buffer (25 mM Tris, 192 mM glycine, 
20% (v/v) methanol) at a constant 200 mA for 90 mins. The blot was blocked for 1 h 
at room temperature with 5% (w/v) BSA or 5% (w/v) skim milk powder (SMP) in Tris 
buffered saline (TBS - 10 mM Tris, 0.5 M NaCl, pH 7.6) with 0.1% Tween-20 (TBST). 
The blocked membrane was incubated with primary antibody diluted in blocking 
buffer and incubated overnight at 4 °C. The blot was then washed for 5 mins in TBST, 
repeating 2 times. After the washes, diluted anti primary species horse radish 
conjugated antibody (1:5000) in blocking buffer was added and incubated for 1 h at 
room temperature. An additional 3 washes of 5 mins each in TBST were performed to 
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remove unbound secondary antibodies. The immune complex bound proteins were 
detected by the addition of ECL prime (GE) and visualised on an X-ray film developed 
using the AGFA CP 1000 film developer. 
 
2.7.2 Quantitative Westerns 
Quantitative Westerns were performed using the Li-cor Odyssey® system with 
a similar workflow to the chemiluminescence Westerns. After transfer, the blot was 
blocked with Odyssey® Blocking Buffer (OBB) at room temperature for one hour. 
The blocking buffer was removed and the primary antibody was diluted in OBB and 
incubated overnight at 4 °C. The blot was then washed for 5 mins in TBST, repeating 
2 times. Anti-rabbit or anti-mouse conjugated with DyLight 680 or DyLight 800 
secondary antibodies diluted at 1:10,000 in OBB was added. Washes of 5 mins each 
of TBST and an addition wash of TBS for 5 mins to remove any residual Tween-20. 
The blot was scanned using a LI-COR® Biosciences Odyssey® Infrared Imaging 
System and data quantified using Image Studio software version 4.0. The blot was 
stripped by incubation at room temperature for 15 mins with Restore™ Western Blot 
Stripping Buffer (Thermo Fisher Scientific) if assessing both phosphorylated and non-
phosphorylated proteins. 
 
2.7.3 Silver staining 
Resolved SDS-PAGE gels were stained using the highly sensitive silver stain 
and the following modified staining protocol listed in Table 2-6. 
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Table 2-6: Silver staining of SDS-PAGE gels using the Pierce™ Silver Stain Kit 
Step Time Reagents 
1-Wash 2x5 mins MilliQ water 
2- Fixing 2x15 mins 30% (v/v) ethanol, 10% 
(v/v) acetic acid 
3- Wash 2x5 mins 10% (v/v) ethanol 
4- Sensitise 1 min 10 μL Sensitiser in 5 mL 
MilliQ water 
5- Wash 2x1 mins MilliQ water 
6- Stain 30 mins 100 μL Enhancer in 5 mL 
stain 
7- Wash 2x20 sec MilliQ water 
8- Develop As required 100 μL Enhancer in 5 mL 
developer 
9- Stop 10 mins 5% (v/v) acetic acid 
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3.1 INTRODUCTION 
Antibodies are glycoproteins produced by the immune system in response to 
foreign antigens. Due to their high specificity, antibodies have been exploited by 
biomedical research as molecular probes (Freise & Wu, 2015), and as targeted 
therapeutics such as Herceptin® (trastuzumab) for the treatment of metastatic breast 
cancer (Hudis, 2007). Historically, laboratory-based antibody production techniques 
were developed in the 1970s and 1980s and extensively described by the work of 
Harlaw and Lane (1988). In brief, animals were challenged with an antigen of interest, 
eliciting an immune response and the production of antigen-specific antibodies. The 
generated antibodies can be recovered from the serum of the animal, or antibody 
producing B-cells harvested and fused with a myeloma cell forming a hybridoma. By 
immortalising antibody producing B-cells, the hybridoma technique allows for the 
unlimited production of an antibody without requiring the use of animal serum and the 
ability to freeze and create an antibody-producing cell bank. However, the underlying 
principle still requires the immunisation of a host animal. Therefore ethical 
implications must be considered. Thus, alternative approaches which require no 
animals were in need of development to overcome these concerns.  
 
Phage display was first described by Smith in 1985 as a method to display 
protein fused to coat proteins of bacteriophage (Smith, 1985). An application of this 
technique, called antibody phage display (APD), allowed for the in vitro selection of 
monoclonal antibodies against virtually any target, including those that were not 
possible by previous methods, such as animal immunisation, due to their toxic nature. 
In addition, because of the link between the DNA sequence and the translated protein 
being displayed, it offers additional flexibility such as recombination expression using 
various hosts (Miller, Weaver-Feldhaus, Gray, Siegel, & Feldhaus, 2005), interchange 
among immunoglobulin formats, and the creation of novel bi-specific antibodies and 
conjugates (Kontermann, 2011). 
 
Human immunoglobulins such as IgG can be truncated into smaller fragments 
and yet retain antigen specificity. One such fragment, called single chain variable 
fragment (ScFv) consists of the variable heavy (VH) and viable light (VL) chains joined 
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by a linker sequence. Because of its smaller molecular weight of 28 kDa compared to 
a full-length IgG molecule of 150 kDa, the ScFv has several favourable properties, 
including that the ScFv format can be used in phage display, unlike the full length IgG. 
Prominent examples of a ScFv based phage display library, developed by the 
laboratory of Dr Winter (Medical Research Council Laboratory of Molecular Biology, 
Cambridge, United Kingdom), are the Tomlinson I + J libraries. Both libraries were 
engineered on the pIT2 phagemid vector (Figure 3-1) and encode for human variable 
heavy chain (VH) based on a single framework (V3-23/DP-47 and JH4b) and variable 
light chain (VL) (O12/O2/DPK9 and Jκ 1) (de Wildt, et al., 2000). Within the pIT2 
phagemid vector, the VH and VL are linked by a (Gly4Ser)3 polypeptide sequence to 
allow correct conformational folding, and fused in frame with the pIII bacteriophage 
coat protein. The expression cassette is controlled by the lac promoter and is induced 
with isopropyl L-D-thiogalactosidase (IPTG) for periplasmic expression in E. coli via 
the pelB signal sequence. An amber stop codon DNA sequence (TAG) between the 
ScFv (VH-VL) and the pIII allows for the ScFv to be fused to pIII during phage display 
as the stop codon is suppressed in TG-1 E. coli strains, while soluble ScFv without the 
pIII fusion can be expressed within a non-suppression strain such as HB2151, which 
recognises the amber stop codon. Polyhistidine and myc tags are incorporated at the 
end of the ScFv sequence to allow for purification by affinity chromatography.   
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Figure 3-1: Tomlinson libraries (I+J) phagemid. Both libraries were built on the 
phagemid vector pIT2 and encodes for human antibody fragments VH and VL fused to 
the phage pIII coat protein and joined by a (Gly4Ser)3 linker.  The amber stop codon 
allows for the expression of VH-VL-pIII in a suppressor E. coli strain. The pelB is an 
export signal, directing the ScFv to the periplasm. The m13 origin of replication allows 
for the production of phage while colE1 origin of replication allows phagemid 
propagation in E. coli strains. The polyhistidine tag (His) is for the affinity purification 
of the ScFv by Immobilised metal ion affinity chromatography (IMAC). An alternative 
affinity tag, myc, can also be used for affinity chromatography. The PCR primers 
LMB3 and pHEN bind upstream of RBS and downstream of the myc tag respectively.  
 
The Tomlinson ScFv libraries have been described and utilised extensively in 
the literature, including the development of potential cancer therapeutics (Patil, et al., 
2015; ten Haaf, et al., 2015) and in the generation of targeted probes for imaging and 
detection (de la Cruz, et al., 2013; Kim, Wang, et al., 2014; Wang, Zhang, Zhang, Liu, 
& Liu, 2012). Of particular relevance to this project are studies which target cell 
receptors with the aim of generating competitive receptor antagonists, examples 
include: lutropin and thyrotropin receptor (Majumdar, Railkar, & Dighe, 2012), 
fibroblast growth factor receptor 3 (Martínez-Torrecuadrada et al., 2005) and the leptin 
receptor (Molek, Vodnik, Štrukelj, & Bratkovič, 2014).  
 
As part of the overall objective of this project, to generate bi-specific function 
blocking antibody against IGF-1R and αv integrin, the aims of this chapter are: 
 Amplification of the Tomlinson ScFv antibody libraries (I, J) and the 
generation of phage displaying antibody fragment repertoire. 
 To independently screen both phage libraries against passively 
immobilised IGF-1R and αv integrin in order to generate ScFv against 
both respective targets. 
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3.2 EXPERIMENTAL PROCEDURES 
3.2.1 Materials 
All general reagents were purchased from various companies and are of highest 
quality. The naïve human ScFv libraries ‘I’ and ‘J’ (Tomlinson I+J), KM13 helper 
phage, Escherichia coli (E. coli) TG1 and HB2151 were purchased from Source 
bioscience (Cambridge, UK). Recombinant human IGF-1R containing the 
extracellular domains was purchased from R&D systems (Minneapolis, US) with 
Human recombinant αv integrin acquired through Abnova (Taipei, Taiwan). 
Odyssey® Blocking Buffer (TBS) was purchased from LI-COR Biosciences (Lincoln, 
US). Anti-IGF-I Receptor β, Phospho-IGF-I Receptor β (Tyr1131) antibody, Anti-
rabbit IgG (H+L) (DyLight™ 680 Conjugate) and Anti-mouse IgG (H+L) (DyLight™ 
800 Conjugate) were all obtained from cell signalling (Danvers, US). Immuno 
MaxiSorp® 5 mL tubes (cat: NUN444202) and MaxiSorp® 96 well plates 
(NUN442404) for phage panning was sourced from Thermo Fisher. All other reagents 
were sourced from Sigma Aldrich (St Louis, US) unless otherwise stated.  
 
3.2.2 Phage display libraries 
The Tomlinson ScFv library repertoire was engineered based on the phagemid 
vector pIT2 and has a complexity of 1.47x108 and 1.37x108 for the ‘I’ and ‘J’ libraries 
respectively. Both libraries were used sequentially in screening to allow for the 
greatest number of positive IGF-1R and αv integrin binders to be selected. Included 
with the libraries are pre-selected E. coli clones encoding for ScFv against bovine 
serum albumin (BSA) and ubiquitin, which were used as positive controls in early 
testing to confirm correct expression of the ScFv and the ability to bind to BSA or 
ubiquitin.  
 
3.2.3 E. coli strain, media, and culture conditions 
E. coli strains used in this project are listed below in Table 3-1. All strains were 
routinely propagated in 2xYT broth (16 g tryptone, 10 g yeast extract, 5 g NaCl per 
litre), supplemented with 4% (v/v) glucose and 200 µg/mL of ampicillin (2xYT AG) 
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as needed. The cultures were grown in disposable Erlenmeyer flasks (Corning, Mount 
Martha, Vic, Australia) with shaking at 250 RPM at 37 °C. In addition, strains were 
also grown on TYE agar plates (10 g tryptone, 5 g yeast extract, 8 g NaCl, 15 g agar 
per litre) supplemented with 4% (v/v) glucose and 200 µg/mL of ampicillin (TYE AG) 
as required. For the selection of single phage colonies, H top agar (10 g tryptone, 8 g 
NaCl, 7 g agar per litre) was used. To maintain the F’-episome in TG1 and JM109, 
which is essential for KM13 phage infection, strains were plated on M9 minimal 
medium glucose plates (Atlas, 2004) before any procedure involving phage infection. 
The F’-episome in the strains used for this project have been engineered to contain the 
pro operon, which was deleted from the chromosome. The loss of F’ will lead to 
proline biosynthesis deficiency and cell death. 
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Table 3-1 E. coli strains used in this project
Strain Genotype Purpose Reference 
TG1 K12 (lac-proAB) supE thi hsdD5/F' 
traD36 proA+B lacIq lacZ M15), 
Phage display Gibson, T.J, 1984 
(Gibson, 1984) 
JM109 endA1, recA1, gyrA96, thi, hsdR17 (rk–
, mk+), relA1, supE44, Δ( lac-proAB), 
[F´ traD36, proAB, aqIqZΔM15] 
Phage display Yanisch-Perron, C, 
1985  
 
HB2151 K12 ara (lac-proAB) thi/F' proA+B 
lacIq lacZ M15 
Production of 
soluble ScFv 
Carter et al, 1985 
(Carter, Bedouelle, & 
Winter, 1985) 
 
3.2.4 KM13 helper phage amplification 
Stock KM13 helper phage from the manufacturer was serially diluted from 10-2 
to 10-8 in PBS. Log phase JM109 or TG1 were infected with each dilution and 
incubated at 37 °C without shaking for 20 mins. Helper phage used in the library ‘I’ 
selection process was produced in JM109 while TG1 produced helper phage was used 
for library ‘J’. Each sample was added to 3 mL of melted H-top agar at 42 °C and 
poured onto pre-warmed TYE agar plates. After overnight incubation at 37 °C, a single 
‘plaque’ was picked and log phase E. coli were reinfected and incubated at 37 °C 
overnight with shaking. The overnight culture was clarified by centrifugation at 4,000 
g for 30 mins. To the supernatant, 1/5 volume of PEG/NaCl (20 % (w/v) Polyethylene 
glycol 6000, 2.5 M NaCl) was added and allowed to incubate on ice for 1 h. The 
resulting precipitated phage was pelleted by centrifugation at 3,300 g at 4 °C for 30 
mins. An additional round of purification was performed by resuspending the pellet in 
5 mL of PBS with 1 mL of PEG/NaCl solution and placed on ice for 10 mins. The 
solution was again pelleted at 3,300 g at 4 °C for 10 mins and resuspended in PBS. A 
final centrifugation was performed at 14,000 g for 10 mins to remove bacterial debris.  
KM13 is a protease sensitive helper phage that has been modified by the 
insertion of a trypsin cleavage site between the D2 and D3 domains of the pIII coat 
protein (Kristensen & Winter, 1998). This allows for elution using trypsin to release 
the substrate bound phage at the end of the panning round in addition to inactivating 
background phage.  
  
Chapter 3: Phage Display selection and screening 43 
 
 
Figure 3-2: The helper phage KM13 encodes for a trypsin sensitive phage protein 
pIII.  
KM13 helper phage used in this project has been modified with a trypsin cleavable 
sequence between the D2 and D3 domain of the pIII coat protein to eliminate 
background phage lacking displayed proteins. A) Wild type pIII -The bound phage at 
the end of a panning round can be recovered by the addition of trypsin which cleaves 
the trypsin cleavage site (EQK-LISEEDLN) within the engineered myc tag. B) 
Modified pIII – Phage which does not display ScFv are cleaved between the D2 and 
D3 domain, rendering it non-infective in subsequent panning rounds. C) Modified pIII 
– When ScFv is correctly displayed, the trypsin cleavage site within the D2/D3 domain 
is shielded. Adopted from Goletz et al. (2002) 
Upon elution with trypsin at the end of a bio-panning cycle, non-antibody 
displayed phage is rendered non-infective with the removal of domains D1 and D2 
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while antibody-pIII with wild type pIII remains unaffected. The consequence of this is 
the removal of background phage since 99% of phage does not display antibody. To 
test for trypsin sensitivity, 45 µL of purified helper phage was treated with 5 µL of 
trypsin solution (1 mg/mL trypsin in PBS) and allowed to incubate at room 
temperature for 30 mins. The trypsin treated and non-treated phage was serially diluted 
and allowed to infect log phase growth E. coli. The mixture was added to melted H-
top agar and poured onto a pre-warmed TYE plate and incubated at 37 °C overnight. 
The titre between the treated and non-treated phage was compared to determine 
sensitivity. 
 
3.2.5 Amplification of phage library repertoire 
A frozen ampule of library ‘I’ or ‘J’ was rapidly defrosted and grown in 200 mL 
of pre-warmed 2xYT AG with shaking at 250 RPM at 37 °C. After 2.5 h, a 50 mL 
aliquot was taken and 2x1011 KM13 helper phage added. Upon infection by helper 
phage, kanamycin resistance was conferred to the E. coli host. This was used to deplete 
non helper phage infected E. coli. The E. coli / phage solution was incubated at 37 °C 
for 30 mins without shaking in a water bath. The culture was centrifuged at 3,300 g 
for 10 mins after which the pellet was resuspended in 100 mL of 2xYT supplemented 
with 100 µg/mL ampicillin, 50 µg/mL kanamycin and 0.1% glucose and shaken 
overnight with the incubator set at 30 °C. The resulting phage library repertoire was 
purified using PEG6000/NaCl in a similar manner to the production of the helper 
phage (Section 3.2.4). In addition to library ‘I’ and ‘J’, preselected phage in E. coli 
encoding ScFv that are reactive to BSA and ubiquitin was also generated and purified 
to act as controls. 
 
3.2.6 Phage titre determination 
The purified helper phage titre was determined by counting clearings on a plate, 
plates with 30-300 clearings were used for counting, and the titre was calculated based 
on the dilution of the counted plate: 
        	      	 	        	       	 	
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Library ‘I’ and ‘J’ titre was determined by infecting log phase E. coli with a 
dilution series of phage and plated on 2xYT AG. The resulting plates were incubated 
overnight at 37 °C. The number of ampicillin resistant clones was counted on plates 
with 30-300 colonies and titre calculated using the same equation outlined above. 
 
3.2.7 Library ‘I’ selection of IGF-1R binders 
Selection of target specific binders involves three rounds of immobilisation of 
the target antigen, incubation of the phage library repertoire, removing unbound phage, 
elution of reactive phage, and reinfection. For the first round of selection, a Nunc 
MaxiSorp immunotube (Scoresby, Vic, Australia)) was coated with 1 mL of 20 µg/mL 
human recombinant IGF-1R extracellular domain (R&D systems, Gymea, NSW, 
Australia) solubilised in PBS. In each subsequent round a reduced concentration of 
IGF-1R was coated (round 2; 10 µg/mL and round 3; 5 µg/mL). The Immunotube was 
rotated overnight at 4 °C in order for the even coating of the entire surface. The coated 
immunotube was washed 3 times with PBS and blocked overnight with 5% (w/v) skim 
milk powder in PBS (MPBS) at 4 °C. An additional non-coated tube was also blocked. 
The tubes were again washed 3 times with PBS before 1012 library ‘I’ phage in 5% 
MPBS was added to the uncoated, blocked tube. This step was included to deplete any 
phage encoding for ScFv’s that are reactive to the immunotube, or skim milk proteins. 
The phage solution was transferred to the IGF-1R coated tube and rotated at room 
temperature for 1 h followed by no rotation for an additional h. The phage solution 
was discarded and a low stringency wash with PBST (PBS supplemented with 0.1% 
(v/v) Tween 20) was used to remove non-binders. The first round of selection 
employed minimal stringency by washing the tube 5 times using PBST followed by 2 
times with PBS. Subsequent rounds increased washing stringency to 10 PBST/2 PBS 
and 20 PBST/2 PBS washes for rounds 2 and 3 respectively. The immobilised IGF-1R 
bound phage was eluted by incubating with trypsin solution (1 mg/mL trypsin in PBS) 
for 10 mins at room temperature with rotation and the enriched phage was rescued by 
re-infection. The E. coli solution was plated onto TYE AG and incubated overnight at 
37 °C. The resulting ampicillin resistant colonies harbouring library phagemid were 
scraped off the agar plate for use in the next round of panning. In order to conserve 
time and maximise the chance of isolating binders, the whole panning process against 
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IGF-1R was repeated, but with both phage libraries I and J combined and panned 
against IGF-1R simultaneously. 
 
3.2.8 Phage selection against αv integrin with library ‘I’ and ‘J’ 
The screening of ScFv binding integrin was conducted in a similar manner to the 
screening of IGF-1R outlined in section 3.2.7. In this instance, recombinant human αv 
integrin was coated onto an immunotube at a concentration of 5 µg/mL for the first 
round of screening, and was reduced to 2.5 µg/mL for the 2nd round. This was further 
reduced to 0.5 µg/mL in the 3rd and final round. For each concentration, 1 mL total 
volume was used. The entire panning process was conducted once against αv integrin 
 
3.2.9 Polyclonal phage ELISA 
To determine the sensitivity and specificity of the panning process, a polyclonal 
phage ELISA was performed. The procedure is similar to the library selection process 
in section 3.2.7 but rather than coating the immunotube with IGF-1R, a Maxisorp® 96 
well plate (Nunc) was used. Maxisorp® plate wells were coated with IGF-1R (5 
μg/mL), BSA (100 μg/mL, Invitrogen) or ubiquitin (100 μg/mL, Sigma) overnight at 
4 °C with rotation, washed with PBS and blocked with MPBS overnight. Phage from 
the selection rounds, along with BSA and ubiquitin reactive phage were diluted in 
MPBS and added to the wells and incubated for 1 h at room temperature followed by 
3 PBST washes. Bound phage was detected with either an α-pIII primary antibody 
(New England Biolabs, Arundel, Qld, Australia) followed by an α-mouse-HRP 
secondary antibody for library ‘I’, or a more streamline α-pIII-HRP primary antibody 
(GE healthcare, Rydalmere, NSW, Australia) for library ‘J”. Subsequent to a wash step 
with PBST, 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate (Millipore, Kilsyth, Vic, 
Australia) was added to all wells, which reacts with the antibody bound HRP to form 
a coloured compound. The development reaction was allowed to continue for 10 mins, 
was acidified with HCl and the resulting signal read at 450 nm. The data is expressed 
as a signal to noise ratio (S:N); determined by: 
        	   	  
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3.2.10 Monoclonal soluble ELISA 
Clones at the end of the panning rounds were picked into a 96 plate containing 
200 μL of 2xYT AG and cultured at 37 °C with shaking at 250 RPM overnight. From 
the overnight culture, 5 μL was used as the inoculum in a new 96 well plate containing 
200 μL of 2xYT AG. The new culture was maintained at 37 °C with shaking at 250 
RPM for 3 h, at which point the plate was centrifuged at 3,200 g to pellet the E. coli 
and the supernatant was discarded. The pellets were resuspended with 2xYT AG 
supplemented with 1 mM IPTG and cultured at 30 °C with shaking at 250 RPM for 16 
h. After which the plate was centrifuged at 3,200 g for 10 mins and 50 μl of the 
expressed ScFv containing supernatant was used in an ELISA as per the polyclonal 
phage ELISA (see section 3.2.9).  
The threshold value for the further characterisation of binders was set as the total 
of average S:N of binders + the standard deviation of the binders.  
 
3.2.11 Sequencing of positive binders 
E. coli clones determined as positive binders from ELISA analysis were cultured 
overnight in 5 mL of 2xYT medium overnight with shaking at 250 RPM at 37 °C. The 
overnight cultures were centrifuged at 3,000 g for 10 mins to obtain the pellet of E. 
coli cells. A miniprep procedure was performed using the QIAGEN QIAprep Spin 
Miniprep Kit to harvest the ScFv encoding phagemid according to the manufacturer’s 
instructions.  
 
 The purified phagemid was submitted to the Australian Genome Research 
Facility (AGRF) for sequencing using the purified DNA (PD) service. The sequencing 
primers used are listed in Table 3-2. The DNA sequences were analysed using CLC 
Main workbench 7.6.2. 
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Table 3-2 Sequencing primers for the phagemid vector pIT2 
Primer Name Sequence 5’ to 3’ Binding location 
LMB3 CAG GAA ACA GCT ATG AC  upstream of the 
ribosome binding site 
pHEN CTA TGC GGC CCC ATT CA 3’ Downstream of myc tag 
 
 
3.3 RESULTS 
3.3.1 rIGF-1R can be passively coated onto MaxiSorp® immunotubes  
To enable phage display selection, the target of interest must be immobilised to 
a solid support. Therefore, in order to determine if rIGF-1R can be passively adsorbed 
onto polystyrene MaxiSorp® immunotubes, 10 μg/mL of IGF-1R prepared in either 1 
mL PBS or 1 mL NaHCO3 buffer was added to individual immunotubes and incubated 
overnight with rotation at 4 °C. Samples were taken prior to and at the conclusion of 
each period of incubation. In addition, a standard curve was constructed ranging from 
0.325-10 μg/mL IGF-1R. The samples were separated on SDS-PAGE, transferred onto 
nitrocellulose, and probed with an anti-IGF-1R-α antibody. 
 
The resulting blot showed that each rIGF-1R sample separated into two anti-
IGF-1R reactive bands, at approximately 160 kDa and 125 kDa (Figure 3-3). The 
heavier molecular weight band corresponds to the un-cleaved single-chain form of 
IGF-1R containing both the α and β chains (truncated). The lighter band, which 
constitutes the majority of immune-reactivity, in each sample corresponds to the α 
chain alone. 
 
Both IGF-1R-α antibody reactive bands were quantified and combined to form 
one signal value. The standard curve series signal values were graphed and the results 
show a high degree of linearity (R2=0.9977) between the concentration chosen and the 
near infrared signal. As demonstrated in Figure 3-3, IGF-1R was successfully coated 
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onto polystyrene based MaxiSorp® immunotubes. The binding capacity of the tubes 
was less than the 10 μg/mL of IGF-1R introduced into the tube, as seen by the residual 
uncoated IGF-1R at the end of day 1 and day 2 under both PBS and NaHCO3 coating 
conditions. The binding capacity of the immunotubes for rIGF-1R in PBS was 
calculated from the average of the amount adsorbed per tube per day and found to be 
3.33±0.91 μg with a maximum adsorption of 5.141 μg per day. The average binding 
capacity for rIGF-1R diluted in NaHCO3 was 3.31±0.15 μg. This suggests that both 
binding conditions are similar and that the surface is being saturated with IGF-1R at 
10 μg/mL by passive adsorption. Given this result, immunotubes used for phage 
display panning were incubated overnight with 10 μg/mL of IGF-1R in PBS to ensure 
saturation.  
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Figure 3-3: Efficiency of IGF-1R passive adsorption onto polystyrene. 
Recombinant IGF-1R was diluted to 10 μg/mL in PBS or NaHCO3 and added to 
individual Nunc MaxiSorp® immunotubes. The tubes were incubated with rotation for 
24 h at 4 °C after which a small sample was taken (Day 1) with the remainder 
transferred into a new tube and put back into rotation. Samples were also taken after 
the 2nd day (Day 2) and the third day (Day 3). A standard curve of recombinant IGF-
1R was constructed ranging from 0.325 μg/mL to 10 μg/mL in order to quantify IGF-
1R adsorption. The standard curve and the post-coated IGF-1R samples were separated 
by SDS-PAGE, blotted onto nitrocellulose, and probed with an anti-IGF-1R-α 
antibody. The blot was visualised on the Licor Odyssey system and the bands were 
quantified using Image Studio 4.0. The standard curve and the adsorbed samples were 
calculated using GraphPad Prism® version 6.0. 
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3.3.2 Panning and polyclonal phage ELISA of IGF-1R binders 
To assess the enrichment of positive IGF-1R binders, phage samples from each 
panning round were tested in a polyclonal phage ELISA against immobilised IGF-1R 
as per outlined in section 3.2.7. The results of the polyclonal phage ELISA with library 
‘J’ are shown in Figure 3-4, with the signal:noise ratio calculated as the absorbance 
ratio between the IGF-1R coated wells and SMP blocked wells. It was expected that 
as the IGF-1R binders increase after each subsequent round of panning, the signal 
should also increase. The maximum signal:noise ratio to IGF-1R of 6.5 was achieved 
after 2 rounds of panning which decreased to 2.7 in round 3. This might be due to 
several factors: 1) enrichment of non-specific binders or; 2) The signal has reached the 
saturation point of the spectrophotometer, therefore unable to detect higher binding 
signal. Based on this data, 96 individual clones were selected from round 2 of selection 
rather than round 3 to minimise the selection of non-specific binders. 
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Figure 3-4: Library ‘J’ polyclonal phage ELISA. IGF-1R (1, 5 and 20 μg/mL), 
BSA, and ubiquitin were coated onto a 96 well Maxisorp® immunoplates. Phage 
samples from before the panning selection (Round 0), and at each round of selection 
(Rd1, Rd2, Rd3) were added to the coated plate. Non binders were determined when 
signal:noise is at 0. The binding assay for round three was conducted in duplicate (Rd 
3 #1, #2). 
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3.3.3 Soluble ScFv IGF-1R expression and Monoclonal ELISA  
To select for individual ScFv clones that encode IGF-1R binders, soluble ScFv 
expression was induced from individual clones from the 2nd round of panning. This 
allowed for selection of ScFv which can bind to IGF-1R. To express the soluble ScFv, 
IPTG was used to induce the lac promoter, driving the expression cassette housed 
within the phagemid. The resulting supernatant containing ScFv was used in an ELISA 
as per 3.2.9 but instead of detection with α-pIII antibody, bound ScFv to IGF-1R were 
detected using protein-L-HRP. The results of the 96 clones screened are shown in 
Figure 3-5 with the the signal to noise (S:N) threshold for further investigation set at 
7 and non-binders at 1.0. Of the 96 clones screened, 7 returned a S:N above the 
threshold Table 3-3. Of the remaining 89 clones, 42 bind to IGF-1R and 47 did not 
bind.  
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Figure 3-5 Soluble IGF-1R ScFv ELISA. 96 clones from the 2nd selection round were induced to produce soluble ScFv. The expressed ScFvs 
were added to IGF-1R coated plate and bound ScFv to IGF-1R was detected using protein-L-HRP. The minimum threshold level (dotted line) is 
set based on 3.2.11. Non-binding is set at Signal:Noise = 1 
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Table 3-3: IGF-1R binding clones above threshold 
Clone Signal to noise 
A4 7.6 
A7 8.6 
A11 9 
D3 7.2 
F1 8 
F2 7.3 
H3 9.6 
H9 9.3 
 
3.3.4 Panning and monoclonal ELISA of αv integrin ScFv binders  
In a similar manner to above, 96 clones at the end of the 3rd round of panning 
against αv integrin were chosen for soluble ScFv expression as per outlined in section 
3.2.10. Given the limited availability of αv integrin, the polyclonal ELISA was 
replaced in favour of a monoclonal ELISA, allowing for the direct selection of 
individual ScFv. The resulting supernatant containing ScFv was used in a monoclonal 
ELISA with plates coated with αv integrin. The results of the 96 clones screened are 
shown in (Figure 3-6) with the signal to noise (S:N) threshold for non-binders set at 
1.0. Of the 96 clones screened, 8 returned a S:N above the threshold (Table 3-4). Of 
remaining 88 clones, 52 bind to αv and 36 did not bind.  
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Figure 3-6 Selection of αv integrin binding ScFvs. 
96 clones from the 3nd selection round were induced to produce soluble ScFv. The expressed ScFvs were added to αv integrin coated plate and 
bound ScFv was detected using protein-L-HRP. The minimum threshold level (dotted line) is set based on 3.2.11. Non-binding is set at Signal:Noise 
= ≤1 
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Table 3-4: αv integrin binding clones above threshold 
 
Clone Signal to noise 
A2 2.46 
B1 1.77 
C1 2.33 
E2 2.64 
F3 3.04 
F5 2.13 
F8 2.42 
G7 1.91 
3.3.5 Sequencing of IGF-1R binding clones 
All 8 IGF-1R binding clones above the threshold of the phage ELISA, when 
panned with both Tomlinson libraries I and J, were sequenced. The sequencing primers 
used are listed in Table 2-3, with the forward sequencing LMB3 primer binding 
upstream of the VH-VL domains of the ScFv while the reverse primer pHEN bound 
downstream of the myc tag. The resulting sequencing chromatograms were analysed 
with CLC Main Workbench with all 8 clones sequenced returned a single unique 
sequence (Figure 3-7). This was not expected as the ELISA results demonstrated 
different binding capabilities between clones, which is indicative of different ScFv 
sequences. The full DNA sequencing chromatogram can be found in Appendix 3. To 
assess if the isolated IGF-1R ScFv was unique, the ScFv CDS was submitted to a Basic 
Local Alignment Search Tool (BLAST) search 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&PAGE_TYPE=BlastSe
arch&LINK_LOC=blasthome). The result, listed in Appendix 4, showed that the top 
ranked result was an α-TNFα ScFv, which differs from the isolated ScFv by 16 amino 
acid residues. All residues were located within the CDRs, with identical framework 
region sequences. Based on the similarity in the framework regions, the α-TNFα ScFv 
was most likely isolated from the Tomlinson phage display library. 
 
Analysis of the sequenced showed an amber stop codon sequence (TAG) at 
position 169-171 within the CDRH2 coding region. This extraneous stop codon was 
introduced as a remnant of the Tomlinson libraries generation process and would 
prematurely terminate the translation of the full length ScFv, requiring removal prior 
to expression. In suppression E. coli strains such as TG1, containing the genotype 
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supE, this amber stop codon is read-through as glutamic acid without termination. 
However, the expression E. coli strain used for this project HB2152 lacks the supE 
genotype and will terminate translation prematurely. Therefore, site-directed 
mutagenesis was required to change the DNA sequence from TAG to GAG, which 
encodes for glutamic acid.  
 
 
Figure 3-7: Sequence map for IGF-1R binding clone. The ScFv DNA sequence 
encoding for the variable heavy complementarity determining region (CDRH2, 
CDRH3) and the variable light complementarity determining region (CDRL2, 
CDRL3) joined by a (Gly3Ser)3 polypeptide linker. The 6 histidine repeats (His tag) 
enable purification of the protein using affinity based chromatography. An amber stop 
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codon (TAG) was detected in the coding sequence of CDRH2. The DNA sequence 
was translated into amino acid sequence in one letter code using Main Workbench 7.0.  
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3.3.6 Sequencing of αv integrin binding ScFv clones 
Based on the results of the αv monoclonal phage ELISA (Figure 3-6), 8 clones 
(A2, B1, C1, E2, F3, F5, F8 and G7) were selected to be sequenced by the Sanger 
reaction. The resulting DNA sequences were compared with each other to determine 
unique ScFv construct sequences. From the 8 sequenced clones, 3 unique sequences 
were returned. The three clones that were unique are A2 clone B1 and clone F3 ( 
Figure 3-8),  All three clones were verified for their sequence fidelity and all 
encode full-length ScFv. Both clone A2 and B1 encode a premature amber stop codon 
sequence (5’ TAG 3’) in the CDRH2 section, which needed to be removal before 
expression. The full DNA sequencing chromatogram can be found in Appendix 5-7.  
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Clone CDRH2 CDRH3 CDRL2 CDRL3 
A2: DNA TCTATTACTT
CGACGGGTGT
GAAGACATAG
TACGCAGACT
CCGTGAAGGG
C 
 
CGTCTGGGGA
CTTTTGACTA
C 
 
 
AAGGCATCCC
ATTTGCAAAG
T 
 
 
CAACAGGGGC
ATGTTCGGCC
TCCGACG 
 
A2: Protein SITSTGVKT*YA
DSVKG 
 
RLGTFDY KASHLQS QQGHVRPPT 
B1: DNA ACTATTCCTC
GGTAGGGTCG
GAATACAAAT
TACGCAGACT
CCGTGAAGGG
C 
 
AGGGCTGCGC
GGTTTGACTA
C 
 
 
AATGCATCCA
CTTTGCAAAG
T 
 
 
CAACAGGCTC
GGCTGAAGCC
TACTACG 
 
B1: Protein TIPR*GRNTNYA
DSVKG 
 
RAARFDY NASTLQS QQARLKPTT 
F3: DNA GGTATTACGA
AGCAGGGTGA
TGGTACACAT
TACGCAGACT
CCGTGAAGGG
C 
 
ACTTCTCGGT
CGTTTGACTA
C 
 
 
 
CGTGCATCCC
TGTTGCAAAG
T 
 
 
 
CAACAGGGGC
ATACGAGGCC
TCCTACG 
 
 
F3: Protein GITKQGDGTHYA
DSVKG 
 
TSRSFDY RASLLQS QQGHTRPPT 
 
 
Figure 3-8: DNA and translated amino acid sequence for αv integrin clones A2, 
B1 and F3 ScFv.  
The ScFv DNA sequence encoding for variable heavy complementarity determining 
region (CDRH2, CDRH3) and the variable light complementarity determining region 
(CDRL2, CDRL3) were determined using Sanger sequencing. Amber stop codon 
(TAG) was detected in the coding sequence of CDRH2. The DNA sequence was 
translated into amino acid sequence in one letter code using Main Workbench 7.0. 
Letters in bold indicates possible mutation sites engineered as part of the Tomlinson 
phage display libraries.  
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3.4 DISCUSSION 
The aim of this chapter was the selection of IGF-1R and αv integrin binding 
ScFv using phage display technologies. The Tomlinson ScFv libraries I & J were 
chosen based on extensive use in the literature and the diverse applications for which 
they have been employed (Eteshola, 2010; Goletz, et al., 2002; Kim, Wang, et al., 
2014; ten Haaf, et al., 2015; Wang, et al., 2012). In addition, as both libraries were 
created from human immunoglobulin sequences, the likelihood of an adverse immune 
reaction, such as the Human anti-mouse antibody (HAMA) reaction, is eliminated 
(Azinovic et al., 2006).  
 
The phage display process is complex and many factors contribute to the 
successful selection of ScFv against the chosen target. The first factor to consider is 
the choice of immobilisation strategies onto a solid substrate. The two most common 
methods are passive adsorption onto polystyrene or an affinity based system such as 
biotinylating the protein and using streptavidin coated beads. The first method, 
adsorption onto polystyrene, is the simplest, requiring only the incubation of the 
antigen in a suitable buffer. However, in some cases the function of the protein can be 
affected (Butler et al., 1992). The use of streptavidin beads would require less target 
protein, since the protein coated beads could be reused in subsequent panning rounds. 
Burtrum, et al. (2003), described the coating of IGF-1R onto plastic for selection in 
phage display experiments, thus, this study served as a guide for the present 
undertaking. The MaxiSorp® surface chosen for this project reached saturation when 
incubated with recombinant human IGF-1R at a much lower concentration than 
expected. In the first round of panning against IGF-1R binders, 1 mL of IGF-1R at 20 
μg/mL was added to a MaxiSorp® surface immunotube to be passively adsorbed. 
Subtractive concentration analysis demonstrated that a maximum of 5.141 μg was 
adsorbed to the surface when using either PBS or carbonate based buffers with average 
adsorption equalling 3.33±0.91 µg and 3.31±0.15 µg respectively. Initially, 20 µg/mL 
was thought to be low as the Burtrum et al. study used 50 µg/mL of IGF-1R as the 
immobilisation concentration for the first round of panning (Burtrum, et al., 2003). 
Practically speaking, significant difficulties were experienced endeavouring to evenly 
coat the immunotube with only 1 mL of liquid, it is thus most likely that >1 mL of 50 
μg/mL IGF-1R was used by Burtrum and colleagues. It is unclear why such a high 
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amount of IGF-1R was used, given the saturation levels observed in the present study. 
Potentially the high levels of IGF-1R guarantees the surface reached saturation, 
allowing for the maximum number of rare IGF-1R reactive phage to bind during the 
first round of phage selection. Also, it is possible that multiple tubes were coated with 
IGF-1R, which would require the high IGF-1R concentration.  
 
Another critical element of phage display is the selection of polystyrene blocking 
agents as the ScFv non-specifically binding to the Immuno tube may give false positive 
binders through the panning rounds. Furthermore, if a blocking agent such as skim 
milk powder (SMP) or bovine serum albumin (BSA) (Adey, Mataragnon, Rider, 
Carter, & Kay, 1995) is used, there may be ScFv selected for binding to this rather 
than the target, in this case IGF-1R and αv integrin. Therefore, to address this issue, a 
polystyrene and SMP depletion step was included at the start of each panning round. 
Similar depletion procedures have been employed in the literature (Eteshola, 2010). 
 
The polyclonal and monoclonal ELISA procedures used for this project are 
routinely used as a screening tool for positive binding during phage display panning 
(Patil, et al., 2015; Petters, Sokolowska-Wedzina, & Otlewski, 2015; ten Haaf, et al., 
2015). One problem was that identical sequence ScFv resulted in different ELISA 
signal levels, when in theory they should be identical. The most likely explanation is 
the different expression levels of clones grown in a 96 well plate, due to varied 
environmental conditions experienced across the plate. In addition, the levels of the 
initial bacterial inoculum was not quantified at the start of the culture, however, since 
an overnight culture was used, the concentration of E. coli would have reached 
saturation and be similar in numbers (Sezonov, Joseleau-Petit, & D'Ari, 2007). To 
maintain consistent ScFv input in ELISA, it is possible to perform a high throughput 
purification with 96 well plates coated with Ni-NTA (Qiagen Ni-NTA HisSorb Plates) 
or protein-L. The resulting purified ScFv could then be quantified normally using a 
standard protein quantification assay.  
 
Due to the inherent random enrichment of clones resulting from the phage 
display process, the selection of clones harbouring identical ScFv CDS is possible. 
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Initially, in order to quickly discriminate among unique clones, a restriction fragment 
analysis using the enzyme BstNI on the ScFv CDS was conducted. However, it was 
unable to discriminate between unique clones fully (results not shown). The clones in 
the Tomlinson libraries are mutated in one of the possible 18 amino acid residues. The 
probability of BstN1 recognising its DNA cleavage sequence (CC’(A/T)GG) at one of 
these positions is low. However, BstN1 digestion has been successfully used in other 
phage display libraries that are more heterogeneous in nature, and potentially 
producing restriction fragments of different sizes (Pansri, Jaruseranee, Rangnoi, 
Kristensen, & Yamabhai, 2009b). Due to the failure of BstN1 discrimination, the 
slower and more expensive method of sequencing was used in order to determine 
unique clones. 
 
Sequencing of the four unique clones which bind either IGF-1R or αv integrin, 
3 (one IGF-1R and 2 αv integrin binders) had a premature amber stop codon sequence 
(TAG) within the CDHR2 encoding sequence. For both IGF-1R ScFv and also αv 
integrin B1, it was located in the sequence encoding the 5th amino acid residue, while 
for αv integrin A2, the amber stop codon was located in the 10th codon of the 
translation sequence. The amber stop codon is ineffective during phage display 
screening as the TG1 E. coli strain reads the codon as glutamic acid rather than a stop, 
due to repression of stop tRNA’s through the supE gene. Amber stop codons have been 
described in selected ScFv clones from the Tomlinson libraries used within previous 
studies (Eteshola, 2010; Wu, Ke, & Doudna, 2007). While the amber stop codon can 
be tolerated in the TG1 strain, when transferring the selected ScFv expressing plasmid 
into an expression E. coli strain, such as HB2151, the amber stop codon requires 
mutation. This can be achieved using site-directed mutagenesis to modify the DNA 
sequence TAG to GAG (Glutamic acid) (Wu, et al., 2007). The following chapter will 
detail the mutagenesis steps required. The enrichment of the desired phage depends on 
equal ScFv-phage expression and growth. If the displayed ScFv sequence has a growth 
disadvantage, such as using rare bacterial tRNAs, that sequence would propagate more 
slowly relative to others. Even if the ScFv has better binding characteristics, leading 
to the enrichment of sub-optimal binding clones among each panning round.  
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It is unclear why the panning of IGF-1R with both ScFv libraries only yielded 
one unique ScFv sequence. The screening process is complex, therefore, isolating the 
underlying cause is difficult. Since the process of IGF-1R immobilisation onto 
polystyrene and the subsequent panning was successful in the study by Burtrum, et al. 
(2003), potentially the problem stems from the Tomlinson libraries. In that study, the 
researchers used a library containing 3.7 x 1010 clones, which is ~100 times more 
diverse than the Tomlinson libraries I & J of 1.47 x 108 and 1.37 x 108 respectively. 
Even with a vastly more complex library, the phage panning process conducted by 
Burtrum et al was only able to yield 4 clones with only one clone demonstrating ligand 
blocking functionality. Other studies using the Tomlinson I & J libraries yielded 3 
unique sequences from 96 characterised (Yan, Ko, & Qi, 2004), 14 from 44 clones 
(Eteshola, 2010) and 3 from 800 clones screened (Patil, et al., 2015). Taken together, 
there is evidence to suggest that the low number of unique binders (total of 4) obtained 
from phage panning could be related to the Tomlinson libraries used. 
 
Therefore, it is likely that in using a smaller library for this project that only one 
IGF-1R binding sequence can be obtained. Since the commencement of this project, 
commercial phage display libraries, which contain a higher magnitude of complexity 
than used herein, have become available and can be sourced from Creative Labs 
(http://www.creative-biolabs.com/). For example, the HuScL-4(R): Human Single 
Chain (ScFv) Antibody Library has a complexity of 1.5x1016. The downside to 
obtaining these libraries is the substantial costs involved, upwards of $20,000. In 
addition to sourcing ScFv libraries with an increasing complexity, alternative libraries 
encoding for different antibody framework could also be investigated. In particular, 
single domain antibodies, which consist of one heavy chain domain (VHH) are gaining 
popularity due to its desirable characteristics such as being non-immunogenic in 
humans, small size, and aggregation resistance (Omidfar & Shirvani, 2012; Rozan et 
al., 2013).  
 
In spite of the technical difficulties encountered, the panning process was able 
to yield 1 IGF-1R and 3 αv integrin unique binding sequences. The next step in 
fulfilling the aims of this project is the expression of these ScFv which is detailed in 
the following chapter.  
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4.1 INTRODUCTION 
The previous chapter described the selection of αv integrin and IGF-1R binding 
ScFv candidates using antibody phage display technologies. As a result of the panning 
procedure, the 4 unique ELISA confirmed clones were selected for expression in order 
to perform structural and functional characterisation studies.  
 
The selected ScFv binding candidates described in the last chapter were chosen 
from a phage display library that has been widely used in the literature (Eteshola, 2010; 
Goletz, et al., 2002; Kim, Wang, et al., 2014; ten Haaf, et al., 2015; Wang, et al., 2012). 
Both Tomlinson libraries (I+J) are housed within the phagemid pIT2 vector (Figure 
3-1) that has features which dictate both the expression and purification methods. The 
ScFv expression cassette is under the control of the lac promoter, which is induced by 
the addition of IPTG to cultures. Through the inclusion of an amber stop codon 
between the ScFv and pIII coding sequences, the construct can produce ScFv-pIII 
fusion for phage display, or alternatively, soluble ScFv when expressed in a non-amber 
suppression strain such as HB2151. Historically, the expression of ScFv using E. coli 
expression systems has been hampered by stability and yield problems, often resulting 
in misfolded proteins contained in inclusion bodies. The inclusion of the PelB signal 
peptide encoding sequence in the pIT2 vector directs the expressed ScFv to be 
exported to the bacterial periplasmic space, a more favourable environment for protein 
folding.  
 
Various purification methods are commonly used for the purification of ScFv. 
The approaches can be broadly divided into two categories: 1) Classical 
chromatographic methods such as affinity, ion exchange, hydrophobic interactions and 
size exclusion, and 2) Alternative methods such as metal chelate affinity precipitation, 
and macroporous cryogels (Malpiedi, Díaz, Nerli, & Pessoa Jr, 2013). One method of 
antibody purification, immobilised metal affinity chromatography (IMAC), relies on 
the attraction between the engineered polyhistidine motif within the protein of interest, 
and immobilised metal ions, usually Ni2+ or Co2+. The main advantage of this approach 
is the ability to conduct the purification process under native or denaturing conditions. 
Advantageously, denaturing conditions can be utilised to recover misfolded proteins 
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from inclusion bodies. There are several ways in which this could be achieved, usually 
the ScFv within the inclusion bodies are encouraged to refold naturally upon stepwise 
dialysis in a favourable environment (Sinacola & Robinson, 2002). However, this 
process is often time consuming and requires large volumes of buffer. Also, several 
parameters such as, high binding, low cost, and mild elution conditions makes IMAC 
attractive for ScFv purification (Block et al., 2009). However, bacterial proteins 
containing sequential histidines can also bind to the IMAC resin, resulting in low 
specificity within the IMAC system. Consequently, additional polishing steps are often 
used in conjunction to IMAC, such as size exclusion chromatography (SEC) or ion 
exchange chromatography. Another affinity purification method which can be 
employed exploits the fact that some bacteria express natural antibody binding proteins 
on their surface. Protein-L has a high affinity to the various classes of immunoglobins, 
including fragments such as ScFv (Björck, 1988). A major advantage of using protein-
L in purification is that it does not require any additional purification motifs such as 
the polyhistidine tag, as in the case of Ni-NTA, as it binds through κ-light chain 
interaction (Nilson, Solomon, Björck, & Akerström, 1992). In addition, there is 
evidence to suggest that purification by protein-L results in a greater purity in 
comparison to Ni-NTA (Das, Allen, & Suresh, 2005; Malpiedi, et al., 2013).  
 
Sequencing results from the last chapter have revealed that out of the 4 unique 
ScFv encoding sequences, 3 contain a premature amber stop codon (TAG) within the 
main ScFv (CDH2) sequence. This stop codon was suppressed during phage display 
using the E. coli strain TG1, allowing for the display of the full length ScFv-pIII fusion. 
However, for large scale periplasmic expression producing soluble ScFv lacking pIII 
a non-suppressive E. coli strain such as HB2151 is required. Therefore, site-directed 
mutagenesis was needed to mutate the amber stop codon (TAG) to one encoding 
glutamic acid (GAG) and enable expression of the full length ScFv.  
 
The aims of this chapter are to: 
 Mutate the extraneous amber stop codon interrupting the translation of 
the CDH2 domain of ScFv in selected clones to allow for expression in 
the non-amber suppressive E. coli strain HB2151.  
 70 Chapter 4: ScFv expression and purification 
 Express the 4 ScFv using E. coli expression system and to purify ScFv 
for both structural and functional characterisations.  
 
4.2 EXPERIMENTAL PROCEDURES 
4.2.1 Materials 
The affinity chromatography resin nickel-nitrilotriacetic acid (Ni-NTA), 
QIAquick Gel Extraction Kit and QIAprep Spin Miniprep Kit were purchased from 
Qiagen (Chadstone, Australia). For protein purification and detection, protein-L 
agarose and HRP-conjugated protein-L were sourced from Thermo Fisher (Scoresby, 
Australia). SnakeSkin™ dialysis tubing (MWCO 3,500 Da), Slide-A-Lyzer™ dialysis 
cassettes (MWCO 10,000 Da) and Slide-A-Lyzer™ mini dialysis devices (MWCO 
3,500 Da) were also sourced from Thermo-Fisher. The Q5® Site-Directed 
Mutagenesis Kit was acquired from NEB (Ipswich, US).  
 
4.2.2 Site directed mutagenesis 
Extraneous amber stop codons in ScFv coding sequences were mutated using site-
directed mutagenesis to alter the codon sequences from TAG to GAG, which encodes 
for glutamic acid. Clones which contained an interrupted CDS are:  α-αv clone A2, α-
αv B1 and α-IGF-1R. The Q5® Site-Directed Mutagenesis Kit was used (NEB). The 
workflow is summarised below in Figure 4-1. 
 
Mutagenic primers were designed using NEBaseChanger 
(http://nebasechanger.neb.com/). The original and the desired DNA sequence were 
submitted into the program and the resulting primers and melting temperature outputs 
are listed in Table 4-1. Each mutagenesis reaction consisted of the DNA polymerase 
master mix, forward mutagenic primer, reverse mutagenic primer and plasmid DNA 
of α-αv-A2, α-αv-B1, or α-IGF-1R independently. The reaction mix and volumes are 
listed in 8. Each complete reaction mix was incubated in a thermocycler according to 
the conditions in  
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Table 4-2. The post PCR samples were separated on a 1% agarose gel to 
visualise amplification of the ~5,000 bp pIT2 phagemid vector and check for non-
specific amplification. The band corresponding to the correct size was excised and a 
gel extraction performed using the QIAquick® Gel Extraction Kit (Table 4-4). After 
PCR cycling, the linear PCR products contained a mixture of unmodified (TAG) and 
modified (GAG) DNA. In order to remove the template sequence, and to re-circularise 
the mutated product for transformation into E. coli, the PCR product is treated with a 
proprietary mixture of kinase, ligase and the restriction enzyme DpnI (KLD) as listed 
in (Appendix 8). The circularised vectors were transformed into competent HB2151 
E. coli cells using the standard heat-shock protocol.  
  
 72 Chapter 4: ScFv expression and purification 
 
 
Figure 4-1: Site-Directed Mutagenesis workflow. A) Exponential PCR 
amplification using the NEBaseChanger™ designed mutagenic primers with the 
mismatched based highlighted as a star.   B) The inverse PCR yields a linear product 
with the mutated base in both DNA strands. C) The kinase, ligase and Dpn1 (KLD) 
reaction. The kinase phosphorylates the 5’ end of the PCR product (C.1), which allows 
the recirculation of the product by ligase (C.2). The Dpn1 restriction digest cleaves the 
template DNA which is methylated (C.3). D) The final product is listed. The forward 
primer is coloured blue while the reverse primer is in orange. 
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Table 4-1: Mutagenic primers for Site-Directed Mutagenesis 
Target Action Sequence (5’ to 3’) Ta 
A2 A2-mut-TAG→GAG F  TGTGAAGACAgAGTACGCAGAC 61
°C  A2-mut-TAG→GAG R  CCCGTCGAAGTAATAGATG 
 
B1 B1-mut-TAG→GAG F  TATTCCTCGGgAGGGTCGGAA 66
°C  B1-mut-TAG→GAG R  GTTGAGACCCACTCCAGC 
 
IGF-1R IGF1R-mut-TAG→GAG 
F 
GATTTCTCAGgAGGGTGATTATA
C 
61
°C 
 IGF1R-mut-TAG→GAG 
R  
CTTGAGACCCACTCCAGC 
 
 
Table 4-2: Site-Directed Mutagenesis PCR cycling conditions 
Step Temp Time 
Initial Denaturation 98 °C 30 seconds 
25 Cycles 98 °C 10 sec 
A2, IGF-1R, 61 °C 
B1, 66 °C 
10-30 sec 
72 °C 20-30 seconds/kb 
Final Extension 72 °C 2 minutes 
Hold 4-10 °C ∞ 
 
 
4.2.3 Preparation of competent HB2151 E. coli 
The E. coli strain HB2151 were made chemically competent using the calcium 
chloride method; briefly, single colonies were obtained by streaking a glycerol stock 
of HB2151 onto a TYE plate and incubating at 37 °C overnight. A single HB2151 
colony was picked from the plate to initiate an overnight starter culture in 5 mL of 
2YT medium and again cultured overnight at 37 °C but with shaking at 250 RPM. This 
overnight culture was diluted 1:100 in a total volume of 100 mL of 2YT and shaken at 
250 RPM while being maintained at 37 °C for 3 hours to allow for exponential growth. 
The E. coli culture was chilled on ice and subsequently harvested in a 4 °C centrifuge 
at 3,000 g. The resulting pellet was resuspended in 10 mL of cold 100 mM CaCl2 and 
placed on ice for 20 mins. The HB2151 was again pelleted and resuspended as above 
and placed on ice for an additional 20 mins. The competent cells were harvested by a 
final centrifugation and resuspended in 5 mL of 100 mM CaCl2 supplemented with 
15% (v/v) glycerol. The competent HB2151 were aliquoted and frozen at -80 °C until 
required. 
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4.2.4 Transformation 
An aliquot consisting of 50 µL competent HB2151 cells was thawed on ice and 
5 µL of post KLD treated DNA (see 4.2.2) from each clone was added. The samples 
were incubated on ice for 30 mins followed by a heat-shock step at 42 °C for 20 sec in 
a water bath. The tubes were chilled on ice for 2 mins and 500 mL of SOC medium 
added to each tube. The tubes were incubated at 37 °C with shaking at 250 RPM for 1 
h. Subsequently, the samples were plated onto TYE AG plates and incubated overnight 
at 37 °C. Single colonies were picked from each plate, cultured overnight in 2xYT and 
plasmids extracted using the QIAGEN Mini-Prep Kit according to the manufacturers 
instructions. The purified DNA were sent for sequence verification by AGRF using 
LMB3 (5’ CAG GAA ACA GCT ATG AC 3’) and pHEN (5’ CTA TGC GGC CCC 
ATT CA 3’) sequencing primers. 
 
4.2.5 Induction time pilot study 
An overnight starter culture was initiated from α-αv clone A2 glycerol stock. 
Five millilitres of 2xYT containing 100 µg/mL ampicillin and 4% glucose (2xYT AG) 
was inoculated from frozen E. coli stock using a sterile pipette tip and shaken at 250 
RPM, 37 °C overnight. The resulting cultures were diluted 1:100 into 500 mL of 2xYT 
AG and placed in a 37 °C incubator and shaken at 250 RPM for an additional 2 h. The 
cell cultures were centrifuged at 3,200 g and the resulting pellet was resuspended in 
500 mL of 2xYT AG with 1 mM IPTG. The incubation temperature was lowered to 
30 °C and the culture shaken at 250 RPM. At 3 h intervals, a sample was taken for 
Western blot analysis to confirm the expression of ScFv, and to determine the ratio 
between periplasmic and supernatant located ScFv.  
 
4.2.6 Detection of the expressed ScFv by Western blotting 
Samples collected at each step of the expression and purification processes were 
separated based on molecular weight using Nu-PAGE SDS-PAGE and immune-
blotted as per section 2.7.1. The expressed ScFv was detected using HRP conjugated 
protein-L, which binds to the kappa light chain of immunoglobins, including truncated 
forms such as ScFv. 
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4.2.7 Large scale ScFv expression  
A starter culture was made by inoculating 5 mL of 2xYT AG from glycerol stock 
and incubating overnight at 37 °C and 250 RPM. The next morning, the culture was 
diluted into 500 mL of pre-warmed 2xYT AG in Erlenmeyer baffled cell culture flasks 
and shaken at 37 °C, 250 RPM for 2.5 h. At this point, the culture was harvested and 
centrifuged at 3,300 g for 10 mins. The resulting pellet was resuspended in 2xYT A 
and supplemented with 1 mM IPTG. The culture was incubated at 30 °C with shaking 
at 250 RPM for an additional 9 hours. The 9 hours post inducting time point was 
chosen from the result of the induction time pilot (section 4.2.5).  
 
4.2.8 Periplasmic extraction 
The phagemid vector pIT2 was engineered to encode the signal peptide PelB 
which allows for the expressed ScFv to be directed to the bacterial periplasmic space. 
To selectively lyse the outer membrane, a periplasmic extraction procedure was used, 
which is based on lysis by osmotic shock. The E. coli expression culture was 
centrifuged at 3,300 g for 10 mins. The supernatant was separated and the pellet 
resuspended in 25 mL of pre-chilled periplasmic extraction solution 1 (20 % (w/v) 
sucrose, 100 mM Tris-HCL [pH 8.0] and 1 mM EDTA). The suspension was slowly 
mixed using a magnetic stirrer at 4 °C for 30 mins. After the incubation, the solution 
was centrifuged at 10,000 g for 10 mins and the supernatant poured off and retained. 
The pellet was resuspended in 25 mL of periplasmic extraction solution 2 (5 mM 
MgCl2) and stirred in the cold room for an additional 20 mins. The supernatant was 
obtained by an additional centrifugation at 10,000 g for 10 mins. The supernatant post 
extraction 1 and 2 were combined and stored at 4 °C for further processing. 
 
4.2.9 Precipitation of ScFv from culture medium using PEG 
Protein was extracted from the culture supernatant using PEG 6000 as the 
precipitation agent. Culture medium containing expressed ScFv was incubated with an 
increasing concentration of PEG 6000 from 0 % to 20 % (w/v) with rotation at 4 °C 
for 1 h. The samples were centrifuged for 10 mins at 10,000 g to obtain the precipitated 
proteins. Samples taken throughout the procedure were separated by molecular weight 
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on SDS-PAGE, immunoblotted onto nitrocellulose, and ScFv was detected using 
protein-L HRP as per section 4.2.6. 
 
4.2.10 Purification using Ni-NTA affinity chromatography  
Approximately 50 mL of periplasmic extracts were dialysed using SnakeSkin™ 
Dialysis Tubing (Thermo-Fisher) against 10 L of Ni-NTA native binding buffer (50 
mM NaH2PO4, 300 mM NaCl, pH 8.0) overnight at 4 °C. The dialysed ScFv extracts 
were added to 1 mL of Ni-NTA resin (equilibrated with binding buffer) and rotated at 
4 °C for 1 h. The Ni-NTA was retained by gravity flow into a disposable 
chromatography column. The column was washed once with 10 mL of Ni-NTA wash 
buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0). The bound ScFv 
were eluted from the column using the Ni-NTA elution buffer (50 mM NaH2PO4, 300 
mM NaCl, 250 mM imidazole, pH 8.0) with 500 µL fractions collected.  
 
4.2.11 Small scale purification using protein-L agarose 
Agarose conjugated with protein-L was employed as an alternative method of 
purifying ScFv. Rather than relying on an affinity tag such as the 6x histidine for Ni-
NTA based purification, protein-L interacts with the kappa light chain of 
immunoglobulins, including ScFv. To determine if protein-L can improve yield or 
purity of the isolated ScFv, a test Ni-NTA eluate fraction from section 4.2.9 was 
dialysed in Slide-A-Lyzer™ mini dialysis device for 4 h at 4 °C against PBS. It was 
then applied to a protein-L agarose column equilibrated with PBS and allowed to flow 
by gravity. The column was washed once with 5 mL of PBS to remove loosely bound 
proteins. Remaining proteins were eluted with protein-L elution buffer (100 mM of 
glycine-HCl solution, pH 2.7) and 500 μL fractions were collected with tubes pre-
filled with 50 μL of protein-L antibody neutralisation buffer (1 M Tris, pH 8.0). 
Samples were interrogated for purity with SDS-PAGE and Western blotting as per 
section 4.2.6. 
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4.2.12 Large scale protein-L agarose expression and purification from culture 
medium 
The procedure for large scale protein-L agarose expression is similar to the 
previously described sections (4.2.7 – 4.2.11), with some modifications. Rather than 
harvesting the E. coli at 9 hours post induction with IPTG, the culture was maintained 
overnight at 30 °C with shaking at 250 RPM. The supernatant was harvested by 
centrifugation at 3,300 g for 10 mins and dialysed against 10 L of PBS overnight at 4 
°C. The material was applied to a pre-equilibrated protein-L agarose column and 
allowed to flow by gravity. The column was washed with 5 mL of PBS and eluted with 
protein-L elution buffer in 500 μL fractions and immediately neutralised with 50 μL 
of protein-L antibody neutralisation buffer. At each step of the purification process, a 
sample was retained for assessment by silver stained SDS-PAGE for quality control.  
  
4.2.13 Expression of αIGF-1R ScFv using EnPresso B 
EnPresso B is a proprietary expression medium system for E. coli claiming to 
guarantee an expression yield increase of at least 5-fold over traditional media such as 
LB medium. A starter culture was initiated by inoculating ScFv transformed E. coli 
into 5 mL of 2xYT A from α-IGF-1R ScFv glycerol stock and incubated at 37 °C with 
shaking at 250 RPM for 6 h. The EnPresso B medium was reconstituted by adding the 
contents of two satchels to 100 mL of sterile water into a 1 L Erlenmeyer baffled cell 
culture flask and supplemented with ampicillin to a concentration of 100 μg/mL. The 
starter culture and 50 μL of proprietary Reagent A was added to the shaker flask and 
incubated overnight at 30 °C with shaking at 250 RPM. Next, IPTG was added to a 
final concentration of 1 mM, along with 2 proprietary booster tablets and 50 μL of 
Reagent A. The culture was again incubated with shaking as previous for an additional 
24 h. After the incubation period, the culture was harvested and centrifuged at 3,300 g 
for 10 mins. The supernatant was retained and subjected to the protein-L agarose 
purification regime as per section 4.2.12. 
 
4.2.14 Protein Quantification 
The protein concentration of the purified ScFv was estimated using the 
Bicinchoninic Acid (BCA) protein assay kit (Pierce) as per the manufacturer's 
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instruction. The protein BSA was used as a protein standard diluted in PBS to create a 
concentration range from 125 μg/mL to 2000 μg/mL. The BCA reaction plate was read 
at 562 nm using the Bio-rad benchmark plus microplate spectrophotometer system. 
The resulting data was curve fitted using the Microplate Manager Software version 6.2 
(Bio-rad). BSA was chosen as the concentration standard rather than an IgG such as 
bovine gamma globulin (BGG) because ScFv lack the post-translational modifications 
of the constant region of an IgG (Huhn, Selman, Ruhaak, Deelder, & Wuhrer, 2009). 
Therefore, BSA is more representative of ScFv than an intact IgG for protein 
quantification.  
 
4.3 RESULTS 
4.3.1 Amber stop codon modification using Site-directed mutagenesis 
Of the 4 unique receptor binding ScFv candidates identified by ELISA (3.3.4 
and 3.3.5), 3 had an amber stop codon within their CDS. Since the phage display 
selection was conducted in TG1 E. coli, a suppressive strain, this premature stop codon 
was suppressed. However, to facilitate the periplasmic expression of the ScFv in a non-
suppressive strain such as HB2151, the sequence encoding for the extraneous amber 
stop codons (TAG) was mutated to one encoding glutamic acid (GAG) using site-
directed mutagenesis. Candidates which underwent SDM were α-αv-A2 and B1 and 
α-IGF-1R. After the mutagenic PCR, each reaction was separated on an agarose gel to 
confirm amplification of the correct 5 kb plasmid product (Appendix ) and the band 
was subsequently excised using a gel extraction kit. Unexpectedly, an additional band 
of 750 bp was detected in the sample B1 reaction which was still present when the 
reaction was repeated. However, given that the 5 kb product was present, that band 
was excised and used in the KLD treatment to re-circularise the PCR product and also 
to remove the original template.  
 
The DNA sequencing results of the procedure are shown in Figure 4-2. The 
sequencing data demonstrated that the SDM steps were successful in changing the 
selected thymine base to guanine and thus modifying the amber stop codon to encode 
a glutamic acid residue. The sequence verified clones were transformed into 
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chemically competent HB2151 E. coli strains for stock generation and expression 
studies.  
 
 
Figure 4-2 Modification of amber stop codon sequence from ScFvs.  
The sequencing data and the translated amino acid sequence from α-αv-A2 and B1 and 
α-IGF-1R clones pre and post site-directed mutagenesis (SDM). The highlighted 
region shows the location of the mutagenesis in which the thymine base, as part of the 
amber stop codon (TAG), was mutated to a guanine (GAG), encoding for glutamic 
acid.  
Before 
After 
Before 
After 
Before 
After 
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4.3.2 Post-induction ScFv expression time course 
In order to determine the optimum time for harvesting of the expression culture 
post induction with IPTG, an expression time course was conducted using α-αv clone 
A2. Samples were collected at 0, 3, 6 and 9 hours post IPTG addition to the culture 
media. The harvested E. coli were centrifuged to separate the pellet and supernatant 
fractions. The E. coli pellet was resuspended in PBS to the same starting volume of 
the original sample. The total, supernatant and pellet samples were resolved by SDS-
PAGE, blotted onto a nitrocellulose membrane and probed using protein-L HRP to 
detect the presence of the expressed ScFv (Figure 4-3). 
 
The resulting blot showed that at 3 hours post induction, the expressed ScFv 
could be detected in the total and pellet samples, most likely present within the 
periplasmic space. Such a result is to be expected due to the pIT-2 phagemid encoding 
the signal peptide PelB, which directs the translated protein into the periplasm. Over 
the period monitored (9 hours), the total yield of ScFv increased in a time depended 
manner. Though the expressed ScFv could be found in high concentration within the 
pellet, a greater total ScFv could be found in the culture medium, which could be 
recovered using a more involved purification approach.  
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Figure 4-3: Time course trial of ScFv expression.  
Clone α-αv A2 expressing E. coli were cultured and induced with IPTG. At time 0 and 
every 3 hours after, samples were taken (total) and centrifuged to separate the culture 
medium (supernatant) and E. coli (pellet). It was expected due to the PelB signal 
peptide that most of the α-αv A2 ScFv detected within pellet are in the periplasmic 
space with the remaining ScFv located in the cytosol. The samples were separated by 
SDS-PAGE and probed with protein-L conjugated HRP in a Western immunoblot. 
 
4.3.3 Precipitation of proteins from culture medium using PEG formed 
insoluble products 
Even though the PelB signal peptide directs the expressed ScFv to the bacterial 
periplasm, some ScFv could be detected in the culture supernatant, as observed in 
Figure 4-3. To determine if the expressed ScFv in the culture medium could be 
recovered for further purification, a protein precipitation procedure using PEG 6000 
was employed. Precipitation of the ScFv from culture medium has a distinct advantage 
because it minimises the volume of liquid for processing by downstream purification 
processes in addition to less protein complexity compared to a periplasmic extract.  
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Test culture medium samples containing expressed ScFv were incubated with 
various increasing concentrations of PEG 6000 (0-20% (w/v)) and centrifuged. 
Samples were taken of the resulting supernatants to determine if the ScFv remains in 
solution and at what minimum PEG % the ScFv were no longer observed. Figure 4-4 
(A) shows ScFv could still be detected at PEG concentrations of 5 and 10 % (w/v). 
When the PEG concentration increased to 15%, ScFv could not be detected in the 
supernatant and was thus inferred to have precipitated. Subsequently, expressed 
culture medium was incubated with 15% (w/v) PEG 6000, incubated at 4 °C with 
rotation for 1 h and centrifuged. The supernatant and pellet were separated and PBS 
added to the pellet for re-suspension but it remained insoluble, requiring the direct 
addition of SDS-PAGE sample buffer and heating in order to solubilise for SDS-PAGE 
analysis. In order to confirm the plausibility of the approach, 15% (w/v) PEG was 
added to a fresh batch of expression culture media, incubated, centrifuged and 
separated into supernatant and pellet samples and probed with protein-L HRP in an 
immunoblot as previously described (Figure 4-4 (B)). ScFv was detected in the pre-
treatment culture media (-PEG) while a reactive band could not be detected in the 
supernatant sample (+PEG). Furthermore, the pellet sample (PPT) could be observed 
to contain a strong immuno-reactive band equivalent to the expected MW of ScFv. 
Together, these data demonstrate high efficiency of the precipitation reaction. The 
insoluble pellet suggests the proteins had aggregated and additional steps would be 
required if this precipitation approach is to be used.  
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Figure 4-4 Precipitation of ScFv by PEG 6000.  
(A) Culture medium containing expressed ScFv was incubated with increasing 
concentrations of PEG 6000, ranging from 5 to 20 % (w/v). The reactions were 
incubated at 4 °C with rotation and centrifuged. The expressed ScFv could not be 
detected at or above a PEG concentration of 15 % (w/v). (B) Samples of the expression 
culture media starting material (-PEG), supernatant (+PEG) and pellet (PPT) of 15% 
PEG treated expression media were subjected to SDS-PAGE and immunoblotted 
against protein-L HRP. Protein-L HRP-reactive ScFv is only observed in the starting 
material and PEG treated pellet. 
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4.3.4 Optimisation of Ni-NTA purification with the addition of urea 
Initially, purification of expressed ScFv was undertaken by Ni-NTA-based 
affinity chromatography to selectively bind the 6xHis C-terminal tag encoded by the 
expression construct, a system widely used with success (Zhao, Chan, Lee, & Cheung, 
2009). Unexpectedly, initial preliminary purification runs using periplasm extracts 
from an α-IGF-1R ScFv expression culture failed to produce pure protein in the Ni-
NTA elution fractions (Figure 4.5 (A) and could be found in the flow-through sample. 
As ScFv was detected in the flow-through sample, it is plausible to assume the running 
and sample conditions are unfavourable for Ni-NTA binding. A common reason for 
proteins not to bind the Ni-NTA moiety is that the proteins adopted a folded 
conformation that hinders access to the polyhistidine tag. In an attempt to circumvent 
this problem, many optimisation steps were performed (Appendix 9). Finally, the 
addition of 1M urea to the starting periplasmic extract, in order to disrupt potential 
hydrophobic interactions among ScFv molecules, before addition to the Ni-NTA 
packed column was found to be successful in enabling efficient protein binding.  
 
Samples were taken at each step of the purification process and interrogated 
using silver-stained SDS-PAGE and Western blot using protein-L HRP. In the process 
without urea (Figure 4-5 (A)), the silver-stained SDS-PAGE shows that no band 
(equivalent to the ScFv or otherwise) was observed in the elution fraction. This was 
confirmed by Western blot which revealed effectively equal amounts of ScFv (protein-
L HRP-reactive band of ~28 kDa) could be found in the load and flow-through 
samples, suggesting the ScFv is unable to bind Ni-NTA under these conditions. On the 
other hand, with the addition of 1M urea (Figure 4-5 (B)), a single protein band of the 
predicted molecular weight could be detected in the elution fraction of the silver-
stained SDS-PAGE and is reactive to protein-L HRP, suggesting that the band is the 
expressed ScFv. Unlike the purification procedure without urea, the absence of 
detectable ScFv in the flow-through shows that the binding process between the ScFv 
and the affinity resin is efficient. The results demonstrate that the addition of 1M urea 
to the starting load facilitates the binding of the ScFv to Ni-NTA. Based on this result, 
1 M urea was included for ScFv purification using the Ni-NTA system. 
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Figure 4-5: Improved Ni-NTA affinity purification of α-IGF-1R ScFv with the 
addition of 1 M urea.  
Periplasmic extracts of an α-IGF-1R ScFv expressing E. coli culture were subjected to 
purification by Ni-NTA and interrogated with silver stained SDS-PAGE (left) and 
Western blotting with protein-L (right). The starting sample (load) without 1M urea 
(A) and with 1M urea (B) were passed through the Ni-NTA packed column with the 
unbound materials (Flow-through) retained. Non-specific binding proteins were 
removed by flowing binding buffer through the resin (Wash). The column was eluted 
by the addition of 250 mM imidazole in binding buffer (Elution).  
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4.3.5 Large scale Ni-NTA purification of ScFv from periplasmic extracts 
Once the conditions for the Ni-NTA purification process were optimised, a large 
scale expression and purification was conducted with the 4 ScFv clones as follows; 
each expression culture, consisting of 500 mL total volume, was harvested 9 h post 
induction by IPTG and a cell pellet obtained by centrifugation. The expressed ScFv 
housed in the periplasmic space of the E. coli was harvested by osmotic shock and the 
resulting extract dialysed against Ni-NTA binding buffer. Urea was added to a final 
concentration of 1M before the addition of pre-equilibrated Ni-NTA resin for batch 
chromatography. Samples were taken at each stage of the process to determine the 
efficiency of the purification process and were subjected to silver-stained SDS-PAGE 
analysis.  
 
The resulting gels (Figure 4-6) show all 4 ScFv could be purified to a high 
degree using Ni-NTA. In all 4 expressions, there was minimal protein found in the 
wash fraction, suggesting minimal non-specific interaction between the affinity resin 
and the crude sample, and also that any bound ScFv was strongly attached.  
 
Each ScFv clone exhibited a slightly different elution profile, with most ScFv 
found in the 2nd or the 3rd elution fractions. The positive elution fractions for each ScFv 
(A2: E2-3, B1: E3, F3: E1-3, IGF-1R: E2-3) were pooled and underwent dialysis 
against PBS overnight followed by filtration with a 0.22 µm device to sterilise the 
sample. Each ScFv was aliquoted and stored at -20 °C. 
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Figure 4-6: Purification of ScFv from E. coli periplasmic extracts using Ni-NTA.  
E. coli clones expressing ScFv α-αv-A2 (top left), B1 (top right) and F3 (bottom left) 
and α-IGF-1R (bottom right) were harvested and the periplasmic extracts obtained by 
osmotic shock. The samples were dialysed against Ni-NTA binding buffer overnight 
and urea was added to a final concentration of 1M. Each sample was incubated with 
Ni-NTA in batch purification. The column was washed once with Ni-NTA binding 
buffer. The bound protein was released using Ni-NTA elution buffer. L= Load, F = 
Flow-through, W= Wash, E1-E5 = Elution fractions 1-5.  
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4.3.6 Verification of the final Ni-NTA affinity chromatography purified ScFv 
The pooled, dialysed and filtered samples of the 4 purified ScFv were subjected 
to silver-stained SDS-PAGE and Western blot analysis to verify the identity and the 
purity of the final product. The results, shown in Figure 4-7, reveal all 4 ScFv were 
purified to a high degree (≥90%) when assessed using silver stained SDS-PAGE. 
Additional protein bands were detected in the α-IGF-1R ScFv sample, indicating the 
sample contained impurities. Western blot analysis using protein-L HRP demonstrated 
the protein bands observed in the silver-stained SDS-PAGE (~28 kDa) were reactive 
to protein-L, while the impurities found in the α-IGF-1R ScFv sample were not 
reactive, confirming their status as impurities. However, based on the staining intensity 
of the ScFv band in both SDS-PAGE and Western blot, the vast majority of the sample 
contained the α-IGF-1R ScFv.  
 
 
Figure 4-7: Verification of the final Ni-NTA purified ScFv by silver-stained SDS-
PAGE and Western blotting.  
Elution fractions from the Ni-NTA purification process which were positive for ScFv 
were combined and dialysed overnight against PBS. The ScFv solutions were filtered 
through a 0.22 µm syringe filter and samples were subjected to silver-stained SDS-
PAGE and Western blotting (protein-L HRP) analysis.  
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4.3.7 Improved purification using protein-L agarose 
During the process of Ni-NTA optimisation, alternative purification methods 
were simultaneously investigated in the hope of increasing yield while also improving 
purity and robustness of the purification process. One such alternative is another 
affinity approach utilising protein-L conjugated to agarose beads. Much like protein-
A, which has been used extensively in the purification of antibodies, protein-L binds 
to the immunoglobulin class of molecules, instead of a specific affinity tag. 
Specifically, protein-L binds to the kappa light chains of immunoglobins, which ScFv 
contain. It was not chosen as the primary purification method due to the considerable 
cost of obtaining the reagent. A 2 mL lot of protein-L agarose cost $478.40 AUD to 
purchase, which is considerably more than the Ni-NTA resin. Nevertheless, to test if 
the protein-L purification method would provide a significant improvement over Ni-
NTA, α-BSA control ScFv was purified using the standardised Ni-NTA procedure 
followed by re-processing of the Ni-NTA elution fraction with the protein-L 
purification strategy (section 4.2.11). The results were electrophoresed onto SDS-
PAGE and silver-stained (Figure 4-8).  
 
The result showed the protein-L affinity purification method can improve the 
purity of ScFv to a greater degree in comparison to Ni-NTA. Ni-NTA elution fraction 
2 is observed to contain two major protein bands. One is consistent with the molecular 
weight of ScFv (28 kDa), and another unknown band between 37 and 50 kDa. This 
elution fraction was reprocessed using protein-L affinity chromatography and the 
result showed that this higher molecular weight band was found in the flow-through 
and did not bind to protein-L. The protein-L elution fractions clearly contain a higher 
purity product as evident by the single band in lanes E2 and E3 (Figure 4-8). To further 
test the purity of the protein-L eluted fraction, the sample was concentrated using a 
microfuge protein concentrator with a molecular cut-off of 7.5 kDa. Any 
contaminating proteins that were below the detection limit of the silver stain in the 
elution fraction should also be enriched and become visible once the concentrated 
sample is interrogated. The resulting concentrated sample (lane ‘Conc elutions’ Figure 
4-8) did not exhibit any additional bands, indicating a very high level of purity was 
achieved using the protein-L affinity chromatography process.  
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Figure 4-8: Two step purification of α-BSA ScFv using Ni-NTA and protein-L 
conjugated agarose.  
The periplasmic extract containing the expressed ScFv was processed using Ni-NTA 
affinity chromatography. The resulting eluate fraction E2 was further processed by 
protein-L agarose affinity chromatography. The protein-L agarose elution fractions E2 
and E3 were combined and concentrated using a spin column concentrator (Conc 
elution). 
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4.3.8 Large scale purification of ScFv from medium using protein-L agarose 
Previous purifications were conducted using the periplasmic extract. Given that 
protein-L has shown improved binding of ScFv over the Ni-NTA based system, in 
addition to yield improvements, all subsequent ScFv batches were purified from the 
supernatant containing the expressed ScFv using protein-L as per section 4.2.11. 
Samples were taken from each step of the purification process, and the resulting silver-
stained SDS-PAGE (Figure 4-9) showed that a band corresponding to the correct 
molecular weight (28 kDa) was detected in the elution fractions, indicating that all 
three ScFv clones targeting the αv integrin (A2, B1, F3) were successfully purified.  
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Figure 4-9: Large scale purification of ScFv using protein-L agarose. 
E. coli supernatant from expression cultures of α-αv-A2, B1 and F3 ScFv were 
harvested by centrifugation. After overnight dialysis against PBS, samples were 
applied to protein-L agarose. The column was washed with 5 mL of PBS and eluted 
with protein-L elution buffer in 500 μL fractions and immediately neutralised with 50 
μL of protein-L antibody neutralisation buffer. Samples were separated using SDS-
PAGE and silver stained. L= load, F=Flow-through, W=wash, E1-E5 = Elution 
fraction 1-5. 
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4.3.9 Expression and purification of αIGF-1R ScFv using EnPresso® medium 
The EnPresso® B expression medium is a proprietary medium from BioSilta 
which guarantees a minimum 5-fold increase in yield in comparison to an E. coli 
expression culture using traditional LB medium. According to the patent document, 
the key technology driving this medium was termed enzyme-based fed-batch (EnBase) 
(Neubauer, Neubauer, & Vasala, 2010) which consists of a controlled release of 
glucose into the medium by breaking down a glucose-polymer enzymatically.  
 
To assess whether this medium can streamline the production of ScFv, an 
expression culture was conducted using EnPresso® B and the α-IGF-1R ScFv clone. 
The expression culture supernatant was harvested via centrifugation and passed 
through protein-L agarose. Samples were taken at each step of the purification process 
for analysis using silver-stained SDS-PAGE and Western blotting, with the result 
shown in Figure 4-10. The purification process was successful in purifying the ScFv 
in the 1st pass of the protein-L agarose with a single band of the expected MW (28 
kDa) in elution fractions 2 and 3 (E2 and E3). There was only a small decrease in the 
intensity of bands between the load and the flowthrough in the Western blot of pass 1, 
suggesting either that the binding efficiency was low, or that the resin had reached 
binding capacity. Therefore, the flow-through from pass 1 was reprocessed onto 
regenerated protein-L agarose. Again, samples were taken at each step and both the 
silver stained gel and Western blot shows pure ScFv was isolated predominantly in 
elution fractions 2 and 3. When comparing the load and the flow-through, there is a 
substantial reduction in band intensity, suggesting that indeed the binding capacity was 
reached in pass 1 and that a 2nd pass was required to isolate the majority of expressed 
protein. The positive elution fractions from pass 1 (E2, E3) and pass 2 (E2, E3) were 
combined and dialysed against PBS. The total yield obtained, as deduced by BCA 
protein estimation, from 100 mL of Enpresso Medium was 2.2 mg, which translated 
to a recovered yield from the supernatant to ~22 mg/L. Given that additional ScFv 
within the E. coli remains (periplasm), further purification could be performed by 
conducting a periplasmic extraction on the E. coli pellet and combining it with the 
supernatant.  
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Figure 4-10: Expression of α-IGF-1R ScFv using EnPresso® medium and 
purification using protein-L agarose 
The supernatant from α-IGF-1R ScFv expressing E. coli cultured using EnPresso® 
medium were flowed onto protein-L agarose. Samples were taken at each stage of the 
purification process and assessed using silver-stained SDS-PAGE and Western 
blotting (protein-L HRP). Given the large quantity of ScFv detected in the flow-
through of pass 1, it was flowed over protein-L agarose for an additional pass. 
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4.4 DISCUSSION 
The chapter herein described the successful expression and purification of the 4 
ScFv generated through the phage panning process detailed in Chapter 3. 
 
Carrying over from the selection of specific binding clones was the fact that 3 of 
the 4 contained an amber stop codon within the CDRH2 coding region. The presence 
of amber stop codons within the Tomlinson I & J libraries can be traced back to the 
methods of their mutagenic generation. The diversity of the Tomlinson phage display 
libraries (I+J) was generated by mutagenesis (Tomlinson & Winter, 2005). The CDRs 
of library ‘I’ have been generated using DVT triplets, targeting a total of 18 resides (D 
= adenine, guanine, thymine, V = adenine, guanine, cytosine, T = thymine). For library 
‘J’ CDR variation was generated by NNK triplet mutations (N = any base, K = 
cytosine, guanine). As a direct consequence of the NNK mutation scheme, there is a 
1/32 chance for insertion of an amber stop codon (TAG) into the CDR coding sequence 
(Cwirla, Peters, Barrett, & Dower, 1990), prematurely stopping the translation of the 
ScFv in non-suppression strains. Of the 4 ScFv candidates as a result of the phage 
display process, 3 contained an amber stop codon and each was successfully mutated 
by SDM to encode for glutamic acid in place of the amber stop codon (Section 4.3.1). 
Mutagenesis to glutamic acid was chosen to maintain homogeneity to the residue 
encoded by the amber stop codon in a suppressive E. coli strain as used during panning.  
 
The signal peptide pelB was successful in the transport of the expressed ScFv 
into the periplasmic place as evident by the success of the periplasmic extraction 
process (Figure 4-3). However, some ScFv was found to have ‘leaked’ into the 
supernatant. This is consistent with other studies which observed that protein destined 
for the periplasm could be detected in the supernatant (Kipriyanov, Moldenhauer, & 
Little, 1997; Ukkonen, Veijola, Vasala, & Neubauer, 2013). In some studies, only the 
periplasmic fractions were used while in others the supernatant and the periplasmic 
extracts were combined in the downstream purification processes, depending on their 
yield requirements (Das, et al., 2005; Patil, et al., 2015; Rouet, et al., 2012; Wang, et 
al., 2012). The periplasmic extraction process required several incubation steps 
followed by centrifugation. In contrast, isolation from the supernatant only required 
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the removal of the E. coli cells. In addition, there is also a reduction on E. coli host 
proteins using the supernatant as the starting material, minimising possible 
downstream contamination during purification steps.  Given the potential in the total 
recoverable ScFv in the supernatant in addition to the reduced purification steps, the 
periplasmic extraction procedure was abandoned in favour of purification directly 
from the supernatant. 
 
The Ni-NTA affinity purification process required extensive optimisation as the 
6x histidine tagged ScFv were not binding to the resin. After numerous repeats, it was 
determined that the addition of 1M urea to the periplasmic extract containing the 
expressed ScFv was required for it to bind to the resin. A possible explanation is that 
since ScFv is prone to form aggregates, such a structural arrangement potentially 
makes the histidine tag inaccessible and therefore cannot bind to the Ni-NTA resin. 
Urea is a potent denaturant and 8 M urea is commonly used for Ni-NTA purification 
under denaturing conditions. The 1 M urea used should not completely denature the 
ScFv but allowed the histidine tag to be accessible. A study by Chen et al. (2006) 
purified ScFv from E. coli inclusion bodies under denaturing conditions with 8 M urea. 
The protein was refolded with buffer containing 1 M urea and subsequent dialysis 
against PBS. Their refolding protocol yielded a high proportion (70%) of soluble 
product. Given that 1 M urea was used instead of 8 M, it is likely that the ScFv was 
not structurally damaged by the use of 1M urea.  
 
The formation of aggregates could be the reason why the PEG precipitation 
procedure was unsuccessful. To test for the presence of aggregates, various techniques 
could be employed, including size exclusion chromatography (SEC) using 
physiological buffers such as PBS or dynamic light scattering (DLS). Indeed, this will 
be undertaken in the next chapter. 
 
Two affinity purification resins were used for this project, Ni-NTA and protein-
L agarose. Even though the Ni-NTA purification system was able to purify ScFv to an 
acceptable level for additional characterisation, protein-L agarose was chosen in 
favour because it yielded a product with even greater purity, achieving a product at 
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>90% purity. Initially, Ni-NTA was selected because of the previous experience of 
using this system and also because of the reduced cost in comparison to protein-L 
agarose. As an example, 25 mL of Ni-NTA cost 686 AUD while 2 mL of protein-L 
agarose from Thermo Fisher cost 478.40 AUD, an 8.7 fold increase in the cost per mL 
for resin of protein-L compared to Ni-NTA sourced from Qiagen. Similar to protein-
L, another alternative that can be considered is protein-A, which can also bind to 
various immunoglobulin molecules, including ScFv (Forsgren & Sjöquist, 1966). 
Ultimately, protein-L was chosen as the immune-affinity purification method because 
of its higher binding strength to ScFv than protein-A (Sheng & Kong, 2012).  
 
Improvements in protein yield and the simplification of the antibody fragments 
expression are sort after in both research and commercial settings. Examples of such 
attempts are the introduction of additives including L-arginine and sucrose to the 
culture medium which have been shown to increase expression yield (Kipriyanov, et 
al., 1997; Schäffner, Winter, Rudolph, & Schwarz, 2001). EnPresso® was recently 
introduced as a novel expression medium for bacterial and yeast expression. The 
results were promising, with between 2 and 5 fold increases in expression of single-
domain antibodies (Ta et al., 2015; Zarschler, Witecy, Kapplusch, Foerster, & Stephan, 
2013). Within the current study the EnPresso® expression medium was able to induce 
α-IGF-1R ScFv expression to a final yield of ~22 mg/mL, which is much higher than 
the yield of ~4.954 mg/L of an α-IGF-1R ScFv batch using LB medium previously 
conducted within this study (results not shown). The lower yield of ScFv using LB 
medium agrees with the literature values of 1-5 mg/L for ScFv from the Tomlinson 
libraries (Rouet, et al., 2012). However, given the relative higher price of the medium 
in comparison to the 2xYT used throughout this chapter, the use of the EnPresso® 
medium might be situational rather than for general purpose. A use could be during 
clonal screening of numerous binding candidates, where small volumes of 
concentrated ScFv are required.  
 
Additional characterisation studies validating the expression process would be a 
valuable addition to the sample characterisation of the purified ScFv. For example, N-
terminal protein sequencing can be performed to ascertain if the cleavage of the pelB 
signal peptide from the mature ScFv was both successful and complete. This is 
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important as nonspecific signal peptide cleavage can occur at unexpected sites, 
generating potentially undesired ScFv heterogeneity (Kotia & Raghani, 2010). In 
addition to N-terminal sequencing, mass spectrometry can be included in the analysis 
workflow. Information that can be generated includes the molecular weight, the amino 
acid sequence and any degradation products (Mo, Tymiak, & Chen, 2013).  
 
The successful expression and purification of the phage display selected binding 
candidates has prepared the way for critical structural analyses. Experiments will be 
undertaken to test the isolated ScFv and determine binding affinity to their target in 
addition to assessment of structural homogeneity.  
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5.1 INTRODUCTION 
Numerous downstream quality control steps are performed on therapeutic 
monoclonal antibodies, including purity, identity, stability and structural integrity 
studies (Beck, Wagner-Rousset, Ayoub, Van Dorsselaer, & Sanglier-Cianférani, 
2013). While the purity of the generated ScFv were assessed and deemed acceptable 
in the previous chapter, SDS-PAGE analysis in a denaturing environment does not 
give a true indication of the native structural integrity of the ScFv sample. Proteins 
including IgG and their smaller fragments such as ScFv can form aggregates, as 
indicated by their non-native quaternary structure (Narhi, Schmit, Bechtold-Peters, & 
Sharma, 2012). There is a diverse range of protein aggregates that can be classified 
based on particle size, reversible or non-reversible, status of the conformation, 
covalent modification or morphology. Aggregation has the potential to affect the 
function and stability of therapeutic proteins, particularly antibodies (Wang, 2005). 
Given the potential impact of protein aggregates on function, additional structural 
studies using analytical size exclusion chromatography (SEC) were conducted to 
assess the structural characteristics of the purified ScFv under physiologically similar 
conditions. The detection and quantification of dimers, trimers and higher ScFv 
aggregates forms the basis of the SEC experiments. 
 
While there is no agreed maximum limit on product aggregation as some 
proteins might be safe, stable and functional with a certain percentage of aggregates, 
ScFv dimers/monomers will be monitored and quantified. Given the propensity of 
ScFv to form dimers (Nieba, Honegger, Krebber, & Plückthun, 1997; Rouet, et al., 
2012), it is expected that all of the ScFv samples will contain various amounts of dimer. 
The formation of dimers can be attributed to many factors, with some intrinsic to the 
inter-domain amino acid sequences (Zhao et al., 2010), while others can arise from 
changes in environment experienced during expression and purification (Telikepalli et 
al., 2014).  
 
In addition to SEC, another parameter which will be assessed is the elucidation 
of the binding affinity between the generated ScFv and its cognate target. The binding 
affinity constant (KD) is a function of on rate (ka) and off rate (kd) and confers particular 
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characteristics in vivo (Pompliano, Meek, & Copeland, 2006). For example, the longer 
the Kd, the longer that the antibody resides bound to the target. For example, a kd value 
of 10-5/s translates to a dissociating time of 18 h, which is ideal for a therapeutic 
designed to have a long retention time (Weiner & Adams, 2000). Conversely, it might 
be desirable for an antibody conjugated with a toxin to have a fast kd in order to deliver 
the payload and quickly dissociate. Therefore, the affinity of the ScFv samples will be 
compared to the affinity of commercially available antibody-based inhibitors to 
estimate the affinity range needed for function.  
The aims of this chapter are to: 
 Detect and assess the presence of monomers and dimers in the ScFv 
preparations using analytical SEC. 
 Determine the affinity of the ScFv to its target using the BIAcore system. 
 
5.2 EXPERIMENTAL PROCEDURES 
5.2.1 Materials 
A Superdex 75 10/300 GL size exclusion chromatography column was 
purchased from GE Healthcare. The molecular weight size standards BSA and 
carbonic anhydrase were obtained from Thermo-Fisher and Sigma-Aldrich 
respectively. All BIAcore reagents, including CM5 sensor chips, amine coupling kit 
and assay specific buffers were sourced from GE healthcare. All other reagents unless 
specified were purchased from Sigma-Aldrich and were of the highest grade.  
 
5.2.2 Analytical size exclusion chromatography  
To assess the structural heterogeneity of the purified ScFv samples in a 
physiological condition, analytical size exclusion chromatography using PBS as the 
mobile phase was conducted. ScFv samples of 50 µL were aliquoted into glass vials 
with a polypropylene insert and injected into a Superdex 75 10/300 GL column 
running on a Shimadzu Prominence HPLC instrument, in order to observe the 
molecular size separation of the sample. Initial optimisation experiments were 
conducted using PBS as the running buffer at an isocratic flow rate of 0.5 mL/min. 
Optimisation of the protocol resulted in all subsequent separation cycles conducted in 
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a high salt condition (PBS supplemented with additional NaCl [500 mM final]). The 
resolved proteins were monitored at both 214 nm and 280 nm wavelengths over a 
period of 40 minutes. To determine the molecular weight of the ScFv peaks, a 
calibration curve was generated by including the protein standard Bovine serum 
albumin (MW: 66 kDa) and carbonic anhydrase (MW: 29 kDa). The standards were 
separated in the same conditions as the samples and repeated three times. A blank 
sample consisting of low salt PBS was injected between each standard injection to 
monitor for protein retention by the column. The data collected was analysed using 
LabSolutions version 5.57 and exported to GraphPad Prism® version 6 and histograms 
generated. The portion of dimers and monomers were determined from the area under 
each peak expressed as a total percentage as calculated by the LabSolutions software.  
 
5.2.3 BIAcore 
The affinity of the interaction between the generated α-IGF-1R ScFv to IGF-1R 
and α-αv integrin ScFv to αvβ3 integrin were measured by Surface Plasmon 
Resonance (SPR) on a BIAcore X-100 instrument. Recombinant human IGF-1R (rh-
IGF-1R) or recombinant human integrin αvβ3 were coupled to the surface of 
individual CM5 sensor chips at pH 4.5 by amine coupling chemistry. In short, N-
Hydroxysuccinimide (NHS, 11.5 mg/mL) and 1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC, 75 mg/mL) were mixed at a 1:1 ratio and injected 
into both flow-cells at 10 µL/min for 420 s to activate the chip surface. The diluted rh-
IGF-1R or αvβ3 in 10 mM sodium acetate buffer, pH 4.5 was injected into flow-cell 
two at 10 µL/min. Even though both flow-cells one and two on the sensor’s surface 
were activated by NHS-EDC amine coupling reagents, only flow cell two was 
immobilised with protein as flow cell one was used as a reference surface. 
Ethanolamine hydrochloride was lastly applied over both flow-cells to deactivate 
remaining active NHS-esters for 420 s at 10 µL/min. The immobilisation level target 
of 260 RU was set for IGF-1R while for αvβ3 the target was set at 450 RU. The relative 
low level of target immobilisations was chosen to minimise the effect of mass transfer 
limitations (GE Healthcare, 2012). Kinetic runs were then conducted in a single cycle 
manner with 5 increasing concentrations of ScFv or antibody control (α-IGF-1R) 
injected sequentially over the sensor’s surface at a flow rate of 30 µL/min (Table 5-1). 
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Different concentration sets were used to assess if there were any concentration 
depended effects.  
 
Table 5-1: Concentration series of analyte used in BIAcore affinity experiments 
Analyte Ligand Concentration 
series 1 
Concentration 
series 2 
Concentration 
series 3 
IGF-1R 
ScFv 
IGF-1R 1500, 500, 166.66, 
55.55, 18.51 nM 
1000, 333.33, 
111.11, 37.03, 
12.34 nM 
 
IGF-1R IgG IGF-1R 50, 16.66, 5.55, 
1.85, 0.61 nM 
40, 13.33, 4.44, 
1.48, 0.49 nM 
30, 10, 3.33, 
1.11, 0.37 nM 
αv IgG αvβ3 70, 23.33, 7.77, 
2.59, 0.86 nM 
  
 
Each ScFv and control IgG were diluted in the BIAcore running buffer HBS-
EP+ (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v Surfactant P20), 
this buffer was also used for blank runs used for reference subtraction. The association 
time for each injection was set at 120 s with the final dissociation phase at 800 s. The 
resulting sensorgrams were double reference subtracted (fc 2-1 and blank injections) 
using the BIAevaluation software version 2.0.1. After each cycle, the surface was 
regenerated by flowing running buffer overnight to facilitate complete dissociation of 
the analyte. The affinity of antibody/antigen pair was calculated using the steady-state 
model within the BIA evaluation software.  
 
5.3 RESULTS 
5.3.1 Generation of a SEC molecular weight calibration curve 
To estimate the molecular weight of the ScFv peaks, protein standards were 
chosen based on their similarity in molecular weight to the calculated molecular weight 
of the ScFv (MW: 28 kDa) and its potential dimer (~56 kDa); Carbonic anhydrase 
(MW: 29 kDa) and BSA (MW: 66 kDa). The standards were resolved on the SEC 
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column (Figure 5-1) and monitored at 214 nm (Figure 5-1: A) and 280 nm (Figure 
5-1: B). The retention times at both wavelengths were identical, with the major peak 
at 17.25 ± 0.05 mins for BSA and two major peaks at 18.25 ± 0.04 and 21.49 ± 0.05 
mins for carbonic anhydrase. The first retention peak of carbonic anhydrase at 18.25 
± 0.04 mins is similar to the peak of BSA at 17.25 ± 0.05, suggesting that this peak is 
the dimerised form (58 kDa) whereas the peak at 21.49 ± 0.05 mins corresponds to the 
expected size for the monomer form. Given the three data points, a linear regression 
model was applied and the resulting R squared value of 0.99 suggests a high degree of 
linearity at the molecular weight tested.  
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Equation Y = -0.1134*X + 24.79
 
Figure 5-1: Size exclusion chromatography of reference proteins.  
Bovine serum albumin (MW: 66 kDa) and carbonic anhydrase (MW: 29 kDa) were 
separated independently using HPLC on a Superdex 75 10/300 GL column. The 
mobile phase consisted of PBS at a flow rate of 0.5 mL/min. Each run was monitored 
simultaneously at A) 214 nm and B) 280 nm over 40 mins. The raw data from three 
experiments were exported from LabSolutions version 5.57 and graphed using 
GraphPad Prism® version 6.0. C) The BSA peak (17.25 ± 0.05 mins) and carbonic 
anhydrase peaks (apparent dimer = 18.25 ± 0.04 mins, monomer = 21.49 ± 0.05 mins) 
were plotted against their molecular weights and a linear regression model applied.  
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5.3.2 Optimisation of SEC resolution of α-IGF-1R ScFv 
Once the molecular weight calibration curve was generated, a sample of the α-
IGF-1R ScFv was separated to assess the molecular weight pattern of the purified 
protein sample (Figure 5-2). The initial running buffer was PBS (Figure 5-2: A) 
which showed a poor resolution of separation as can be seen by the lack of sharp peaks. 
In addition, the chromatogram did not regress back to baseline, suggesting some non-
specific ionic-based interaction between the ScFv and the Superdex chromatography 
matrix (Arakawa, Ejima, Li, & Philo, 2010). Therefore, an additional run was 
performed where the PBS running buffer was supplemented with additional NaCl to a 
final concentration of 500 mM. The result (Figure 5-2: B) showed vastly improved 
peak separation and the ScFv separated into two distinct peaks at 17.79 ±0.031 and 
20.70±0.039 mins. In conjunction with the molecular weight standard curve from 
section 5.3.1, the first peak was determined to be the dimer form of the ScFv with a 
calculated MW of 61.72 kDa based on a retention time of 17.79 ± 0.031 mins. The 
second peak, with a retention time of 20.70 ± 0.039 mins, was calculated to represent 
a MW of 36.07 kDa. Therefore, this second peak was inferred to be the ScFv monomer, 
based on the similarity when in comparison to the expected MW of 28.3 kDa.  
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Figure 5-2: Size exclusion chromatography of α-IGF-1R ScFv.  
Samples were separated on a Superdex 75 10/300 GL column using HPLC. The mobile 
phase consisted of A) PBS and B) PBS supplemented with high salt (total 500 mM 
NaCl) at a flow rate of 0.5 mL/min. The higher salt concentration in the mobile phase 
reduced the charge interaction between the ScFv and the Superdex stationary phase, 
allowing for separation between the monomers and dimers. Each run was monitored 
over 40 mins at both 214 nm (green) and 280 nm (black).  
 
 Retention 
Time (mins) 
Calculated Size 
(kDa) 
Expected size 
(kDa) 
Possible 
Identity 
Peak 1 17.79 ± 0.031 61.72 56.6 Dimer 
Peak 2 20.70 ± 0.039 36.07 28.3 Monomer 
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5.3.3 Fractionation of α-IGF-1R ScFv 
To confirm the identity of the two major peaks during the separation of the IGF-
1R ScFv by SEC, fractions were collected over the course of the run (Figure 5-3). 
Four fractions were collected overall, with E1 and E2 representative of the larger dimer 
while E3 and E4 included the suspected monomer form of α-IGF-1R ScFv (Figure 
5-3:A). The collected fractions (E1-E4) were interrogated by SDS-PAGE and silver 
stained. The resulting gel (Figure 5-3:B), run under denaturing conditions, 
demonstrated that there was no discernible difference in molecular weight (~28 kDa) 
between the monomer and dimer fractions. These data suggest that the observed 
difference in retention time in (Figure 5-3:A) is due to transient interactions among 
ScFv between the VH and VL of two or more ScFv molecules rather than a mixed 
population of single molecule ScFv with different molecular weights. To confirm that 
the fractionation process was successful, the monomer fractions (E3-E4) were 
combined and re-analysed by SEC. The result (Figure 5-3:C) contained only one 
elution peak equivalent to the monomer derived previously, demonstrating that the 
SEC process was successful in obtaining the monomer fraction within the ScFv 
sample.  
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Figure 5-3: Fractionation of α-IGF-1R ScFv monomers and dimers using HPLC.  
A) α-IGF-1R ScFv were separated using SEC and collected as four elution fractions 
(E1-E4). B) The dimer (E1-E2) and monomer population (E3-E4) were resolved on 
SDS-PAGE and silver stained. C) Fraction E3 and E4 were combined and analysed 
using SEC to confirm the fractionation of monomer within the sample. Each run was 
monitored over 40 mins at both 214 nm (green) and 280 nm (black).  
 
 110 Chapter 5: Biophysical characterisation 
5.3.4 SEC characterisation of α-αv ScFv 
The three purified α-αv ScFv (A2, B1, F3) were resolved using SEC to assess 
the molecular weight pattern of the protein sample. The resulting chromatograms 
(Figure 5-4) demonstrate that all three ScFv were successfully resolved by SEC under 
pseudo-physiological conditions and were separated into two major peaks with similar 
retention times compared to α-IGF-1R. For ScFv sample A2, the two major peaks 
could be detected at a retention time of 17.53 and 20.475 mins, B1 at 17.9 and 
20.233mins and for F3, 17.79 and 20.68 mins. Based on the MW calibration curve 
(Figure 5-1 C), the first major peak represents the dimer population (56 kDa) while 
the second major peak represents the monomer fraction (28 kDa). The area under both 
curves were determined using the LabSolutions software expressed as a % area, which 
directly correlates as the proportion of dimers and monomers. All three ScFv 
candidates contained >50 % monomer ScFv; with A2 containing 54.71%, B1 - 64.27% 
and the F3 clone containing the highest ratio of monomer  at 71.13 %.  
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Figure 5-4: Characterisation of α-αv ScFv by SEC.  
α-αv ScFv samples (A2, B1, F3) were separated on a Superdex 75 10/300 GL column 
using HPLC. The mobile phase consisted of PBS supplemented with higher salt (total 
500 mM NaCl) at a flowrate of 0.5 mL/min. Each run was monitored over 40 mins at 
both 214 nm (green) and 280 nm (black). The integrative area for each peak is 
expressed as a percentage of the total area when observed at 280 nm. 
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5.3.5 Affinity of α-IGF-1R ScFv to IGF-1R 
To determine the affinity between α-IGF-1R ScFv and its target, IGF-1R, 
BIAcore experiments were conducted. The recombinant IGF-1R was immobilised 
onto a CM5 sensor surface using amine coupling to a density of 452 RU. The affinity 
of a commercially available α-IGF-1R IgG antibody to IGF-1R was also measured in 
order to both act as a positive control and also as an affinity strength reference. For 
kinetic analyses, concentration series of ScFv or positive control IgG were flowed over 
the immobilised IGF-1R. The resulting double referenced sensorgram (Figure 5-5) 
showed that both the ScFv and IgG control can bind to IGF-1R. The response from 
each injection of α-IGF-1R IgG was plotted against concentration (Figure 5-5: A1) 
and a curve fit using a steady-state affinity model was applied. The calculated affinity 
(KD) between α-IGF-1R IgG and IGF-1R from three experiments was 3.2x10-8 ± 
1.31x10-8 M. The affinity of the α-IGF-1R ScFv (Figure 5-5: B1) was calculated in 
the same manner as the IgG control, with the resulting response from each injection 
plotted against concentration (Figure 5-5: B2). The calculated KD between α-IGF-1R 
ScFv and IGF-1R was 2.58x10-7 ± 3.236x108 M. There was an ~8 fold difference in 
affinity between the commercial IgG and the ScFv.  
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Figure 5-5: BIAcore affinity determination of ScFv and IgG targeting IGF-1R.  
Representative sensorgrams of: A:1) Five increasing concentrations of a commercial 
α-IGF-1R IgG was sequentially flowed over IGF-1R A:2) The resulting response 
plotted against concentration and steady state affinity model was applied. B:1) Five 
increasing concentrations of α-IGF-1R ScFv was also sequentially flowed over IGF-
1R B:2) The resulting response plotted against concentration and steady state affinity 
model was applied. C) The KD values for three experiments were exported from 
Biaevaluation 2.0.2 and the mean ± SEM were graphed using GraphPad Prism® 
version 6.0.  
 
Mean
ScFv IGF-1r (KD, M)
2.580e-007
IGF-1R IgG (KD, M)
3.200e-008
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5.3.6 Affinity of α-αv integrin ScFv to αvβ3 integrin 
In a similar manner to the IGF-1R BIAcore experiments, the affinity of αv 
integrin targeting ScFv to αvβ3 was determined using BIAcore analysis. Recombinant 
αvβ3 was immobilised onto a CM5 sensor surface using amine coupling to a density 
of 260 RU. A concentration series of a commercial α-αv IgG antibody (Table 5-1) was 
flowed over the immobilised αvβ3 in a single cycle manner. The IgG antibody was 
chosen as the positive control to assess αvβ3-Ab binding response and also as an 
affinity reference to the generated ScFv. The resulting double referenced sensorgrams, 
(Figure 5-6A) showed that the control IgG did bind to αvβ3 and the response from 
each IgG injection was plotted against concentration (Figure 5-6B). From three 
independent experiments, the steady-state affinity model was applied to the binding 
responses and the calculated KD was 2.589 x 10-8 ± 4.866 x 10-9 M. The 3 generated 
ScFv targeting αv were also flowed over αvβ3. The initial affinity runs did not result 
in any response, therefore, to demonstrate non-binding, a high concentration of each 
ScFv (1 μM) was injected over αvβ3. Even at this higher concentration, there was a 
continued trend on non-binding for all three ScFv against αv integrin (Figure 5-6C-
E). 
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Figure 5-6: BIAcore analysis of αv targeting ScFv and IgG to αvβ3 integrin.  
Representative sensorgrams of: A) Five increasing concentrations of a commercial αv 
targeting IgG was sequentially flowed over immobilised αvβ3. B) The resulting 
response plotted against concentration and steady state affinity model was applied with 
the resulting affinity (KD) from three experiments expressed as ±SEM. C, D and E) 
High concentration (1 μM) of each ScFv was flowed over αvβ3. 
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5.4 DISCUSSION 
This chapter set out to characterise the structural heterogeneity of ScFv 
expressed and purified in the preceding chapters. It is important to establish the 
samples structural state/s as the presence of aggregate has the potential to impact 
function. Dimerised ScFv could be detected in all ScFv samples, ranging from a low 
of 27% for sample α-αv integrin-F3, to a high of 39% for α-αv integrin-A2 (Figure 
5-4). The propensity of ScFv to form dimers is widely known in the literature. ScFv 
have been engineered with a modified linker sequence length which favours the 
formation of ScFv heterodimers termed diabodies (Asano et al., 2008). In this case 
however, the dimerised ScFv were fully functional and shown to bind to their 
respective target with equivalent capacity as the monomeric form (Asano, et al., 2008). 
Indeed, a study has revealed that the length of the linker sequence between the VH and 
the VL domains plays a key role in the formation of higher order structures (Völkel, 
Korn, Bach, Müller, & Kontermann, 2001). By reducing the length of the linker from 
15 amino acid (aa) residues (as found in ScFv used within this study) higher order 
structures such as diabodies (9 aa), triabodies (5 aa) and tetrabodies (1 aa) can be 
generated. Given that the ScFv generated within this study contained a linker length 
of 15 aa, it is unlikely that the dimer detected are defined diabodies.  
 
Therefore, the potential impact of dimers on function still needs to be determined 
and assessed. Obviously, if the dimerised ScFv were found to be non-functional this 
would have a significant impact on effective yield, require further processing (to 
remove or refold the dimers) and/or necessitate higher sample concentrations in 
functional applications. Ideally the ScFv should be fractionated using preparative SEC, 
however, the analytical HPLC instrument used has a maximum injection volume of 
100 μL, which is problematic in processing larger volumes. Also, given that SEC 
considerably dilutes the recovered proteins in the elution fractions, the ScFv load 
solution should be at a high concentration, which has inherent problems since 
aggregation is concentration-dependent (Zhao et al., 2011)  
 
The affinity between the generated ScFv against IGF-1R (KD= 2.58 x 10-7 ± 
3.236 x 10-8 M) was approximately 8 fold weaker than the commercially available IgG 
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inhibitor (KD= 3.2. x 10-8 ± 1.31 x 10-8 M). However, an antibody with high affinity 
does not necessarily translate to an ideal tumour targeting agent, mainly because of 
their poor tumour penetration (Adams et al., 2001). The poor tumour penetration is 
due to a low dissociation (kd) rate, therefore limiting available antibody for binding 
once the initial antibodies have bound to the tumour’s surface and causing 
heterogeneous distribution. The term ‘binding site barrier’ effect has been termed to 
describe this process (Juweid et al., 1992). For example, a study by Adams, et al. 
(2001) performed a biodistribution study on mice with anti-HER-2/neu ScFv mutants, 
with various affinities ranging from 10-7 to 10-11 M, it was concluded that tumour 
retention did not increase with affinity beyond 10-9 M. It is therefore suggested that 
additional parameters such as avidity and specificity should also be considered in 
addition to affinity (Rudnick & Adams, 2009).  
 
Even so, the affinity of the IGF-1R targeting ScFv could be improved by the 
process of affinity maturation, a process traditionally applied to B-cell antibody 
selection and enrichment (Tangye, Ma, Brink, & Deenick, 2013). Through somatic 
hypermutation of the antibody encoding variable regions, B-cells which express high 
affinity antibody to the target antigen are positively selected and enriched. The in vitro 
affinity maturation process using phage display aims to mimic this process; starting 
with a selected clone, mutations are introduced into the variable encoding regions of 
the antibody gene, followed by additional selection procedures. Mutagenesis methods 
such as error-prone PCR, E. coli mutant strains and site-directed mutagenesis have all 
been used to introduce mutations into the antibody coding sequence and therefore 
increasing antibody diversity for additional selections (Kim, Stojadinovic, & Izadjoo, 
2014). Other non-mutagenic methods are based on the shuffling of the antibody coding 
sequences, such as chain shuffling, DNA shuffling, and CDR shuffling (Mandrup, 
Friis, Lykkemark, Just, & Kristensen, 2013; Rojas et al., 2004).  
 
Antibodies which have undergone the affinity-maturation process can have a 
substantial increase in affinity (Ahmed et al., 2015; Petters, et al., 2015; Wang et al., 
2011). Another study, using PCR based mutagenesis of clones generated from the 
same phage library (Tomlinson I + J) used in this project, described a modest 2 fold 
increase (387 nM to 185 nM) in KD and 6 fold decrease of the off rate (7.63 x 10-2 1/s 
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to 1.23 x 10-2 1/s) (Petters, et al., 2015). On the other hand, using a similar technique, 
the affinity of a ScFv targeting a tumour-inhibitory ligand was increased 160 fold to a 
KD of 0.9 nM (from 144 nM) (Ahmed, et al., 2015).  
 
The response between αvβ3 and the positive control IgG αv targeting antibody 
was low, suggesting the surface was not fully functionalised in an active state. From a 
theoretical perspective, the maximum response (Rmax) of any interaction can be 
calculated using the formula: 
    	(  ) = 	
       	  
      	  
	×           	      	     	(  ) 
Given that ~260 RU of αvβ3 was immobilised, the theoretical Rmax: 
    	(  ) = 	
   	(155	   )
αvβ3	(191.3	kDa)	
	× 260	(  ) = 210	   
Even though the calculated Rmax value of 210 RU is only theoretical, in practice 
when using amine coupling a response in the region of 70% of the Rmax can be 
achievable (GE Healthcare, 2012). The response reached between αv and the IgG 
antibody was much lower than 210 RU, suggesting that the αvβ3 immobilised to the 
sensor’s surface was not fully active, caused potentially by the amine coupling 
procedure, or by structural issues with the recombinant protein. Even though integrins 
in cells require bivalent cations such as Mg2+ or Mn2+ for structural stability and 
function, the addition of 1 mM Mg2+ and Mn2+ to the HBS running buffer did not 
increase binding response (Appenix 11). 
 
The binding interaction model originally chosen to assess the binding of control 
IgG/ScFv to their cognate target using BIAcore was the 1:1 binding kinetics model. In 
contrast to the steady-state affinity model used for this project, the 1:1 binding model 
allows for the determination of the rate constants, association (ka) and dissociation (kd), 
from which the affinity constant (KD) could be calculated. Both the ka and kd allow for 
better assessment of binding than simply an end point value. Given that the kinetics 
model was the preferred option, the steady-state affinity option was chosen instead 
because the IGF-1R ScFv sensorgram (Figure 5-5:B1) did not fit the 1:1 model. Given 
that the binding of ScFv to IGF-1R was expected to be a 1:1 interaction, optimisation 
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studies were conducted which ruled out two-state interaction (data not shown). 
Therefore, all BIAcore runs were analysed using the steady-state model. It is likely 
that given the presence of dimers in each ScFv sample, fractionation of the monomers 
using SEC could improve response fitting to the 1:1 model. However, since SEC 
dilutes the input sample considerably, this option was not investigated further for this 
project due to the substantial time investment required to produce sufficient quantities 
of ScFv for fractionation and subsequent BIAcore analyses. 
 
The decision of using a steady-state affinity model could also have an impact 
when comparing the calculated KD between the intact IgG/IGF-1R (KD= 3.2. x 10-8 ± 
1.31 x 10-8 M) and the α-IGF-1R ScFv/IGF-1R (KD= 2.58 x 10-7 ± 3.236 x 10-8 M). 
The main factor to consider was avidity effects caused by the potential of a IgG 
antibody binding to two IGF-1R molecules simultaneously. Avidity effects will slow 
down the dissociation rate of the IgG/IGF-1R interaction, leading to an overestimation 
of the KD value (Klein et al., 2009). In the BIAcore assay format chosen, avidity will 
play a role with the full Ab but not with the ScFv. In an attempt to counteract the effect 
of avidity, experiments were conducted using low ligand immobilisation levels (IGF-
1R). However, potentially the difference in affinity between the full Ab and the ScFv 
is lower than the 8 fold as calculated.  
 
The heterodimer αvβ3 was chosen for affinity analysis preferentially over the 
integrin subunit αv even though the phage panning process enriched for only αv 
binders. This was because integrins exist in nature as a heterodimer consisting of one 
α subunit and one β subunit. If panning were performed using αvβ3 as the target, ScFv 
binding the β3 may have been selected, something that would have been deleterious to 
the aim of generating pan-αv binding ScFv. In addition, αvβ3 was readily available 
and substantially cheaper to obtain and thus fit the requirements for the BIAcore 
analyses. Also, the binding affinity between αv targeting ScFv and αvβ3 is more 
physiologically relevant than between only the αv subunit and ScFv. However, it was 
soon discovered that even when injecting high concentrations of ScFv over αvβ3, there 
was a lack of response observed. One possible explanation was that the αv binding site 
for the ScFv was obscured by the β subunit. Therefore, given the lack of a response 
from the αv ScFv candidates against αvβ3, the next logical step was to assess if the 
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ScFv can bind to the αv monomer. It was expected that the ScFv should bind because 
the phage panning process enriched for αv binders and this binding has been confirmed 
by ELISA. Surprisingly, the αv protein failed to immobilise onto the BIAcore sensor 
chip using amine coupling chemistry (data not shown). Up to this point there was no 
reason to doubt the integrity of the recombinant αv protein. The protein was sourced 
from a reputable company in which the protein was expressed using their proprietary 
technology, with their own quality control. In addition, antibody screening was listed 
as one of the applications for this protein (Appendix 11). Given the spurious results 
of the α-αv ScFv and the lack of immobilisation of the αv protein onto the BIAcore 
sensor chip, the protein was subjected to analysis by silver-stained SDS-PAGE and 
Western blotting (Appendix 12). The results showed that the αv protein contained a 
high portion of aggregates creating a high MW smear on the silver-stained SDS-
PAGE. In addition, no immune-reactive bands could be detected when interrogated 
with an α-αv antibody in Western blotting (Appendix 12). Given the SDS-PAGE and 
Western blotting results, along with the amine coupling failure, there is a strong 
indication the recombinant αv integrin used for phage panning might not be 
representative of αv structure in vivo. The rationale for using αv monomer in phage 
display screening rather than the heterodimer was that it was hoped that a pan-αv 
inhibitor could be generated. Because the 3 ScFv generated against αv demonstrate no 
binding affinity against αvβ3 in BIAcore studies (Figure 5-6), it potentially points to 
lack of inhibitory function.  
 
The chapter herein described the biophysical assessments of the isolated ScFv 
for their properties. All 4 ScFv contained a majority of monomers when interrogated 
using SEC. The α-IGF-1R ScFv showed the most potential, with a high portion of 
monomers (Figure 5-2) in addition to quantifyable binding affinity to IGF-1R (Figure 
5-5). The next chapter will use cell-based assays to assess the inhibitory function of 
the ScFv in the relevant setting of tumour growth and metastasis.  
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 Functional characterisation 
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6.1 INTRODUCTION 
The tumour micro-environment (TME) and its interaction with growth factors 
(GFs) and the extracellular matrix (ECM) plays an important role in tumour cell 
biology. One such interaction is between the insulin like growth factor (IGF) and 
integrin axes. The insulin-like growth factor (IGF) system consists of ligands (IGF-I 
and IGF-II), receptors (IGF-1R, IGF-2R) and IGF binding proteins (IGFBP 1-6). Upon 
receptor ligand binding, the receptor is autophosphorylated leading to downstream 
signal transduction and activation of mitogenic pathways such as PI3K/AKT and 
MAPK/ERK. In breast cancer, several abnormalities in the IGF family can be found, 
including an increase in IGF-I and IGF-II ligands (Hankinson et al.), a decrease in 
IGFBP (Hoeflich & Russo, 2015), and altered IGF-1R expression. Recently, it was 
found through mRNA analysis that over 45% of breast cancer samples showed a 
molecular alteration in at least one member of the IGF system (Farabaugh, et al., 2015). 
Antibodies that are targeting the IGF-1R have been demonstrated in vitro to inhibit 
cancer cells lines (Burtrum, et al., 2003; Hollier, et al., 2008; Lu et al., 2004) 
 
Cell migration is a key step in the progression of malignant cells from a primary 
localised tumour to an invasive metastatic phenotype (Vinci, Box, Zimmermann, & 
Eccles, 2013). This is mediated by the interaction of extracellular matrix proteins such 
as vitronectin with its cognate integrin receptor. It has been demonstrated that there is 
crosstalk between the IGF associated tyrosine phosphatase SHP-2 and the focal 
adhesion kinase which plays a role in cell migration, and survival (Beattie, McIntosh, 
& van der Walle, 2010; Mañes et al., 1999; Zheng et al., 2009).  
 
The breast cancer cell line MCF-7 has been widely used as a cancer model for 
studying the role GFs and integrins in relevant cell processes (Hollier, et al., 2008; 
Kashyap, et al., 2011). Even though the MCF-7 cell line has been extensively used as 
a breast cancer model, it is particularly suited to application herein because it expresses 
both IGF-1R and the αv integrins αvβ3 and αvβ5. In addition, in vitro studies have 
revealed that MCF-7 cells in basal medium have a low propensity to migrate and attach 
to tissue culture plastic. Therefore, functional effects observed when investigating cell 
migration and attachment are confidently attributable to the treatment.  
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Transwell® assays, or Boyden chamber assays (Chen, 2005), have been used to 
determine the migration response of MCF-7 upon simulation with VN+IGF-I, and 
subsequent blunting of VN+IGF-I response by blocking their cognate receptors with 
ScFv or control antibodies. Newer methods of measuring cell migration exist, such as 
the real time cell monitoring xCELLigence RTCA-DP instrument. Given the extensive 
literature on MCF-7 migration using the established Transwell® assays, this assay was 
opted as the method of choice for this project (Hollier, et al., 2008; Kashyap, et al., 
2011; Van Lonkhuyzen, et al., 2007).  
As described in the previous chapter, phage display screening yielded one IGF-1R and 
three αv binding candidates. These candidates were subsequently expressed and 
purified to a high degree of purity. The next step of this project was to assess the 
inhibitory function of the ScFv in a breast cancer cell line MCF-7 upon stimulation by 
IGF-I and VN. To do so, MCF-7 cells were treated with the generated ScFv along with 
commercially available receptor blocking monoclonal antibodies in proliferation, 
attachment, and migration assays. 
 
The aim of this chapter was to: 
 Assess the functionality of the ScFv in cell based assays to determine if 
it can inhibit the metabolic activity, attachment, and migration when 
induced with IGF-I and VN.  
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6.2 EXPERIMENTAL PROCEDURES 
6.2.1 Materials 
All reagents, unless stated, were purchased from Sigma-Aldrich and are of the 
highest quality. Transwell® plates containing 8.0 µm pore size insert for migration 
assays were obtained from Corning (Mount Martha, Vic, Australia). The CellTiter 96® 
AQueous One proliferation assay was sourced from Promega (Madison, USA). 
Human VN purified from serum was purchased from Promega while recombinant 
human IGF-I produced in E. coli was obtained from GroPep (Adelaide, SA, Australia). 
Commercially available receptor blocking monoclonal antibodies against IGF-1R 
(αIR3) and αv integrin (AV 1) were sourced from Merck Millipore. Isotype control 
mouse IgG antibody (G3A1) was bought from Cell signalling (Beverly, MA, USA).  
 
6.2.2 Cell culture 
The human breast adenocarcinoma cell line MCF-7 (ATCC: HTB-22) was 
routinely cultured in growth media (GM) containing Dulbecco’s Modified Eagle 
Medium/F12 (1:1 DMEM/F12) supplemented with 10% fetal bovine serum (FBS), 0.1 
mg/mL streptomycin, 50 units/mL penicillin, 1 μg/mL gentamicin. The cell line was 
maintained in a humidified incubator at 37 °C with 95% air and 5% CO2 with a change 
of media every 3-4 days or upon 80% confluence, at which point cells were passaged 
at a ratio of 1:3. Cells were detached from the tissue culture flasks using TrypLE™ 
Express, a trypsin replacement dissociation agent. All functional assays were 
performed using serum free media (SFM) supplemented with 0.05% (w/v) bovine 
serum albumin (BSA).  
 
6.2.3 Metabolic assay 
The CellTiter 96® AQueous One proliferation assay is based on the conversion 
by viable cells of the tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS into a 
coloured formazan product. This coloured product is measured spectrophotometrically 
and correlates to metabolically active cells. MCF-7 cells were passaged the day before 
the assay at a ratio of 1:1 and cultured in GM in a humidified incubator at 37 °C with 
95% air and 5% CO2. The cells were then serum starved for 4 h by aspirating the GM, 
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washing twice with PBS, before the addition of SFM. A series of treatments including 
a commercial IGF-1R blocking antibody, matched isotype control and increasing 
concentrations of IGF-1R targeting ScFv were set up in SFM+0.05% BSA. Serum 
starved MCF-7 cells were dissociated from the culture flask using TrypLE™, 5,000 
cells added to each treatment within a microfuge tube and allowed to incubate at room 
temperature for 30 mins. After this incubation period, the treated cells were transferred 
into individual wells of a 96 well plate and stimulated with or without VN at a final 
contraction of 1 µg/mL and IGF-I at 30 ng/mL. The treated cells were incubated at 37 
°C with 5% CO2 for 24 h, at which time 20 µL of CellTiter 96® AQueous One Solution 
Reagent was added into each well and a further 1.5 h incubation at 37 °C was 
performed for the formation of the coloured formazan product. The absorbance of each 
well was measured at 490 nm using the Benchmark Plus microplate spectrophotometer 
(Bio-rad).  
 
6.2.4 Migration assay 
To investigate the effect of ScFv as inhibitors of VN and IGF-I dependent 
migration, a Transwell®-based assay was performed. MCF-7 cells were passaged the 
day before the assay to maintain cells in the proliferative phase. On the experiment 
day, cells were serum starved by aspirating the GM, twice washing with SFM and 
incubating with SFM for an additional 4 h. During the SFM incubation, the lower 
chambers of the Transwell® plates were incubated with both IGF-I (30 ng/mL) and 
VN (1 µg/mL) diluted in SFM+0.05% (w/v) BSA. The serum starved cells were 
harvested by washing the monolayer with PBS/EDTA followed by TrypLE™ 
application. In a similar approach to the metabolic assay, treatments of commercial 
IGF-1R or αv integrin function blocking antibody along with the unique ScFv clones 
generated from phage display were diluted in SFM+0.05% BSA to concentrations of 
10 μg/mL for the IGF-1R IgG and 5 μg/mL for the αv integrin antibody. For the ScFv 
treatments, a concentration range from 10 - 100 μg/mL was generated. The serum 
starved MCF-7 cells were added at 60,000 cells per treatment, in microfuge tubes, and 
allowed to incubate with the antibody-based treatments for 0.5 h at room temperature 
before seeding into the upper chamber of a Transwell®. Plates were then incubated for 
15 h at 37 °C with 5% CO2 within a humidified incubator. At the completion of the 
migration period, the non-migrated cells were physically removed from the upper 
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surface of the semi-porous Transwell® membrane by cotton buds in a circular motion. 
Cells which had migrated to the lower surface of the membrane were fixed in ~3.7% 
formaldehyde and stained with 0.01% (w/v) crystal violet in PBS. To quantify 
migrated cells, the crystal violet was extracted from the stained cells using 10% (v/v) 
acetic acid and subsequently transferred into a 96 well plate. The absorbance was 
measured at 595 nm using the Benchmark Plus microplate spectrophotometer.  
 
6.2.5 Attachment assay 
MCF-7 cells were passaged the day before the assay to synchronise the cell 
cycles before serum starving for 4 h by aspirating the GM, washing twice with SFM 
and finally incubating with SFM for the starvation period. Treatments targeting the αv 
integrin and antibody controls were diluted in SFM+BSA at various concentrations. 
Serum starved cells were harvested by aspirating the SFM, washing once with 
PBS+EDTA before the addition of TrypLE™. The detached MCF-7 cells were added 
at 20,000 cells per treatment and incubated for 30 mins at room temperature. During 
this incubation, a 10x solution of IGF-I and VN (300 ng/mL, 10 μg/mL) was made and 
added to individual 96 well plate wells. After the 30 mins incubation, the treated cells 
were seeded into the IGF-I+VN containing 96 well plate and incubated for 30 mins at 
37 °C with 95% air and 5% CO2 to allow for cell attachment. Cells which have not 
attached after this period were aspirated, and washed twice with PBS. The cellular 
attachment was determined by the addition of 100 μL of SFM + 20 μL MTS reagent 
to each well and incubating for 1.5 h at 37 °C with 95% air and 5% CO2 for the 
conversion of MTS into a coloured product. This product was quantified at 490 nm 
using the Benchmark Plus microplate spectrophotometer.  
 
6.2.6 Isolation of functional Insulin-like growth factor receptor 
MCF-7 Cell lysis 
MCF-7 cells were grown until 80% confluent in growth media (GM) containing 
Dulbecco’s Modified Eagle Medium/F12 (DMEM/F12) supplemented with 10% fetal 
bovine serum (FBS), 0.1 mg/mL streptomycin, 50 units/mL penicillin, 1 μg/mL 
gentamicin. The cultures were maintained in a humidified incubator with 5% CO2 and 
95% atmospheric air at 37 °C. The cells were serum starved for 4 hours by firstly 
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removing the old media, washing once with PBS, then adding SFM. After 4 hours, the 
media was aspirated and 2 mL of non-denaturing lysis buffer consisting of 50 mM Tris 
(pH 7.4), 100 mM NaCl, 1% (v/v) Triton X-100 and complete protease inhibitor 
(Roche) was added to each of the T-175 flasks. The cells were harvested from the cell 
culture flasks using cell scrapers and transferred into pre-chilled low protein binding 
microfuge tubes. To assist with cell lysis, the samples were immersed in a sonication 
water bath at 4 °C for 5 mins. The tubes were then centrifuged at 14,000 g for 20 mins 
and the supernatant was retained and stored at -80 °C for protein quantification and 
purification.  
 
Cell lysate quantification of protein content 
The protein concentration of the cell lysate was estimated using the the 
Bicinchoninic Acid (BCA) protein assay kit (Pierce) as per the manufacturer's 
instruction. BSA was diluted in PBS to form a concentration range from 125 µg/mL 
to 2000 µg/mL and was used as the protein concentration reference. The BCA reaction 
plate was read at 562 nm using the Biorad benchmark plus microplate 
spectrophotometer system. The resulting data was curve fitted using the Microplate 
Manager Software version 6.2 (Biorad) 
 
Wheat Germ Agglutinin purification 
Wheat Germ Agglutinin (WGA) conjugated to agarose beads were used to enrich 
for the glycoprotein IGF-1R from MCF-7 cell lysates. The beads were firstly washed 
in PBS to remove the N-acetyl-D-glucosamine (GlcNAc) from the storage buffer. 
MCF-7 cell lysates containing 24 mg of protein in 10 mL were added to the 1 mL of 
equilibrated beads and mixed overnight at 4 °C. The lysate/bead mixture was slowly 
transferred into a disposable column and beads allowed to settle. Once the sample 
passed through, 5 mL of wash buffer consisting of 50 mM Tris (pH 7.4), 100 mM 
NaCl, 0.1% Triton X-100 and complete protease inhibitor (Roche) was added to the 
top of the resin. To elute the bound proteins, elution buffer containing 50 mM Tris (pH 
7.4), 100 mM NaCl, 0.1 % (v/v) Triton X-100, and 500 mM GlcNAc was added. Eluted 
fractions were collected in 0.5 mL increments and stored at -80 °C. 
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6.2.7 SDS-PAGE and Western immunoblotting 
Samples collected throughout the purification process were prepared for 
electrophoresis by the addition of NuPAGE® LDS sample buffer and reducing agent 
to a final concentration of 141 mM Tris base, 2% LDS, 10% Glycerol, 0.51 mM 
EDTA, 0.22 mM SERVA Blue G, 0.175 mM Phenol Red, 50 mM DTT, pH 8.5 and 
heated at 70 °C for 10 mins. The protein samples were separated based on molecular 
weight on a precast NuPAGE® 4-12% SDS-PAGE gel with NuPAGE® MES-SDS 
running buffer. The electrophoresis proceeded at a constant 200V for 35 mins. SDS-
PAGE separated proteins were transferred onto a nitrocellulose membrane using the 
wet tank blotting system (Biorad) containing Towbin buffer (25 mM Tris, 192 mM 
glycine, 20% v/v methanol) at a constant 200 mA for 90 mins. The blot was blocked 
for 1 h at room temperature with 5% (w/v) BSA in Tris buffered saline (10 mM Tris, 
0.5 M NaCl, pH 7.6) with 0.1% Tween-20 (TBST). The blocked membrane was 
incubated with α-IGF-1R antibody (1:1000) diluted in blocking buffer and incubated 
overnight at 4 °C. The blot was then washed for 5 mins in TBST, repeating a further 2 
times. After the washes, diluted α-rabbit horse radish peroxidase (HRP) conjugated 
antibody (1:5000) in blocking buffer was added and incubated for 1 h at room 
temperature. An additional 3 washes of 5 mins each in TBST were performed to 
remove unbound secondary antibody. The immune complex bound proteins were 
detected with the addition of ECL prime (GE) and visualised on an X-ray film 
processed using the AGFA CP 1000 film developer. 
 
Quantitative Westerns were performed using the LI-COR Odyssey® system 
with a similar workflow to the chemiluminescence Westerns described above. After 
transfer, the blot was blocked with Odyssey® Blocking Buffer (OBB) at room 
temperature for one hour. The blocking buffer was removed and 1:1000 diluted rabbit 
α-phospho IGF-1R β antibody in OBB was added and incubated overnight at 4 °C. 
The blot was then washed for 5 mins in TBST 3 times. Anti-rabbit conjugated with 
DyLight 800 secondary antibody diluted at 1:10,000 in OBB were added. Three 
washes of 5 mins each of TBST and an addition wash of TBS for 5 mins was performed 
to remove any residual tween. The blot was scanned using a LI-COR® Biosciences 
Odyssey® Infrared Imaging System and data quantified using Image Studio software 
version 4.0. The blot was stripped by incubating the blot at room temperature for 15 
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mins with Restore™ Western Blot Stripping Buffer. The blot was re-blocked and 
probed with a total IGF-1R antibody diluted at 1:1000 in OBB overnight at 4 °C. Anti-
rabbit conjugated with DyLight 680 secondary antibody diluted at 1:10,000 in OBB 
was added. The resulting blot was imaged and processed in the same manner as the 
blot probing for phosphorylated IGF-1R.  
 
6.2.8 Receptor in vitro phosphorylation assay 
Elution fractions from the Wheat-germ agglutinin purification determined to be 
IGF-1R positive were used to performed in vitro phosphorylation assays. A dose curve 
was set up with each reaction consisting of 2 µL of purified IGF-1R, 100 µM ATP, 5 
mM MnCl2 and an increasing concentration of IGF-I (5-500 ng/mL). The reaction was 
incubated at room temperature for 10 mins before the addition of NuPAGE® LDS 
sample buffer and reducing agent as above. The resulting samples were subjected to 
SDS-PAGE and immunoblotted firstly with α-phopho-IGF-1R, stripped, and re-
probed with total IGF-1R as per section 6.2.7. 
 
To allow for the potential of high throughput screening, without the time 
consuming step of performing a SDS-PAGE and subsequent immunoblot transfer, a 
dot blot process was employed whereby each IGF-1R + IGF-I reaction was spotted 
directly onto nitrocellulose membrane and allowed to dry. The resulting dot blot was 
processed as per the above SDS-PAGE/Western blot protocol (6.2.7), post-transfer.  
 
Quantification of the elution fraction 
Recombinant human IGF-1R consisting of the extracellular domain portion was 
used as the concentration standard in order to estimate the IGF-1R concentration in the 
WGA purification elution fractions. The recombinant IGF-1R was serially diluted 1:1 
with PBS from 50 µg/mL to 97.65 ng/mL, yielding 10 dilution standards. Each 
standard concentration and WGA eluted fractions were separated by mass using SDS-
PAGE and electro-transferred onto nitrocellulose. Quantitative Westerns were 
performed using an α-IGF-1R (total) antibody using the method in section 2.7.2. The 
resulting signal unit for each standard concentration band was plotted against protein 
concentration using GraphPad Prism® version 6.0.  
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6.3 RESULTS 
6.3.1 The effect of IGF-1R targeting ScFv on MCF-7 cell metabolic activity 
The ScFv developed in previous chapters was designed to inhibit cell activation 
and migration with the ultimate aim being to repress cancer cell metastasis and 
survival. To determine if the generated α-IGF-1R ScFv can inhibit the functional effect 
of IGF-I stimulation in a cell growth setting, MCF-7 cells were treated with various 
concentrations of α-IGF-1R ScFv, along with control antibodies, before inducing with 
either IGF-I or IGF-I combined with VN. The relative response of each treatment was 
measured in a 24 h cell metabolic assay (Figure 6-1). The raw absorbance data was 
shown in addition to normalised data where the Iso IgG response (uninhibited) was set 
at 100% and each treatment group expressed as a comparative percentage. When 
comparing the IgG isotype control absorbance values between IGF-I (0.36 ±0.02) and 
the VN+IGF-I (0.48 ±0.02) treated samples, the addition of VN induced a significant 
metabolic increase (p<0.05) in MCF-7 cells. Interestingly, a commercial IGF-1R 
targeting antibody did not reduce the effect of IGF-I induced metabolic activity. No 
significant difference was observed between the iso control samples (green bars) and 
IGF-1R targeting IgG (red bars) in response to either IGF-I or VN+IGF-I. Treatment 
with α-IGF-1R ScFv produced a dose dependent reduction in metabolic activity (blue 
shaded bars). Indeed, ScFv added at 40 µg/mL drove significant inhibition (IGF-I: 
75.26 ± 2.34%, VN+IGF-I: 73.37 ± 1.77%) of cell metabolism compared to the isotype 
control (ρ <0.05).  
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Figure 6-1: MCF-7 proliferation with IGF-1R inhibitors.  
Serum starved MCF-7 cells were treated with a commercial antibody against IGF-1R 
(10 µg/mL), matched IgG isotype control (10 µg/mL), and three increasing 
concentrations of generated α-IGF-1R ScFv (10, 20, 40 µg/mL) before stimulation 
with either IGF-I (30 ng/mL) or VN (1 µg/mL) and IGF-I (30 ng/mL). Cells were 
cultured for 24 h before the addition of MTS reagent into each treatment. The 
conversation of MTS into coloured formazan product by metabolically active cells was 
quantified at 490 nm. The raw absorbance results (top) were normalised against iso 
IgG within each treatment group (Bottom) (IGF-I or VN+ IGF-I). Values shown are 
mean ± SEM (n=9). * ρ < 0.05.  
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6.3.2 The effect of IGF-1R targeting ScFv on MCF-7 cell migration 
In addition to cell viability, another fundamental aspect of cancer cell metastasis is cell 
migration, thus the generated IGF-1R targeting ScFv were assessed for their ability to 
inhibit IGF-I+VN stimulated migration in a TranswellTM-based assay (Figure 6-2). 
The IgG isotype control, which is understood to have no effect on cell responses, was 
defined as 100% and treatments were assessed in terms of response relative to this 
uninhibited control (green bar). In contrast to the viability assay, the IGF-1R targeting 
commercial antibody demonstrated significant inhibition of MCF-7 cell migration 
when compared to the iso control (ρ <0.05), with migration reduced to 38.37 ± 6.51 
%. Mirroring the proliferation assay, increasing concentrations of IGF-1R targeting 
ScFv showed a dose depended inhibitory trend. Although treatments of 10 μg/mL 
(purple bar, 99.23 ± 13.63 %), 20 μg/mL (orange bar, 97.29 ±7.99 %) and 40 μg/mL 
(black bar, 82.95 ± 2.779 %) did not inhibit migration to a significant extent, compared 
to the iso control, the highest ScFv treatment tested (100 µg/mL) reduced MCF-7 
migration to 47.67 ± 14.18% which was a significant inhibition of MCF-7 cell 
migration (ρ <0.05). 
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Figure 6-2: MCF-7 migration with IGF-1R inhibitors.  
Serum starved MCF-7 cells were treated with a commercial antibody against IGF-1R 
(10 µg/mL), matched IgG isotype control (10 µg/mL), and four increasing 
concentrations of generated IGF-1R ScFv (10, 20, 40, 100 µg/mL) before seeding into 
an upper chamber of a Transwell®. The lower chamber was pre-filled with IGF-I (30 
ng/mL) and VN (1 µg/mL). The cells were allowed to migrate for 15 h. The number 
of migrated cells in response to each treatment was expressed as a percentage relative 
to IgG isotype control. Values shown are mean ± SEM (n=6) from three independent 
experiments. * ρ < 0.05.  
 
6.3.3 Effect of αv-integrin targeting ScFv on MCF-7 cell attachment 
Prior to cellular migration, MCF-7 cells have to firstly attach to a substrate, to 
which the activation of various integrin receptors is necessary. Therefore, the 
functional effect of αv-integrin targeting ScFv with respect to attachment was assessed 
(Figure 6-3). The IgG isotype control was defined as 100% and responses were 
measured relative to this control. Coating culture wells with VN+IGF-I facilitated 
significant levels of cell attachment (VN+IGF-I) in comparison to the non-coated 
controls (SFM, orange bar, -3.68 ± 5.63 %). The α-αv integrin commercial antibody 
was able to significantly inhibit cell attachment to IGF-I+VN (purple bar, 40.52 ± 8.48 
%, ρ < 0.05). In terms of the 3 ScFv treatments, no significant functional effect relative 
to the isotype control was observed at any concentration tested.  
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Figure 6-3: MCF-7 attachment with αv integrin inhibitors.  
MCF-7 cells were treated with a commercial antibody against αv integrin (5 µg/mL), 
matched IgG isotype control (5 µg/mL), and three unique ScFv in increasing 
concentrations (20, 40, 100 µg/mL) before seeding each treated cells into individual 
wells in a 96 well plate containing IGF-I and VN (final concentration IGF-I: 30 ng/mL, 
VN 1 µg/mL). Cells were incubated at 37 °C to facilitate cell attachment at which point 
the unattached cells were removed. The attached cells were measured using the MTS 
reagent and quantified at 490 nm. Values shown are mean ± SEM (n=9) from three 
independent experiments. * ρ < 0.05.  
 
6.3.4 The effect of αv-integrin targeting ScFv on MCF-7 cell migration  
As part of the dual targeting approach of this thesis, the functional effect of ScFv 
targeting the αv integrins was investigated in a similar migration assay to that 
described above. The IgG isotype control was again defined as 100% (green bar) and 
treatments were assessed in terms of response relative to the IgG isotype control 
(Figure 6-4). The commercial antibody against αv integrin was able to significantly 
inhibit the effect of IGF-I+VN (purple bar, 4.29 ± 2.32%). Indeed, this treatment was 
comparable to the SFM negative control (orange bar, 8.72 x 10-7 ± 1.86 %) 
demonstrating almost complete inhibition of the VN stimulation. In terms of MCF-7 
cells treated with the various concentrations of three different ScFv, no significant 
functional effect relative to the isotype control was observed in any of the treatments. 
The largest inhibition response was clone B1 at 40 µg/mL (red bar, 40.28 ± 7.24 %), 
but no significant difference was observed.  
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Figure 6-4: MCF-7 migration with αv integrin inhibitors  
MCF-7 cells were treated with a commercial antibody against αv integrin (5 µg/mL), 
matched IgG isotype control (5 µg/mL), and three unique ScFv in increasing 
concentrations (20, 40, 100 µg/mL) before seeding into an upper chamber of a 
Transwell®. The lower chamber was pre-filled with IGF-I (30 ng/mL) and VN (1 
µg/mL). The cells were allowed to migrate for 15 h. The number of migrated cells in 
response to each treatment was expressed as a percentage relative to IgG isotype 
control. Values shown are mean ± SEM (n=6) from three independent experiments. * 
ρ < 0.05, ** ρ < 0.01.  
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6.3.5 Isolation of IGF-1R was successful using WGA agarose 
The recombinant human IGF-1R used for phage display screening contained 
only the extracellular domain. It lacks the kinase domain required for signal 
transduction post binding with its ligand, predominantly IGF-I. Both ELISAs to 
determine phage/ScFv binding only yielded information about if there is an interaction 
between the ScFv and the extracellular domain of IGF-1R. Therefore, a ScFv could 
potentially be binding strongly to the non-essential portion of the receptor that is 
needed for ligand-receptor activation. In other words, a positive binding candidate for 
the receptor might not necessary prevent ligand activation, which is the goal of this 
project. A more refined model for ScFv screening might be to determine if a ScFv 
candidate has the capability to prevent phosphorylation of the receptor upon ligand 
addition. Therefore, full length IGF-1R was needed containing both the extracellular 
domain, and also the tyrosine kinase domain to be suitable as the test model. The goal 
of this section was to develop a high through-put screening system using the isolated 
receptors including auto-phosphorylation studies when induced with the ligand IGF-I. 
 
To isolate native IGF-1R, MCF-7 cells were lysed using a non-denaturing lysis 
buffer containing the non-ionic detergent Triton X-100. The silver stained SDS-PAGE 
in Figure 6-5 revealed that most proteins are non-reactive to WGA due to the similar 
protein staining found between the load and the unbound protein flow-through. This 
was expected as WGA can only bind to glycoproteins containing N-acetylglucosamine 
or chitobiose, such as IGF-1R. Washing of the resin resulted in the removal of the non-
specifically bound proteins. Analysing the elution fractions, the majority of retained 
protein is eluted in fraction 2 from whence the intensity decreases across the 
subsequent fractions. 
 
The same samples were interrogated by Western immunoblotting using an α-
IGF-1R-α antibody. The difference in total intensity of the IGF-1R band between the 
load and the flow-through suggested that IGF-1R is being captured by the WGA with 
high efficiency. This is further evidenced as no IGF-1R could be detected in the wash 
sample. The majority of IGF-1R could be detected in elution fraction 2, with a smaller 
portion in fraction 3.  
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Figure 6-5: Wheat Germ Agglutinin (WGA) purification of IGF-1R from MCF-
7 cell lysate.  
MCF-7 cells were lysed using a non-denaturing lysis buffer (50 mM Tris (pH 7.4), 100 
mM NaCl, 1% Triton X-100 and complete protease inhibitor) and batch affinity 
purified using agarose bound WGA. At each step of the purification process, a sample 
was taken for A) Silver stained SDS-PAGE and B) Western blot analysis with an IGF-
1R antibody. Load = Starting lysate, Flowthrough = unbound protein to WGA, Wash 
= loosely/unspecific bound protein, Elution= competitive removal of bound proteins 
to WGA by N-acetylglucosamine. 
The yield of IGF-1R isolated in elution fraction 2 was determined using quantitative 
Western blotting on the LI-COR® Odyssey system. A standard curve was generated 
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using known concentrations of recombinant IGF-1R. The standards and the elution 
fraction 2 were separated using SDS-PAGE as per section 2.7.1 and probed using an 
α-IGF-1R-α antibody using the procedure described in 2.7.2. The resulting blots are 
shown in Figure 6-6 A. The IGF-1R-α bands were quantified using Image Studio 4.0 
and the concentration of the unknowns were determined in duplicate to be 0.899 and 
0.862 µg/mL respectively. Given that the elution fractions were collected in 0.5 mL 
increments, the total IGF-1R recovered was calculated to be 0.440 ± 0.00925 µg from 
10 confluent T-175 flasks. In addition, the WGA purified IGF-1R exhibit only one 
immune-reactive band to the IGF-1R-α antibody, unlike the recombinant IGF-1R with 
two. This suggests that the pro-IGF-1R in the isolated sample has been correctly 
cleaved into the α and β chains and would likely be functional.  
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Figure 6-6: Concentration determination of WGA purified fractions using 
quantitative Western immunoblotting. Known concentrations of recombinant 
human IGF-1R extracellular domain (50-0.097 µg/mL), and WGA purified elution 
fraction 2 underwent SDS-PAGE, transferred onto nitrocellulose membrane, and 
interrogated using α-IGF-1R-α antibody. The single chain form of IGF-1R has an 
approximate mass of 160 kDa while the alpha chain has a mass of 125 kDa. The blot 
was visualised on the LI-COR® Odyssey system and quantified using Image Studio 
4.0. The standard curve was construction using the signal of the IGF-1R standards 
(0.097 - 25 µg/mL) on GraphPad Prism® version 6.0.  
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6.3.6 Development of a functional screen for in vitro IGF-1R activation 
To achieve the aim of developing a screening tool for IGF-1R activation, it was 
required to determine if the IGF-1R isolated from cell lysates was functional. Samples 
of purified IGF-1R were stimulated with an increasing concentration of IGF-I (0, 5, 
10, 25, 50, 100, 500 ng/mL). The samples were subsequently separated by SDS-PAGE 
and electro-blotted onto nitrocellulose. Blots were initially probed for receptor 
phosphorylation using an α-phospho-IGF-1R-β antibody, the blot was then stripped 
and re-probed with an α-IGF-1R (total) antibody. The results shown in Figure 6-7 
demonstrate that isolated IGF-1R can be activated by IGF-I in a dose depended 
manner. Two different Western blotting system were utilised; A) traditional X-ray 
filmed based with the use of a HRP conjugated secondary antibody and B) Near 
infrared based Odyssey system using Dylight conjugated fluorescent secondaries. The 
IGF-1R antibodies have been optimised and tested in the traditional HRP based 
system, therefore it was used as a positive control to the Odyssey system, which has a 
higher linear dynamic range than X-Ray film, allowing for more accurate 
quantification of the detected proteins.  
 
For both systems, both phospho-IGF-1R and IGF-1R antibodies exhibit 
sufficient specificity as minimal non-specific bands could be detected. In both systems, 
the addition of increasing IGF-I leads to an increase in IGF-1R activation in a dose 
dependent fashion as evident by the increasing intensity of the phospho-IGF-1R β band 
(95 kDa). This indicates at the isolated IGF-1R is functional and can be activated by 
the addition of IGF-I. The intensity of the total IGF-1R bands across all samples 
remains consistent which is an indicator of equal protein loading.  
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Figure 6-7: IGF-I stimulation on WGA purified IGF-1R. An increasing 
concentration of IGF-I (0, 5, 10, 25, 50, 100, 500 ng/mL) was added to WGA purified 
IGF-1R receptor supplemented with ATP and MnCl2. The reactions were separated by 
SDS-PAGE and transferred onto nitrocellulose membrane. Anti-phospho-IGF-1R-β 
was added (WB: p-IGF-1R) to the membrane, imaged, stripped and probed with a total 
IGF-1R antibody (WB:IGF-1R). A) Imaging using HRP conjugated secondary 
antibody and development onto X-Ray films using enhanced chemiluminescent 
reagent. B) LI-COR® Odyssey system was used to visualise blots probed with 
DyLight™ 680 (red) or DyLight™ 800 (green) conjugated antibodies. 
kDa 
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6.3.7 High throughput of IGF-1R stimulation assay 
Having established an IGF-1R activation screening process, in order to realise 
the aim of generating an assay capable of screening a large number of potential 
modulators, further optimisation was required. The process of protein separation by 
SDS-PAGE and the downstream immune-blotting is both time consuming and does 
not scale with large numbers of samples. Therefore, to determine if similar activation 
responses could be achieved by an alternative method, IGF-1R which has been 
activated by IGF-I in a dose curve fashion, was blotted directly onto nitrocellulose, in 
a dot blot fashion, and probed with phospho-IGF-1R, stripped, and reprobed with IGF-
1R total in a similar manner as above and according to section 6.27. 
 
The resulting dot blots Figure 6-8:A were scanned and each protein spot 
quantitated using Image Studio 4.0. The signal for each phospho-IGF-1R spot (upper 
panel, green) was normalised against the total IGF-1R signal (lower panel, red). The 
fluorescence intensities were plotted with the normalised signal units against log IGF-
I concentration using GraphPad Prism® version 6.0. The resulting graph, Figure 
6-8:B, displays the classical sigmoidal dose-response curve.  
 
This high throughput IGF-1R activation model has the potential to be used as a 
screening method of receptor inhibition for large sample numbers. 
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Figure 6-8: IGF-I stimulation on WGA purified IGF-1R. An increasing 
concentration of IGF-I ranging from 0-500 ng/mL was added to WGA purified IGF-
IR receptor. Each reaction was spotted onto nitrocellulose, and processed as per section 
6.27. A) The dot blot was probed with an α-phospho-IGF-1R-β antibody, stripped, 
then re-probed with an α-IGF-1R (total) anybody. The image was visualised on the LI-
COR® Odyssey system at 700/800 nm wavelengths. B) The signal from each spot was 
quantified using Image Studio 4.0 and the normalised values curve fitted using 
GraphPad Prism® version 6.0. An increase in p-IGF-1R fluorescence signal indicates 
an increase in receptor activation. 
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6.4 DISCUSSION 
The aim of this project was to generate ScFv which can inhibit two pathways 
which have been implicated in tumour progression, namely the IGF and integrin 
systems. Both systems have been implicated in the proliferation, attachment and 
migration of tumour cells and have as such been a target for drug development.  
 
The IGF-1R ScFv was able to inhibit both IGF-I depended metabolic activity 
(Figure 6-1) and migration (Figure 6-2) in MCF-7 cells. In terms of metabolic 
activity, the IGF-1R targeting ScFv demonstrated a dose depended response and was 
able to significantly reduce stimulation to 75.26%  ±2.34 % and 73.37 ± 1.77% when 
MCF-7 cells were induced with IGF-I or VN+IGF-I respectively. In addition, it was 
also able to significantly reduce migration to 47.67 ± 14.18% at 100 μg/mL of ScFv 
tested.  
 
Even though this demonstrates that the ScFv was functionally active, the exact 
mechanism of inhibition was not determined. The control blocking antibody against 
IGF-1R (αIR3) used for this study, binds to IGF-1R as an allosteric inhibitor of IGF-I 
(Doern et al., 2009). Signalling studies will be required to confirm if the ScFv acts to 
block the binding of IGF-I and the subsequent activation of IGF-1R. This could be 
performed by interrogating the cell lysate in Western blots and probing for 
phosphorylated IGF-1R which is a measure of receptor activation. In addition, 
signalling molecules downstream of IGF-1R such as MEK/ERK and PI3K should be 
monitored for activation or inhibition as further evidence of IGF-1R modulation by the 
ScFv (Hollier, et al., 2008). Another method in which an antibody against IGF-1R 
could modulate the effects of IGF-I is through the down regulation of the receptors 
expression. For example, a monoclonal antibody currently in clinical trials, termed 
A12, has been shown to prevent ligand-dependent signalling, and also down-
modulation of IGF-1R (Burtrum, et al., 2003). To determine if the isolated ScFv can 
act in a similar manner, MCF-7 cells could be incubated with or without ScFv and the 
relative amount of IGF-1R could be determined using fluorescence-activated cell 
sorting analysis.  
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Given the BIAcore results of the αv ScFv in the previous chapter, there was a 
potential that the phage display derived ScFv would be non-functional in inhibiting 
integrin activation. The results in the chapter showed that all of the candidates were 
not effective in ablating the action of VN in both migration and attachments studies at 
the concentrations tested (Figure 6-3, Figure 6-4). Even higher concentrations of α-
αv ScFv beyond 100 μg/mL could be tested, however, due to lack of any response 
trend observed so far, it was unlikely that a higher dose would produce a positive 
response. Given the amount of resources invested into the generation of the αv integrin 
ScFv, this was an extremely disappointing result.  
 
The screening of positive binders used in this project only discriminated between 
binding or non-binding ScFv. There is a need for a functional screening process in 
which additional selection criteria such as preventing receptor activation are included 
in addition to binding. In order to address this need, partially purified IGF-1R was 
isolated from MCF-7 lysate using WGA agarose (Figure 6-5). Upon in vitro 
stimulation with IGF-I, the receptor was successfully autophosphorylated and 
quantified using a high throughput process (Figure 6-8). Despite the isolated IGF-1R 
being functional, further optimisation steps are required before it can be used as a 
screening tool. One is that WGA agarose has a high affinity to not only IGF-1R, but 
also to other glycoproteins such as the insulin receptor and epidermal growth factor 
receptor (Akiyama, Kadooka, & Ogawara, 1985; Burant, Treutelaar, & Buse, 1986). 
In order to obtain a pure IGF-1R sample free of other glycoproteins, an 
immunoprecipitation procedure using an IGF-1R specific antibody (Cell signalling, 
#3027) could be used. Upon the completion of further optimisations, this assay would 
allow for the functional screening of phage clones, which would give a better 
indication of a positive clone earlier in the characterisation process. 
 
A total of 1 unique ScFv against IGF-1R and 3 targeting αv integrin were tested 
for their ability to inhibited VN and IGF-I depended activities on MCF-7 cells. Of 
particular interest was the α-IGF-1R ScFv, which demonstrated functionalities in 
inhibiting both cell metabolic activities and also migration, which are highly relevant 
to a potential breast cancer therapeutic.  
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Breast cancer remains pervasive in the community, with 1 in 8 women 
developing the disease. Even with improved detection and treatments, it is still the 
second most common cause of cancer related death in Australian women (Australian 
Institute of Health and Welfare, 2014). The treatment of breast cancer can be broadly 
divided into two main groups; 1) Surgery and radiation therapy targets cancer locally 
and 2) systemic approaches such as chemotherapy, hormonal therapy, and targeted 
molecular therapy. In addition, the choice of treatments depends on various factors 
such as the cancer stage, status of hormone receptors (oestrogen, progesterone), and 
the status of human epidermal growth factor receptor 2 (HER2) (Gradishar, Anderson, 
et al., 2015). Breast cancer treatments such as surgery and chemotherapy can have 
severe side effects, including hair loss, nausea, fatigue, increased risk of heart failure, 
and physical and emotional stress (Love, et al., 1989; Maunsell, et al., 1993; Volkova 
& Russell, 2011). Also, treating metastatic breast cancer (MBC), or cancer which has 
spread from the confines of the primary tumour to secondary sites remains 
problematic, with an average five year survival rate of 24% (Siegel, et al., 2014). As a 
result of such side effects, coupled with limited success in treating MBC, researchers 
have been focused on generating therapeutic treatments with greater specificity and 
thereby minimal side effects. Targeted molecular therapy is an avenue of particular 
interest due to the potential specificity the process promises, targeting only malignant 
cancer cells. An example of a well-known targeted therapy is Herceptin® 
(trastuzumab), a monoclonal antibody for the treatment of breast cancer. Herceptin® 
binds to HER2 tyrosine kinase, preventing ligand activation and downstream signal 
transduction, leading to inhibition of tumour cell proliferation (Vu & Claret, 2012). A 
study conducted on 4,046 patients has compared the value of Herceptin® when used 
in conjunction with chemotherapy, compared to chemotherapy treatment alone. The 
study revealed that Herceptin® therapy increased the 10 year survival rate by 37% in 
addition to increasing the disease-free survival at 10 years by 40% (Perez et al., 2014). 
Given the need for improved therapeutics against MBC, and the proven success of 
targeted therapy, this project aims to generate novel single chain variable fragments 
(ScFv) which inhibit the Insulin-like growth factor (IGF) and the αv integrin systems, 
in order to impede the migration and survival of breast cancer cells.  
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The interaction between tumour cells and the micro environment has a profound 
effect on the cells ability to metastasise into distal sites. Complex interactions between 
growth factors such as insulin-like growth factors (IGF-I) and extracellular matrix 
(ECM) proteins such as vitronectin (VN) have been shown to increase migration, 
survival and proliferation of cancer cells (Hollier, et al., 2008; Kashyap, et al., 2011; 
Noble, Towne, Chopin, Leavesley, & Upton, 2003; Van Lonkhuyzen, et al., 2007). 
With this knowledge, the study contained in this thesis described the production and 
functional assessment of ScFv targeting αv integrin and IGF-1R, with the goal of 
ablating the functional effect of IGF-I and VN on breast cancer cells. Ultimately, the 
project sought to combine the αv integrin and IGF-1R targeting ScFv through the 
creation of a dual-targeting or bi-specific antibody (BsAb). The rationale for 
generating a single BsAb compared to 2 individual ScFv molecules targeting IGF-1R 
and αv integrin are that BsAb 1) streamline production and quality control as one single 
molecule compared to a number of molecules, and 2) assuming preclinical success, 
require a single clinical trial compared to separated safety trials for each component 
followed by a combination efficacy trial. The total cost of assessing a single cancer 
therapeutic candidate in phase I to phase IV clinical trials was conservatively 
calculated to be US$78.6 million (Office of the assistant secretary for planning and 
evaluation, 2014). Clearly, there is potential cost savings in conducting a single clinical 
trial for a BsAb compared to a combination treatment. Furthermore, associated with 
cost is the lengthy timeline from the start of clinical testing through to approval, which 
has been estimated to be 7.5 years (DiMasi, Hansen, & Grabowski, 2003). Taken 
together, BsAb are an attractive strategy of inhibiting two known pathways which have 
been implicated in cancer progression.  
 
To generate IGF-1R and αv integrin targeting ScFv, Phage display was chosen 
as the method of antibody selection for this project. It has advantages over alternative 
methods using laboratory animals including: 1) all selection steps are performed in 
vitro, therefore bypassing ethical considerations in animal maintenance and wellbeing; 
and 2) allows for the selection of human antibodies without cross-species reaction or 
resorting to transgenic mice encoding for human antibody genes. Of the present 
monoclonal cancer therapeutic antibodies approved for use in the United States, a large 
proportion were derived from a non-human host such as mice and were subsequently 
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humanised (n=9/23) or are a chimeric entity (n=4/23). Indeed, an analysis of pre-
clinical and under investigation antibodies listed in the Therapeutic Antibody Database 
((Tabs), http://tabs.craic.com), demonstrated that the use of animal derived antibodies 
remains the most prevalent source for potential treatments. The Therapeutics Antibody 
Database was queried based on the discovery platforms and the clinical trial status ( 
Figure 7-1). The results revealed that antibodies generated by humanising 
rodent antibodies had the highest percentage at each stage of the approval process, 
ranging from a low of 32 % (n=140/434) in the preclinical stage, to a high of 54 % in 
phase II (n=68/124). Phage display derived antibodies ranked 2nd in the early approval 
stages, with both preclinical and phase I at 19% (n=83/434 and n=20/105 respectively). 
Given the advantages of phage display technologies mentioned previously, the reason 
for the relatively low percentage of antibodies derived from phage display 
technologies is unclear. It may be due to the well characterised and mature process of 
creating chimeric and humanised antibodies from animal sources (Jones, Dear, Foote, 
Neuberger, & Winter, 1986; Neuberger et al., 1984). In addition, phage display is 
dependent on the library used for antibody screening, which translates the ownership, 
patents and licencing to be of key commercial importance, and could limit use in 
industrial and/or commercial settings. Finally, because of the long development time 
between preclinical and approval stage, improvements in phage technologies maybe 
not have reached the therapeutic pipeline.  
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Figure 7-1: Antibody discovery platform and their clinical trial status. 
The total antibody candidates from preclinical to approval of the five major platforms 
(rodent, chimeric rodent, humanised rodent, phage display and transgenic mouse) was 
determined using data sourced from The Therapeutics Antibody Database 
(http://tabs.craic.com) 
 
The phage display selection process is complex. Both the adsorption and the 
panning of IGF-1R and αv integrin was conducted in PBS without calcium or 
magnesium. This selection choice was made due to the previous studies involving the 
panning of IGF-1R. Of integral importance is that the substrate being panned against 
is in a structural state representative of the in vivo conformation. On the cell surface, 
integrins exist as heterodimers of one α and one β subunit. Critical to this structure are 
divalent cations which stabilise the receptor and allow ligand binding (Pesho, Bledzka, 
Michalec, Cierniewski, & Plow, 2006; Zhang & Chen, 2012). It was however 
undertaken in this study to pan against an αv monomer instead of an αv containing 
heterodimer. It was theorised that by using the αv monomer instead of a heterodimer 
such as αvβ3 in the phage selection process, a pan αv integrin ScFv binder could be 
selected and therefore be able to block all members of the αv integrin family. Rather 
than selectively targeting αvβ3 or αvβ5, a pan αv ScFv would inhibit both αv integrins 
which have been implicated in breast cancer progression (Goodman & Picard, 2012). 
It has been demonstrated that a pan αv inhibitor is more effective in inhibiting 
migration compared to a specific αvβ5 inhibitor (Hollier, et al., 2008), likely due to 
additional αv integrins targeted in addition to αvβ5. Should an αv dimer such as αvβ3 
or αvβ5 have been used for panning, the addition of 1 mM calcium or 1 mM 
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magnesium would have been employed during panning. In addition to the binding 
conditions, another critical aspect of the phage display selection process is the library 
itself. The complexity of the phage display library dictates the number of unique 
antibody fragments it encodes. Because the phage selection process is random, a more 
complex library has a greater chance of selecting high affinity binders. The library 
used in this project, the Tomlinson I & J libraries, has a complexity of 2.8 × 108, which 
when compared to newer libraries such as the Morphosys proprietary HuCAL® 
PLATINUM® with 4.5 × 1010 is ~160 times less diverse (de Wildt, et al., 2000; 
Prassler, et al., 2011). The reduced diversity of the libraries used may explain yielding 
only 1 unique binder for IGF-1R. Indeed such a trend has been observed in previous 
studies using the Tomlinson I & J libraries, Yan and colleagues described 3 unique 
sequences from 96 binders (Yan, et al., 2004), 14 from 44 clones were generated by 
Eteshola et al. (Eteshola, 2010) and a further study found 3 from 800 clones screened 
(Patil, et al., 2015). Historically, phage display libraries were generated and used in an 
academic setting. It was quickly recognised that phage libraries have 
commercialisation potential, leading to spinoff companies and the acquisition of 
libraries by commercial entities. Given the commercial importance of display libraries, 
publicly available libraries are limited. An alternative, which was considered at the 
start of this project, is the creation of a naïve phage display library, which would be 
valuable in future phage display projects, in addition to bypassing licencing and 
intellectual property issues. In brief, the library construction involves the amplification 
of variable heavy and variable light regions from donor B-cells, ligated into phagemid 
vectors, and subsequent transformation into an E. coli host (de Haard et al., 1999; 
Pansri, et al., 2009a; Sheets, et al., 1998). Donor B-cells can be sourced from the blood 
of volunteers or, after ethical clearance, from blood stocks with the Australian Red 
Cross. However, due to potential time constrictions, a commercial phage display 
library was believed to be a more prudent resource and was obtained instead. Recently, 
the antibody Portrazza™ (Necitumumab) derived from a naïve library described by de 
Haard, et al. (1999) was approved by the FDA, giving evidence supporting this method 
of library generation.  
 
As part of the standard phage panning procedure, an ELISA was performed after 
each round to select clones that bind the target with high affinity. While identification 
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of binders is important, in the setting of the current study ScFv that not only bound but 
also blocked receptor activation were the aim, something an ELISA could not select 
or test for. Thus, an additional screening tool to identify ScFv binding in such a way 
as to block receptor activation would have been of great benefit to the project. One 
such possible method is the inclusion of biotin labelled IGF-I or VN during the 
monoclonal ELISA screening process. In this competitive ELISA, ScFv which have 
high affinity to the target should displace the labelled ligand, which can be quantified 
and ranked. A similar assay was performed by Burtrum, et al. (2003), with the IGF-I 
labelled with a radioisotope instead of biotin. However, this method still does not 
assess the state of activation of the target receptor. In an attempt to address this short 
coming, a high throughput IGF-1R stimulation assay was partially developed in this 
project. IGF-1R was enriched from MCF-7 cell lysate using agarose bound wheat germ 
agglutinin (WGA). The isolated IGF-1R was observed to autophosphorylate upon in 
vitro stimulation with IGF-I, suggesting that the receptor is functional and can bind to 
IGF-I (Figure 6-8). Using this assay to improve the screening process would involve 
applying the ScFv clones to immobilised receptor followed by addition of IGF-I and 
analysing for receptor activation. An ScFv would be considered positive if it could 
inhibit the activation of IGF-1R upon stimulation with IGF-I. This approach is similar 
to the kinase assays used for compound screening for IGF-1R kinase inhibitors, in 
which only the kinase domains of IGF-1R are used (Moriev et al., 2013).  
 
Full length antibodies are large glycoproteins which require complex folding and 
are post-transactionally modified, making expression in prokaryotic hosts such as E. 
coli generally unsuitable (Robinson et al., 2015). However, due to the reduced size and 
the lack of the glycosylated Fc region, ScFv are commonly expressed using an E. coli 
host (Frenzel, Hust, & Schirrmann, 2013). Furthermore, the panning process involved 
selection of E. coli expressed ScFv on the surface of the phage, therefore, an E. coli 
expression system was chosen to produce the ScFv in this project. Since the phage 
selection process relied on displayed proteins generated using an E. coli host, the large 
scale expression of the ScFv would have similar binding characteristics to the ScFv-
pIII fusion in the phage display. A disadvantage of using E. coli is that 
Lipopolysaccharide (LPS) is a major component of the outer membrane and may 
contaminate the sample. LPS is a potent endotoxin and must be removed before any 
 154 Chapter 7: General discussion 
in vivo and therapeutic use (Schwarz, Schmittner, Duschl, & Horejs-Hoeck, 2014). 
Recently, a LPS free E. coli strain has been developed, which would minimise 
downstream steps and potentially reduce production costs (Mamat et al., 2015). This 
strain of E. coli, termed ClearColi®, is already commercially available and should be 
a target for use in future expressions of ScFv that are destined for in vivo studies.  
 
In preparation for ScFv purification, literature was consulted in depth and the 
vast majority outlined simple, straightforward protocols for purifying ScFvs generated 
using the Tomlinson libraries (Eteshola, 2010; Kim, Wang, et al., 2014; Wang, et al., 
2012; Yan, et al., 2004). Therefore, that the major obstacle encountered in this project 
was the difficulties in purifying the expressed ScFv using the Ni-NTA based system 
was an unexpected turn of events. Different binding and wash conditions for Ni-NTA 
were trialled, however, the expressed ScFv did not bind to the affinity resin. Since this 
purification process required the polyhistidine affinity tag to be accessible, potentially 
the tag was obstructed due to ScFv aggregating into higher order structures such as 
dimers. To test this hypothesis, ScFv samples were analysed using SEC with PBS as 
the running buffer. The resulting chromatogram revealed two major populations of 
ScFv containing the monomer and dimer form (Figure 5-2,Figure 5-4). In order for 
the ScFv to bind to Ni-NTA, 1M urea was added during the purification process. The 
goal of urea is to weaken hydrophobic interaction among ScFv molecules, without 
denaturing (Wörn & Plückthun, 1998; Zangi, Zhou, & Berne, 2009). The formation of 
aggregates can be difficult to eliminate. Therefore, there has been considerable effort 
in researching ways to produce aggregation resistant antibodies. Of particular interest 
is the identification of key residues within the antigen binding sites (VH: amino acids 
28, 30-33, 35; VL 24, 49-53, 56) that when substituted for an aspartic acid or glutamic 
acid residue, improved biophysical properties including aggregation resistance were 
observed (Dudgeon, Rouet, & Christ, 2013; Dudgeon et al., 2012). Researchers have 
already ‘retro-fitted’ commercial therapeutic antibodies in this fashion to successfully 
reduce aggregation, thus, potentially the same technique can be applied to the ScFv 
isolated in this project. Alternative expression hosts such as mammalian or insect cell 
based systems could also be used to express ScFv and BsAb molecules. It has been 
shown that E. coli have difficulties in the expression of higher complexity antibodies 
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such as BsAb (~56 kDa) and alternatives such as CHO may be a better choice (Mack, 
Riethmüller, & Kufer, 1995).  
 
Given the inefficacy of Ni-NTA, alternative affinity based solutions were 
investigated. In the commercial production of recombinant therapeutic IgG, protein-A 
chromatography is commonly used in the purification process, enabling capture 
through highly specific interaction with the Fc region. The resulting product is of high 
purity and achieved in a single step (Liu, Ma, Winter, & Bayer, 2010). Because binding 
is via interactions with the Fc regions, the addition of extraneous amino acids residues 
such as polyhistidine are not required, therefore eliminating any immunogenicity 
concerns related to such tags. Furthermore, it has been demonstrated that the addition 
of the peptide affinity tag can adversely affect protein function (Schmeisser et al., 
2006). Therefore, purification strategies which do not employ the use of an affinity tag 
have distinct advantages. However, protein-A binding requires the presence of VH3 
domains, which most antibody fragments such as ScFv lack (Nilson, Lögdberg, 
Kastern, Björck, & Åkerström, 1993). Therefore, protein-L affinity chromatography 
was chosen for this project, which can bind with high affinity to antibody fragments 
via kappa light chain interactions (Nilson, et al., 1993). By using protein-L in the 
purification of ScFv from expression culture supernatant, an increase in purity was 
observed compared to Ni-NTA (Figure 4-8). This is consistent with other studies that 
used protein-L in comparison to Ni-NTA, concluding that protein-L was a more 
versatile and robust method (Das, et al., 2005; Rouet, et al., 2012). Furthermore, the 
use of protein-L enables utilisation of antibody phage display libraries which do not 
encode a purification tag.  
 
In order to assess the binding affinity of ScFv to its target, the purified ScFv 
were interrogated using the BIAcore system. The goal was to compare to binding 
affinity between the generated ScFv and commercially available antibodies as a guide 
to potential functionality in cells. Recombinant IGF-1R or αvβ3 was successfully 
immobilised onto a BIAcore sensor chip using amine coupling chemistry. 
Corresponding ScFv was sequentially injected over the sensor surface and the 
interaction measured in real time. The calculated affinity (KD) between the commercial 
IGF-1R targeting antibody and IGF-1R was 3.2 ± 1.31 x10-8 M (Figure 5-5). In 
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comparison, another similar study returned a KD value of 1.3 ± 0.5 x10-9 M, which was 
~25 times stronger to the results from this study (Mehrnaz Keyhanfar, 2005). This 
difference in binding affinity could be due to the immobilisation method used, which 
may have impacted binding. In this study, IGF-1R was covalently immobilised onto 
the sensor surface whereas the Mehrnaz Keyhanfar (2005) study used a capture system 
to immobilised the antibody and receptor was injected over. Potentially this would 
allow the receptor to be less structurally constrained due to it being assessed in a 
solution phase. In comparison to the commercial antibody, the calculated KD between 
the generated α-IGF-1R ScFv and IGF-1R was 2.58x10-7 ± 3.236x108 M, which was 
an ~8 fold difference in binding affinity. Given the confirmation of dimers in the ScFv 
samples upon SEC analysis, it is likely that a mixed population consisting of ScFv 
dimers/monomers would decrease binding affinity, compared to a homogeneous 
sample consisting only of monomers (Figure 5-2). A similar BIAcore analysis was 
performed on a commercially available IgG targeting αv integrin and 3 generated ScFv 
candidates. The heterodimer αvβ3 was chosen preferentially in BIAcore binding 
analysis over the αv monomer used during the panning process because integrin exists 
on cells as a heterodimer. The commercial antibody returned a calculated KD of 2.589 
x 10-8 ± 4.866 x 10-9 M, however, none of the 3 ScFv candidates showed any binding 
response even at high concentrations (Figure 5-6). Given the lack of binding to αvβ3, 
the next logical step was to determine if the ScFv could bind to αv monomer, for which 
it was generated against. Surprisingly, the αv protein failed to immobilise onto the 
BIAcore sensor chip, raising questions about the integrity of the commercially sourced 
integrin protein, and the potential functional influences in cell assays.  
 
The purified ScFv against IGF-1R and αv integrin were tested for their ability to 
inhibit key cancer progression mechanisms using MCF-7 breast cancer cells. This cell 
line has been extensively used as a test model for the study of VN and IGF-I 
interactions. The IGF-1R ScFv generated from this study was able to inhibit both IGF-
I depended metabolic activity (Figure 6-1) and migration (Figure 6-2). In terms of 
metabolic activity, the IGF-1R targeting ScFv demonstrated a dose depended response 
and was able to significantly reduce stimulation by 24.74% ±2.34 % and 26.63 ± 
1.77% when MCF-7 cells were induced with IGF-I or VN+IGF-I respectively. In 
addition, it was also able to significantly reduce migration by 52.33 ± 14.18% at a dose 
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of 100 μg/mL. Direct comparison in potency among preclinical antibodies is difficult, 
due to differences in the cell line used, functional assays and the lack of studies 
generating ScFv molecules against IGF-1R or αv integrin (Tabs, 
http://tabs.craic.com/). In addition, because a dose response curve of the ScFv was not 
generated from this project, comparing half maximal inhibitory concentration (IC50) 
is not possible. However, 5 µg/mL of 4D5, the parental murine antibody of 
Herceptin®, was able to inhibit the proliferation of the SK-BR-3 breast cancer cell line 
by 56% (Hudziak et al., 1989). A recent patent filing on an antibody targeting IGF-1R 
detailed testing with doses ranging from 0.8 µg/mL to 100 µg/mL on the prostate cell 
line DU145 (Chang, Losman, & Goldenberg, 2015). Cells were stimulated with IGF-
I at 10 ng/mL and metabolic inhibition was measured using MTS reagent in a manner 
similar to this project. Significant inhibition compared to the control was achieved at 
20 µg/mL (p<0.01) and 100 µg/mL (p<0.001), reducing stimulation to ~66% and 
~50% respectively. Given that ScFv molecules are smaller in size compared to IgG, 
100 µg/mL of the IGF-1R ScFv is ~25 molar excess to 20 µg/mL of IgG. However, as 
discussed earlier, aggregates were detected in the ScFv samples and may have reduced 
the potency of the ScFv in binding to their targets. Ideally the ScFv preparations would 
have been fractionated to allow harvest of the monomer fraction for functional 
assessment. A small scale analytical HPLC fractionation study was performed in 
Section 5.3.3, however, it was clear a large amount of preparation would be required 
to produce enough monomer for assessment. Therefore, due to the time scale pressures 
of this study, additional optimisations are required for the large scale preparative 
separation of ScFv monomer. A comparative analysis of aggregate vs monomer in cell-
based assays would be an intriguing investigation. If the results were to indicate that 
the aggregate fraction is non-functional the implication would be that the monomer 
fraction would show inhibition at much lower concentrations than those observed in 
the current undertaking. The 3 αv integrin ScFv candidates were also functionally 
assessed in attachment and migration assays. Given the lack of binding shown in 
BIAcore studies, it was likely that the isolated ScFv were also non-functional in cell-
based assays. The results from the assays showed that this was indeed the case, with 
all the candidates showing a lack of inhibition at all concentrations tested (Figure 
6-3,Figure 6-4). In contrast, the αv targeting IgG was able to significantly inhibit cell 
attachment by 59.48 ± 8.48 % and cell migration by 95.71 ± 2.32 % supporting the 
idea of αv integrin as a therapeutic target. Integrins, such as αvβ3 and αvβ5, belonging 
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to the αv family have been linked to cancer metastasis. Given this knowledge, one aim 
of this project is to develop as part of a BsAb a pan-αv integrin inhibitor, which would 
inhibit both αvβ3 and αvβ5. By using the monomer αv instead of the heterodimer in 
the phage display screening process, it was hoped that the isolated ScFv would inhibit 
all αv integrins. However, BIAcore studies revealed that the isolated ScFv did not bind 
to αv integrin (Figure 5-6), furthermore, function assessment in MCF-7 cells also 
returned negative results (Figure 6-3,Figure 6-4). 
 
Given the BIAcore and the functional results for the αv integrin ScFv candidates, 
there was doubt about the recombinant αv integrin protein used during the phage 
screening process. Therefore, the recombinant αv integrin was interrogated using SDS-
PAGE in order to determine protein purity and integrity. The results showed that the 
commercially generated and sourced αv integrin protein was not in its native 
conformation (Appendix 12) potentially explaining why the generated ScFv against 
αv integrin was observed to be non-functional in assays. This suggests that there was 
a breakdown in the in vitro wheat germ expression system (Nozawa et al., 2011), 
purification, or quality control steps employed by the manufacturer. In contrast, a 
recombinant αvβ3 integrin sourced from another supplier demonstrated high purity in 
silver stained SDS-PAGE, with the staining revealing a distinct band corresponding to 
the calculated molecular weight for the αv and β3 monomers. In addition, the band 
corresponding to the suspected αv subunit was immune-reactive to an α-αv antibody, 
whereas no such immunoreactivity was observed with the commercial αv integrin 
protein. As an alternative, the αv integrin protein could have been expressed and 
purified in-house, using a mammalian expression system such as HEK293 cells. It was 
reported by Tartaglia et al. (2013) that functional heterodimer αvβ3 was produced in 
this system, and thus, an αv subunit generated in this way could be used in future 
experiments. Clearly, at the beginning of this study there was no reason to doubt the 
integrity of the purchased αv protein and by the time it was deduced to be unsuitable, 
there was no possibility of rerunning the panning procedure let alone expressing and 
purifying the αv monomer beforehand. Despite problems encountered in the αv 
integrin selection, it remains a variable therapeutic target. Currently, a total of 14 
antibodies targeting αv integrins are under investigation, with half in preclinical 
assessment. The most developed is abituzumab, which is currently at stage 2/3 ( 
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Appendix 2).  
 
Due to experimental difficulties encountered throughout the project, a singular 
ScFv targeting IGF-1R was developed and demonstrated functionality. However, as a 
consequence of the selection of non-functional αv integrin ScFv, the ultimate goal of 
this project, the generation of a BsAb, was not able to be fulfilled. Nevertheless, the 
IGF-1R targeting ScFv demonstrated functionality in a 2D culture. The next logical 
step is to retest the ScFv with MCF-7 cells cultured in 3D. There is evidence that breast 
cancer cells cultured in 3D, as compared to a 2D monolayer, mimic more closely 
tumour cells in vivo and their interaction with the tumour microenvironment. 
Differences in cells cultured in 3D compared to 2D include altered drug responses (dit 
Faute et al., 2002), changes in gene expression (Kenny et al., 2007) and altered 
proliferation and morphology (Krause, Maffini, Soto, & Sonnenschein, 2010). In 
addition to providing a more representative ScFv-tumour response, this assay would 
also give evidence if the generated smaller ScFv (~28 kDa) confers any advantages 
over IgG (~150 kDa) given generally a smaller molecule can penetrate deeper into a 
tumour (Yokota, Milenic, Whitlow, & Schlom, 1992). To achieve this, the ScFv and 
control IgG conjugated with Quantum dots would be added to fluorescence labelled 
MCF-7 cells cultured in 3D. Both the size of the tumour in addition to the spatial 
distribution of the labelled ScFv would be monitored using fluorescence imaging. (Xu, 
et al., 2012). 
 
Throughout the cell-based assay, it was evident, with the exception of α-IGF-1R 
in the MTS assay, that the control antibodies elicited significant inhibition. Indeed, 
these properties may be exploited as an alternative strategy for the development of a 
BsAb against IGF-1R and αv integrin. An overview of three possible alternative 
methods for BsAb production are detailed in Figure 7-2. The first method requires the 
de novo sequencing of intact commercially available IgG-based inhibitors to deduce 
the amino acid sequence in order to obtain the VH and VL coding sequences. From 
there, ScFv could be ‘reverse engineered’ based on the sequences obtained. 
Historically, Edman degradation has been the default choice for protein sequencing, 
but is time consuming and routinely returns only 15-20 residues per run (Pham, 
Tropea, Wong, Quach, & Henzel, 2003). Today, newer techniques based on tandem 
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mass spectrometry called Comparative shotgun protein sequencing (CSPS) can be 
used to sequence large proteins such as antibodies (Bandeira, Pham, Pevzner, Arnott, 
& Lill, 2008). CSPS has advantages over Edman degradation including comparatively 
rapid turnaround and an increase in sequence coverage. The resulting amino acid 
sequence can be back-translated into nucleotide sequences using informatics tools such 
as EMBOSS Backtranseq (http://www.ebi.ac.uk/Tools/st/emboss_backtranseq/) 
which can take into account codon usage requirements. Once both VH and VL 
sequences are obtained, an expression vector encoding for the ScFv would be 
constructed, followed by the expression, purification and characterisation and 
subsequently, BsAb generation. De novo sequencing is particularly important in 
antibodies derived from an immunised host, in which sequence determination is 
essential for patent filing, FDA approval and for quality control purposes (Center for 
Biologics Evaluation and Research (CBER), 1996; Pham et al., 2006).  
  
 162 Chapter 7: General discussion 
 
 
Figure 7-2 Alternative workflows for the generation of BsAb against αv integrin 
and IGF-1R.  
Methods of generation for BsAb by recombinant and chemically conjugation which 
can incorporate the α-IGF-1R ScFv sequence isolated from this project. Three main 
approaches can be employed: 1) Reverse engineering of commercially available 
antibodies against IGF-1R and αv integrin by de novo sequencing followed by the 
generation and recombinant expression of the BsAb (orange box). 2) Reselection of 
αv integrin binding ScFv by phage display and subsequent expression (blue box). 3) 
Redox method of BsAb generation using commercially available antibodies (green 
box.  
 
The second alternative method is a hybrid approach which incorporates the IGF-
1R sequence obtained from this project, using additional sequence information for αv 
integrin ScFv sourced either from de novo sequencing in method one, or repeating the 
phage display panning process using recombinant αv integrin generated as per 
Tartaglia, et al. (2013). Once the VH and VL coding sequences are deduced, the 
workflow continues in an identical manner to method one. 
 
The third alternative method of BsAb generation is the redox method, where 
each of the two parental antibodies are selectively reduced at the heavy inter chain 
bond using the mild reducing agent 2-mercaptoethanesulfonic acid sodium salt 
(MESNA) (Carlring, De Leenheer, & Heath, 2011; Owais, Kazmi, Tufail, & Zubair, 
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2014). The partially reduced antibodies are combined in an oxidising environment, 
allowing for the re-formation of the parental antibody, or the novel formation of a 
BsAb. The antibody mixture is put through two affinity based purification steps to 
remove the parental antibody, leaving only IgG-based BsAb. Out of the three methods 
discussed, the redox method has the potential to be the simplest to perform. However, 
this process is inefficient, with only 19% of BsAb recovered from 1 mg of each of the 
parental antibodies as a starting point (Carlring, et al., 2011). This would need to be 
scaled down due to cost considerations. In addition, while the generation of this IgG 
based BsAb would be useful as a proof of concept and as a control antibody in 
functional assays, its usefulness is limited, due to 1) requiring the purchase of both 
monospecific antibodies, and 2) the generated BsAb is at a structural endpoint, 
therefore, unable to improve the binding affinity using processes like affinity 
maturation. There is also likely to be intellectual property issues which will likely limit 
commercial usefulness.  
 
In summary, this project aims to generate function blocking ScFv targeting IGF-
1R and αv integrin with the goal of inhibiting the growth and migration of tumour 
cells. Phage display technologies were used to screen for ScFv binders against IGF-
1R and αv integrin. The result of the panning process returned 1 unique IGF-1R and 3 
αv integrin ScFv binders which were expressed and purified. Problems were 
encountered using the conventional Ni-NTA based affinity purification scheme, an 
alternative protein-L based system was used and yielded ScFv of high purity. The 
binding affinity for the purified ScFv against IGF-1R was comparable to the 
commercially available antibodies when assessed using BIAcore. However, none of 
the αv integrin candidates showed any binding activities. Subsequent cell-based 
functional assays revealed that the α-IGF-1R ScFv generated was able to functionally 
inhibit both the metabolic activity and migration of breast cancer cells to a significant 
degree. However, all three αv integrin binding candidates had no functional effects. 
Given that the α-IGF-1R ScFv demonstrated functionality, the next logical steps are to 
perform affinity maturation in order to increase its affinity towards IGF-1R along with 
optimisation of the ScFv sequence and production process to generate preparations 
with a very high proportion of monomers. Subsequently, the optimised ScFv should 
be assessed using MCF-7 3D culture based assays before progressing into a mouse 
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xenograft model to determine if the in vitro results observed in this project can be 
translated into an in vivo animal setting.  
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8.1 INTRODUCTION 
The preceding chapters of this dissertation described studies conducted with the 
goal of generating bi-specific antibodies (BsAb) targeting pathways critical to tumour 
development and progression. The BsAb’s were designed to specifically inhibit both 
insulin-like growth factor (IGF) and the integrin systems, as previous studies have 
shown the activation of both pathways promote cancer cell growth and survival 
(Hollier, et al., 2008; Kricker et al., 2010; Van Lonkhuyzen, et al., 2007). The proposed 
recombinant BsAb construct was to consist of two arms, each made up of an 
independent IGF-1R and αv integrin binding single chain variable fragment (ScFv). 
To identify the monospecific ScFv binders, a phage display screening process was 
undertaken using a ScFv library. In respect to the IGF-1R arm, a single ScFv clone 
was found to bind the receptor with high affinity and was demonstrated to inhibit 
MCF-7 cell proliferation and migration (Figure 6-1, Figure 6-2). Although the phage 
enrichment process was successful, the resulting clones against αv integrin 
demonstrated no function in cell-based assays, as observed by the lack of significant 
difference in responses compared to controls in both metabolic and migrations assays. 
Additional receptor binding studies using surface plasmon resonance also yielded no 
response from each clone isolated against αv integrin. In order to ascertain the reason 
for the observed lack of function, it was discovered that the the αv integrin protein 
sample used as the target in ScFv selection was degraded and may not have been 
representative of the true αv integrin structure, therefore, the panning process would 
not have selected specific αv integrin binding ScFv. In spite of the difficulties 
experienced in this project, the results obtained with the IGF-1R targeting ScFv 
demonstrate that the rationale is sound and the ultimate aim of generating a function 
blocking BsAb would be possible with further investigation. In an effort to provide a 
fulsome body of work, this chapter sets out to describe a refined methodology for the 
further development and successful generation of an IGF-1R-av integrin targeting 
BsAb able to inhibit cancer cell survival and metastasis 
 
As detailed in chapters 5 and 6 of this document, the major obstacle encountered 
was the lack of function demonstrated by the α-αv integrin ScFv clones resulting from 
the phage display screening process. Without the isolation of a ScFv targeting the αv 
integrin, the generation of the proposed BsAb targeting both IGF-1R and αv integrin 
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was, therefore, not possible. To address this problem, the phage display panning 
process can be repeated using an alternative source of αv integrin. However, the 
commercial availability of recombinant αv integrin from other vendors is limited. 
Previous studies have shown that integrins can be expressed using insect or 
mammalian systems (Mathias, Galleno, & Nemerow, 1998; Tartaglia, et al., 2013). 
Furthermore, in these instances the expressed recombinant protein retained the ability 
to bind cognate ligands, such as vitronectin. This suggests that the expressed proteins 
are functional and retain their native confirmation. Even with the use of an accurate 
αv-integrin sample as the selection target, there remains the possibility that the newly 
isolated ScFv could still exhibit limited functionality, despite the input of additional 
time and resources. For example, the ScFv could bind to a non-critical portion of the 
target receptor uninvolved with signalling activation. Thus, although positive binding 
ScFv would be isolated, inhibitory function as required may not be exhibited. Thus, to 
provide adequate confidence and detail for a fulsome proposal within this chapter an 
alternative strategy is required. 
 
 A substitute process for selecting αv integrin targeting antibody sequences may 
be to search the literature and patent databases for proven antibodies effective at 
targeting and inhibiting the function of αv integrins. While such an approach would 
deliver a proven functional candidate without the rigours of selection, it would, 
however, be undesirable as the use of published sequences would significantly limit 
both the novelty of the project and the commercial potential/value of the final BsAb. 
A promising monoclonal antibody currently in clinical trials specifically targeting the 
αv integrin is abituzumab (EMD 525797, 17E6) (Élez et al., 2015; Mitjans et al., 1995; 
Uhl, Zühlsdorf, Koernicke, Forssmann, & Kovar, 2014; Wirth et al., 2014). It was 
modified from antibody clone (17E6) generated from a mouse immunised with 
placental-derived αvβ3 (Mitjans, et al., 1995). It has demonstrated the ability to inhibit 
cell attachment and tumour cell proliferation in both in vitro and in vivo studies. In 
preclinical studies, abituzumab was able to inhibit the attachment of melanoma cells 
to substrate bound vitronectin by ~75% (Mitjans, et al., 1995). To complement the in 
vitro studies conducted, an in vivo nude mouse model was used to examine the effect 
of abituzumab on tumour development. The results showed that not only was 
abituzumab able to suppress tumour growth, but also the frequency of metastasis. The 
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preclinical data demonstrated the potential of abituzumab and subsequently phase I 
clinical trials were conducted to assess the pharmacokinetics and safety profile (Uhl, 
et al., 2014; Wirth, et al., 2014). An increasing single dose of abituzumab was 
administrated in both studies, ranging from 35 to 1500 mg. From the phase I trial 
results it was ascertained that abituzumab was well tolerated at all concentrations, and 
supported the advancement to phase II trials using 750 mg and 1500 mg doses. 
Recently, the results of a phase II study on patients with metastatic prostate cancer 
revealed that progression-free survival did not significantly increase in response to 
abituzumab treatments (Hussain et al., 2016). However, there was evidence 
demonstrating prostate cancer–associated bone metastasis inhibition, further 
strengthing the role of αv integrin in tumour metastatic progression. Taken together, 
abituzumab has demonstrated functionality that makes it an ideal candidate from 
which to base the αv integrin targeting arm of the BsAb. Given that abituzumab has 
shown activity in blocking αv integrin-dependent processes, a patent search was 
conducted to ascertain the amino acid sequence of the heavy and light chains which 
were found to be detailed within US patent US8562986. The heavy and light chain 
amino acid sequences from abituzumab can, therefore, form the basis of a theoretical 
ScFv construct through incorporation into an appropriate vector structure. Although 
there are numerous instances where ScFv sequences have been converted to IgG 
format for use as monoclonal Ab therapies (Bujak, Matasci, Neri, & Wulhfard, 2014; 
B. Liu et al., 2007), the reverse (which is required in this instance) has also proven 
successful (Asano et al., 2013). Using the abituzumab sequences in combination with 
the IGF-1R targeting ScFv described in this thesis would enable the generation of a 
functional BsAb fulfilling this projects aims of targeting the IGF-1R and αv integrins. 
Functional assessment of this newly generated BsAb has the potential to validate the 
BsAb generation approach, in which two independent targeting ScFv molecules are 
recombinantly expressed as one dual targeting entity through the use of a linker 
sequence. Furthermore, the functional data generated from cell-based assays would 
also increase our understanding of targeting both the IGF and integrin pathways as a 
possible tumour inhibiting mechanism. 
 
The choice of the ScFv expression host and vector should also be investigated, 
given the problems encountered as previously described in chapter 4 of this thesis. Of 
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the four ScFv clones isolated from the phage display screening process, three 
contained an amber codon within the coding sequence, requiring modification prior to 
large scale expression. The Tomlinson phage display libraries I+J were constructed on 
the pIT2 vector backbone and paired with the HB2151 E. coli strain for expression. As 
demonstrated from results presented in this thesis, there were some shortcomings in 
using this particular phage display library in combination with the HB2151 strain. 
Firstly, an inherent property of the Tomlinson libraries was the potential for the 
random generation of amber stop codon sequences (TAG) within the ScFv CDS. In a 
non-amber codon suppression strain such as HB2151, this would lead to premature 
termination of translation. Mutation of the amber stop codon (TAG) DNA sequence, 
through SDM, to encode for glutamic acid (GAG) resulted in maintained translation, 
which was equivalent to that observed during phage selection rounds. The SDM 
procedure, detailed in Section 4.2.2, required extensive additional time and resources: 
1) Generation of a new mutagenic primer set for each ScFv clone; 2) The mutagenesis 
process can be lengthy with PCR, cloning, and transformation steps; and, 3) 
Verification of the SDM process can only be done by DNA sequencing, which is slow 
and resource intensive. A second shortcoming of the pIT2/HB2151 system was the 
observed low expression yield. When using a routine medium such as 2YT, the final 
recovered ScFv of a single candidate was ~4.95 mg/L of culture. The low yield was 
problematic as this required multiple expression and purification batches in order to 
produce enough ScFv for both the biophysical and function characterisation assays. In 
addition, the expression culture volume was limited by commonly available laboratory 
equipment. An attempt was made to counteract the yield problem by using the 
EnPresso B medium, which increased the ScFv yield to ~22 mg/L, however, it was 
still limited by the phage display focused pIT2 vector.  
 
Recently, a new vector termed pET-ScFv (https://www.addgene.org/67843/) 
was designed in order to address the limitations of the pIT2 and HB2151 E. coli 
expression system (Ossysek et al., 2015). Specifically, the problem with amber codon 
generation within the ScFv coding sequence. During the phage display process using 
an amber suppression E. coli strain such as TG1, the amber codon has no negative 
effect. However, it prevented full length ScFv expression in a non-suppressor strain 
such as HB2151, which has been traditionally chosen as the expression strain in studies 
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utilising the pIT2 vector in Thomlinson I & J libraries (Scott et al., 2008; Xiong, Li, 
Yang, Burgess, & Dynan, 2009; Xu et al., 2004). In addition to the problems associated 
with amber stop codons, the pIT2 vector was generated to include a lac promoter. This 
promotor has been demonstrated to be loosely regulated, causing basal level 
expression which can affect the growth rate of E. coli and subsequent protein yield 
(Rosano & Ceccarelli, 2014). To address the limitations outlined herein, a new vector 
was constructed based on the popular pET expression platform, under the control of a 
T7 promoter (Wurm et al., 2016). The T7 promoter has been demonstrated to facilitate 
higher expression yield, and also greater control when compared to the lac promoter 
found in pIT2 (Tegel, Ottosson, & Hober, 2011). In combination with 
RosettaBlue(DE3)pLysS E. coli, ScFv selected from the Tomlinson libraries were 
successfully expressed at high levels. Indeed, an almost tenfold increase in protein 
yield was achieved using pET-ScFv/RosettaBlue(DE3)pLysS compared to 
pIT2/HB2151 in LB medium. In addition to the increased expression yield, the 
RosettaBlue(DE3)pLysS strain suppresses the undesirable translation of amber stop 
codons to terminate protein synthesis. This would allow for large-scale protein 
expression post-phage panning without additional intermediate steps. Given the 
advantages of the new vector and E. coli combination even when using LB medium 
during expression, it would be expected that the ScFv yield would further increase 
when a specialised medium such as Enpresso B is utilised. Given the problems in 
obtaining sufficient ScFv for both functional and biophysical characterisations, an 
increase in yield would decrease to amount of time and resources required and allow 
the undertaking of additional assays, such as the fractionation of the ScFv monomer 
and dimer for comparative functional assessment.   
 
As part of the biophysical characterisation process to assess the integrity of the 
purified ScFv, samples were separated based on molecular shape and size using size 
exclusion chromatography (SEC). The results demonstrated that each ScFv 
preparation contained populations of dimers (Figure 5-2, Figure 5-4). Heterogeneity 
presented within ScFv samples has the potential to impact downstream 
characterisations, such as in BIAcore and functional studies (Vázquez-Rey & Lang, 
2011). Ideally, each ScFv preparation would have been fractionated into the monomer 
and dimer for comparative functional assessment. While improvements in the 
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expression host and vector system previously outlined above would be expected to 
reduce the generation of dimers, another complementary strategy is for the 
minimisation of dimer formation through modification to the purification process. Of 
particular concern was the low pH buffer (100 mM of the glycine-HCl solution, pH 
2.7) used to elute the bound ScFv from protein-L agarose. It has been shown that 
antibody aggregates can form from various stressors, including low pH conditions 
(Sahin, Grillo, Perkins, & Roberts, 2010). Although samples were immediately 
neutralised, the low pH environment of the elution process can be inferred to have 
contributed to dimer formation. To overcome this problem, it has been demonstrated 
that the addition of sodium chloride (0.1-1.0 M) or Ethylene glycol to elution buffers 
raised the pH required (pH 7.0) to recover bound proteins (Vázquez-Rey & Lang, 
2011), thus minimising the generation of additional aggregates due to the elution 
process. The reduction in the generation of potential dimers in addition to fractionation 
with SEC would further increase the stringency of the final product leading to 
increased confidence in the data generated.  
 
The binding affinities of the generated ScFv were compared to commercially 
available Ab’s using Surface Plasmon Resonance (SPR) on the BIAcore X-100 
instrument. Originally, the Langmuir kinetics model (1:1) of binding was chosen as 
the model of interaction between ScFv and its target when evaluating BIAcore results. 
However, experimental results obtained did not fit this model, likely due to the 
presence of dimers increasing the complexity of the interaction. Therefore, an 
alternative model, the steady-state affinity model, was used for this project. Even 
though both models can calculate the KD of the interactions, the steady-state affinity 
model does not yield the association (ka) and dissociation (kd) rate constants. This 
detail has significant implications upon data interpretations as it has been demonstrated 
that two compounds with identical KD can have vastly different pharmacokinetics due 
to the differences in ka and kd (GE Healthcare, 2012) . In addition, the presence of ScFv 
dimers would exhibit avidity effects, resulting in the overestimation of the KD value. 
A ScFv sample containing a higher proportion of dimer would give results less 
reflective of the actual affinity value compared to a sample with lower dimer 
proportions. Given each ScFv sample contained varying amounts of dimers, 
comparison of relative affinity can be problematic. Ideally, a sample with reduced 
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heterogeneity would allow for the improved fitting of the interaction to the Langmuir 
kinetics model, allowing for the determination of the unique ka and kd values. In 
particular, kd values alone can be used to rank antibody candiates in a non-
concentration dependend manner, allowing for the screening of non-purified antibody 
samples (Rouet, et al., 2012).  Taken together, improvements in the BIAcore assay can 
be achieved by the fractionation and/or greater control of ScFv heterogeneity.  
 
Functional characterisation of the generated ScFv was performed using the 
breast cancer cell line MCF-7 as detailed in chapter 6. These functional studies were 
successful in demonstrating that the α-IGF-1R ScFv significantly inhibited IGF+VN 
dependent metabolic activity and migration. To build on these positive results, 
additional functional assays would give further insights into the ScFv’s potential 
behaviour in an in vivo situation, as it was the ultimate goal of this project to produce 
a concept molecule for a novel human therapeutic. Compared to the traditional two-
dimensional (2D) monolayer culture used in this study (Hongisto et al., 2013; Weigelt 
& Bissell, 2008), there is increasing evidence that cancer cells grown in three 
dimensional (3D) cultures may be more physiologically representative of the in vivo 
situation. In particular, MCF-7 cells cultured in 3D form round spheroids that closely 
resemble in vivo primary breast tumours (Vantangoli, Madnick, Huse, Weston, & 
Boekelheide, 2015). The difference in morphology between cells cultured in 2D vs. 
3D has been demonstrated to result in altered drug responses, differences in gene 
expression and signalling pathways (Dhiman, Ray, & Panda, 2005; Vantangoli, et al., 
2015). Of particular relevance to the goals of this project was the assessment of the 
growth kinetics of MCF-7 cells in 3D by Vinci et al. (2012). In this approach, the size 
of fluorescently labelled MCF-7 spheroids is monitored in real-time using the 
IncuCyte® Live Cell Analysis platform in response to treatments. In addition to 
providing a more representative tumour physiology, the use of a 3D spheroid assay 
would also give an indication as to whether the generated smaller BsAb (~56 kDa) 
confers any advantages over larger IgG (~150 kDa) given smaller therapeutics have 
been shown to penetrate deeper into tumours (Yokota, et al., 1992). The increase in 
penetrative depth could potentially translate into more effective inhibition of tumour 
growth, as monitored by the IncuCyte® system. Given the advantages over the 2D 
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cell-based assays, 3D cell-based assays will form part of the proposed workflow to be 
detailed in this chapter.   
 
While the combination of 2D and 3D cell-based assays are the initial steps in the 
function assessment of the BsAb, in vivo testing of the BsAb in an animal model is 
critical in the pathway for regulatory approval as a human therapeutic. Both the 2D 
and 3D in vitro models are limited as they do not yield information about the 
pharmacokinetics, nor the biodistribution and uptake of the ScFv/BsAb. All three 
limitations imposed by the in vitro models can be addressed using a labelled BsAb and 
subsequent injection into an in vivo system. Currently, there are several methods in 
labelling antibodies and antibody fragments such as ScFv. These include radioisotope 
labelling, use of near-infrared (NIR) fluorescence probes and labelling with 
fluorophores such as green fluorescence protein (GFP) via a conjugation reaction, or 
co-expression as a fusion protein (Hilderbrand & Weissleder, 2010; Lu, Gong, Yu, & 
Li, 2005; Pavlinkova, Beresford, Booth, Batra, & Colcher, 1999). However, 
radioisotope labelling requires specialised handling and detection methods (Kaur et 
al., 2012). Also, the direct expression of a large GFP molecule similar in MW to the 
ScFv (26.9 kDa) has the potential to both perturb expression as well as alter the 
biological function of the labelled antibody. The large size of GFP can be partially 
overcome using a split-GFP system, in which only the CDS of the 11th strand of GFP 
(GFP11), encoding the 16 amino acid sequence RDHMVLHEYVNAAGIT, is fused 
into the CDS of the protein of interest, in this case the BsAb (Ferrara, Listwan, Waldo, 
& Bradbury, 2011; Kamiyama et al., 2016). It has been demonstrated since GFP11 
consists only of 16 amino acid residues, it does not interfere with the proper function 
and expression of the attached protein (Kamiyama, et al., 2016). To restore 
fluorescence, a recombinant protein consisting of the 10 strands of GFP (GFP1-10) is 
incubated with the ScFv-GFP11 fusion, at which point the complex self-assembles into 
the complete fluorophore. The split GFP system has been demonstrated to be 
successful in imaging cells and lower order organisms such as C. elegans, however, 
the delivery of the GFP1-10 protein for live imaging in an animal such as a mouse has 
not been demonstrated. Potentially, this problem can be mitigated through the 
determination of spatial information for the ScFv after the animal has been sacrificed 
and the tissue harvested.  
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Due to the potential shown by the α-IGF-1R ScFv, this chapter aims to extend 
the results obtained from this study and provide the theoretical framework for the 
generation of a BsAb construct, subsequent expression and purification, and functional 
assessment.  
 
8.2 EXPERIMENTAL PROCEDURES 
8.2.1 Selection of ScFv encoding sequences 
In order to facilitate the generation of the tandem BsAb constructs, the amino 
acid sequence of each component were determined (Table 8-1). The IGF-1R ScFv 
amino acid sequence was obtained from this project as a result of phage display 
screening. For the generation of the negative controls, preselected ScFv targeting BSA, 
derived from the Tomlinson phage library, will be used. It is assumed that the 
incorporation of BSA targeting ScFv will have negligible effect in cell-based 
functional assays and will thus serve as a control domain in the BsAb’s. However, in 
binding BSA, it may potentially increase the pharmacokinetic characteristics of the 
BsAb by increasing the molecular weight (Müller et al., 2007). The amino acid 
sequence of the heavy and light chains of abituzumab were obtained from US patent 
no US8562986 (appendix 14). However, since it is an IgG monoclonal antibody, in 
silico modifications were needed to convert from IgG to ScFv format. Therefore, the 
VL and the VH regions were isolated, with a (GlySer)3 linker joining the two domains.  
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Table 8-1: The amino acid sequence of the IGF-1R, BSA and αv integrin 
targeting ScFv.  
 
ScFv Amino acid sequence 
IGF-1R ScFv 
(Phage 
display) 
 
AMAEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSRISQ
EGDYTLYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGRGVFDYWGQG
TLVTVSSGGGGSGGGGSGGGGSTDIQMTQSPSSLSASVGDRVTITCRASQSISSYLN
WYQQKPGKAPKLLIYRASHLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSRK
SPPTFGQGTKVEIKRAAAHHHHHH 
BSA ScFv 
(Phage 
display) 
 
AMAEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSTIYY
AGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGYYVFDYWGQG
TLVTVSSGGGGSGGGGSGGGGSTDIQMTQSPSSLSASVGDRVTITCRASQSISSYLN
WYQQKPGKAPKLLIYYASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSDT
SPTTFGQGTKVEIKRAAAHHHHHH 
αv integrin 
ScFv (EMD 
525797)  
 
QVQLQQSGGELAKPGASVKVSCKASGYTFSSFWMHWVRQAPGQGLEWIGYINPRS
GYTEYNEIFRDKATMTTDTSTSTAYMELSSLRSEDTAVYYCASFLGRGAMDYWGQGT
TVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQDISNYLAW
YQQKPGKAPKLLIYYTSKIHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQGNTFP
YTFGQGTKVEIK 
8.2.2 Construction and synthesis of the BsAb constructs 
Four constructs based on the isolated CDS are here proposed (Figure 8-1). All 
four BsAb present in the tandem ScFv format consisting of two ScFv joined using a 
middle linker: A) α-IGF-1R:α-αv, B) α-IGF-1R:α-BSA, C) α-αv:α-BSA and D) α-
BSA:α-BSA. Constructs B and C were produced to ensure that the binding activity of 
α-IGF-1R or α-αv ScFv is retained when converted into the BsAb format. The middle 
linker chosen will consist of the amino acid sequence STDGNT, an optimised linker 
for the expression of tandem format BsAb in E. coli (Korn, Nettelbeck, Völkel, Müller, 
& Kontermann, 2004).  
 
Each complete expression construct will be synthesised using the GeneArt© 
Strings service (Thermo Fisher Scientific, Scoresby). The resulting double-stranded 
linear DNA fragments are much more economical compared to traditional gene 
synthesis service. During this process, the desired amino acid sequence for each BsAb 
construct will be submitted for codon optimisation for E. coli expression, and also the 
addition of the restriction sites NcoI to the 5’ and NotI to the 3’ ends. The full codon 
optimised CDS and the translated amino acid sequence for all constructs can be found 
in Appendices 15-18. 
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(A) α-IGF-1R+α-αv BsAb 
 
 
(B) α-IGF-1R+α-BSA BsAb 
 
 
(C) α-αv+α-BSA BsAb 
 
 
(D) α-BSA+α-BSA BsAb 
 
 
 
 
Figure 8-1:Proposed tandem bispecific antibody constructs against IGF-1R and 
αv integrin. 
 
Schematics of four tandem bispecific antibody DNA construct encoding for A) α-IGF-
1R:α-αv B) α-IGF-1R:α-BSA C) α-αv:α-BSA D) α-BSA:α-BSA. The middle linker 
encodes for the amino acid sequence STDGNT. The restriction sites NcoI and NotI 
have been added 5’ and 3’ of the CDS respectively to facilitate the cloning of the insert 
into an expression vector. All constructs encode the GFP11 tag at the 3’ end, allowing 
for the detection of the BsAb using the split GFP system. 
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8.2.3 Cloning of BsAb constructs into the expression vector pET-ScFv-T 
To insert the BsAb CDS into the pET-ScFv-T, double restriction digests using 
NcoI and NotI will be performed on both the vector and the BsAb CDS containing the 
engineered restriction sites (Figure 8-2) . The linearised vector will be incubated with 
the digested fragment insert in T4 ligase, followed by transformation into chemically 
competent E. coli. Successful clones containing the insert will be screened using 
colony PCR using the 5′ sequencing primer TAATACGACTCACTATAGG and 3′ 
sequencing primer GCTAGTTATTGCTCAGCGG.  
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Figure 8-2 Cloning workflow of BsAb encoding fragment into the pET-ScFv-T 
vector. 
 
The BsAb encoding fragment synthesised by GeneArt will contain the restriction 
enzyme sites Nco1 and Not1 to match the cloning site of the pET-ScFv-T vector 
backbone.  
 
8.2.4 Transformation of BsAb constructs 
A 20 µL aliquot of chemically competent RosettaBlue(DE3)pLysS cells will be 
thawed on ice. The expression vector samples will then be mixed with cells and 
incubated on ice for 5 mins followed by a heat-shock step at 42 °C for 30 sec in a water 
bath. The tubes are chilled on ice for 2 mins and 500 µL of SOC medium added to 
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each tube. The tubes will be incubated at 37 °C with shaking at 250 RPM for 1 h. 
Subsequently, samples will be plated onto TYE + Kanamycin (50 µg/mL) plates and 
incubated overnight at 37 °C. Single colonies will be picked from each plate, cultured 
overnight in 2xYT and plasmids extracted using the QIAGEN Mini-Prep Kit according 
to the manufacturer’s instructions. The purified DNA will be sent for sequence 
verification by AGRF using GCTAGTTATTGCTCAGCGG (5’) and 
TAATACGACTCACTATAGG (3’) sequencing primers. 
 
8.2.5 Expression of BsAb 
EnPresso B is a proprietary expression medium system for E. coli claiming to 
guarantee an expression yield increase of at least 5-fold over traditional media such as 
LB medium. A starter culture will be initiated by inoculating E.coli encoding the BsAb 
into 20 mL of 2xYT+ Kanamycin (50 µg/mL) and incubated at 37 °C with shaking at 
250 RPM for 6 h. The EnPresso B medium will be reconstituted by adding the contents 
of one silver bag (20 tablets) to 500 mL sterile water in a 2.5 L Erlenmeyer baffled cell 
culture flask. The starter culture and 250 μL of proprietary Reagent A will be added to 
the shaker flask and incubated overnight at 30 °C with shaking at 250 RPM. Next, 
IPTG will be added to a final concentration of 0.6 mM, along with Booster 500 powder 
and 520 μL of Reagent A. The culture will again incubate with shaking as previous for 
an additional 24 h. After the incubation period, the culture will be harvested and 
centrifuged at 3,300 g for 10 mins. The supernatant will be retained and subjected to 
protein-L agarose purification. 
 
8.2.6 Affinity purification of BsAb using protein-L agarose 
The Supernatant containing the expressed BsAb will be purified using protein-
L agarose chromatography. Initially, the supernatant will be filtered through a 0.45 μm 
membrane before dialysis against PBS. The clarified supernatant will then be applied 
to a protein-L agarose column equilibrated with PBS and allowed to flow by gravity. 
The column will be washed once with 5 mL of PBS to remove loosely bound proteins. 
Bound ScFv will be eluted from the beads using elution buffer (100 mM NaCl, 100 
mM of glycine-HCl, 20% v/v Ethylene glycol, pH 7.0) and collected in 500 µL 
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fractions. Samples will be interrogated for purity by SDS-PAGE and Western blotting 
as per section 4.2.6. 
 
8.2.7 Expression and purification of αv integrin 
Based on the difficulties encountered with obtaining a commercial source of 
recombinant αv integrin, the expression and purification will be conducted in-house. 
The expression and purification of the αv integrin protein will be used only for 
BIAcore characterisation experiments. A study by Tartaglia, et al. (2013) 
demonstrated the successful expression and purification of the extracellular domains 
of αvβ3 by co-transformation of two vectors encoding for either αv or β3 integrins. The 
expression and purification of only the αv integrin monomer will be based on that 
study with modifications. In short, the CDS of the extracellular domains of αv integrin 
will be synthesised using GeneArt© Strings service, with the addition of NcoI and 
XhoI restriction sites at the 5’ and 3’ end, respectively. In addition, CDS encoding for 
6 histidine residues will be added to the 3’ end. The codon optimised CDS will be 
cloned into the pQE-TriSystem vector for expression using the HEK 293 cell line. The 
resulting recombinant αv integrin will be purified using Ni-NTA affinity 
chromatography.  
 
8.2.8 Fractionation of BsAb monomers 
The affinity purified BsAb will be fractionated using SEC on an HPLC 
instrument. In short, samples will be separated on a HiLoad Superdex 75 prep grade 
column that has been calibrated using a Low Molecular Weight (LMW) Kit which 
contained 5 protein standards spanning from 6 500 to 75 000 Daltons. The running 
buffer used will consist of high salt PBS (500 mM NaCl) as the running buffer at an 
isocratic flow rate of 0.5 mL/min. The resolved proteins will be monitored at both 214 
nm and 280 nm wavelengths with 0.5 mL elution fractions will be collected. Monomer 
and dimer BsAb fractions collected will be individually pooled for affinity analysis 
using the BIAcore instrument.  
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8.2.9 N-Terminal sequencing 
Purified BsAb will be submitted for N-terminal sequencing by Edman 
degradation to assess the correct cleavage of the PelB signal peptide from the N-
terminal of the mature BsAb protein.  
 
8.2.10 Surface Plasmon Resonance (SPR)-based affinity determination 
The BIAcore X100 system will be used to determine the binding affinity of the 
generated BsAb (α-IGF-1R:α-αv) and controls to IGF-1R and αv integrin. IGF-1R or 
αv integrin will be immobilised using amine coupling chemistry to a BIAcore sensor 
chip surface. In order to reduce avidity effects, the immobilisations levels will be kept 
low for all reactions. Due to the high structural homology of the insulin receptor (IR) 
to IGF-1R (Ullrich et al., 1986), the binding of BsAb to immobilised IR will also be 
conducted to measure potential cross-reactivity. Subsequently, five sequential 
injections consisting of increasing concentrations of BsAb will be applied over the 
sensor surface at a flow rate of 30 µL/min. The interaction will be analysed using a 1:1 
kinetics model. The experiment will be repeated immobilising the BsAb on the 
sensor’s surface and injecting either IGF-1R, IR, αv integrin monomer or αv integrin 
dimers such as αvβ3 as the analyte.  
 
8.2.11 Metabolic assessment of the BsAb on MCF-7 cells 
The CellTiter 96® AQueous One proliferation assay is based on the conversion 
of the tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS into a 
coloured formazan product by viable cells. MCF-7 cells will be passaged the day 
before the assay. The cells will then undergo serum starvation for 4 h by aspirating the 
GM, washing twice with PBS, before the addition of SFM. A series of treatments 
including commercially available IGF-1R blocking antibody, αv blocking antibody, 
matched isotype controls and a concentration range of BsAb and BsAb controls will 
set up in SFM. A combination treatment consisting both α- αv integrin and α-IGF-1R 
IgG will be used to benchmark the generated BsAb. Serum starved MCF-7 cells will 
be dissociated from the culture flask using TrypLE™, 5,000 cells added to each 
treatment within a microfuge tube and allowed to incubate at room temperature for 30 
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mins. After this incubation period, the treated cells are transferred into individual wells 
of a 96 well plate and stimulated with or without VN at a final contraction of 1 µg/mL 
and IGF-I at 30 ng/mL. The treated cells are then incubated at 37 °C with 5% CO2 for 
24 h, after which 20 µL of CellTiter 96® AQueous One Solution Reagent is added 
into each well and a further 1.5 h incubation at 37 °C performed for the formation of 
the coloured formazan product. The absorbance of each well is then measured at 490 
nm using the Benchmark Plus microplate spectrophotometer (Bio-rad). 
 
8.2.12 Migration assay 
MCF-7 cells will be serum starved for 4 h. During the SFM incubation, the lower 
chambers of the Transwell® plates will be incubated with both IGF-I (30 ng/mL) and 
VN (1 µg/mL) diluted in SFM. Treatments consisting of the four generated BsAb 
(IGF-1R:αv integrin, IGF-1R:α-BSA, αv integrin:α-BSA, α-BSA:α-BSA) and a 
combined treatment consisting of two commercially available inhibitors of IGF-1R 
and αv integrin will be prepared in SFM at multiple concentrations. The serum-starved 
MCF-7 cells will be harvested and incubated at 60,000 cells per treatment, in 
microfuge tubes and allowed to incubate with the antibody-based treatments for 0.5 h 
at room temperature before seeding into the upper chamber of a Transwell®. Plates 
will then be incubated for 15 h at 37 °C with 5% CO2 within a humidified incubator. 
At the completion of the migration period, the non-migrated cells will be physically 
removed from the upper surface of the semi-porous Transwell® membrane. Cells 
which had migrated to the lower surface of the membrane will be fixed in ~3.7% 
formaldehyde and stained with 0.01% (w/v) crystal violet in PBS. To quantify 
migrated cells, the crystal violet will be extracted from the stained cells using 10% 
(v/v) acetic acid and 100 µL aliquots transferred into a 96 well plate. The absorbance 
will be measured at 595 nm using the Benchmark Plus microplate spectrophotometer.  
 
8.2.13 Attachment assay 
MCF-7 cells will be passaged the day before the assay to synchronise the cell 
cycles before serum starving for 4 h.. Treatments consisting of the four BsAb, α-αv+α-
IGF-1R IgG and control IgG treatments will be diluted in SFM+BSA at various 
concentrations. Serum-starved cells are harvested and are then added at 20,000 cells 
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per treatment and incubated for 30 mins at room temperature in a microcentrifuge tube. 
During this incubation, a 10x solution of IGF-I and VN (300 ng/mL, 10 μg/mL) is 
prepared and added to individual 96 well plate wells. After the 30 mins incubation, the 
treated cells will be seeded into the IGF-I+VN containing 96 well plate, diluting the 
IGF-I+VN to 1x, and incubated for 30 mins at 37 °C with 95% air and 5% CO2 to 
allow for cell attachment. Cells which have not attached after this period are aspirated 
and wells washed twice with PBS. The cellular attachment is determined by the 
addition of 100 μL of SFM + 20 μL MTS reagent to each well and incubating for 1.5 
h at 37 °C with 95% air and 5% CO2 for the conversion of MTS into the coloured 
product. This product will be quantified at 490 nm using the Benchmark Plus 
microplate spectrophotometer.  
 
8.2.14 Cell signalling 
A method to determine if the generated BsAb can prevent the activation of IGF-
1R or αv integrin through binding of IGF-I and VN respectively is to assess receptor 
activation using Western blotting. MCF-7 cells will be seeded onto six-well plates at 
7.5x105 cells per well and cultured overnight in growth medium. The growth medium 
will be aspirated and cells serum starved for 4 hrs. Increasing concentrations of the 
BsAb and control treatments will be added to the cells and pre-incubated for 1 hr at 37 
°C, before stimulation with the addition of IGF-I and VN. Cells will be harvested and 
lysed at different time points. The resulting cell lysates will be separated based on MW 
through SDS-PAGE and blotted onto a nitrocellulose membrane. The blot will be 
probed with Phospho-IGF-1R Ab to directly determine IGF-1R activation, or 
Phospho-FAK (Tyr397) Antibody for integrin activation. Levels of activated 
downstream signalling pathways such as AKT and ERK will also be assessed.  
 
8.2.15 3D tumour spheroid assays 
Briefly, 5,000 MCF-7 expressing nuclear-restricted RFP (Essen BioScience) 
will be seeded into each well of a 96 well ultra-low attachment plate (Corning). A 
centrifugation step at 1000 rpm for 10 mins will pellet the cells onto the bottom of 
each well. The spheroid formation rate will be monitored over the next 96 hrs using 
the IncuCyte ZOOM® instrument at which point the spheroids will be pre-treated with 
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BsAb against IGF-1R/αv integrin, IGF-1R/BSA, αv integrin/BSA or BSA/BSA and 
IgG against IGF-1R and αv integrin before stimulation with IGF-I and VN. The size 
of the spheroids as indicated by the Total Fluorescence Object Area will be monitored 
for an additional 10 days. In addition to the total size and volume of the MCF-7 
spheroid, the metabolic activity will be determined using the CellTiter-Glo® 3D Cell 
Viability Assay (Promega).  
 
8.2.16 Xenograft model and stability testing 
Xenograft models will be performed as previously reported using luciferase 
labelled MCF-7 breast cancer cells (Burtrum, et al., 2003). Mice will be implanted 
with estradiol pellets one week prior to injecting tumour cells. Two million MCF-7 
cells will be injected into the 4th inguinal mammary fat pad of 5-6 week old NOD/SCID 
mice. Tumours will be allowed to reach 150-300 mm3 before intraperitoneal 
administration of vehicle control (saline), generated BsAb or commercial antibodies. 
Tumours will be measured twice a week using the formula pi/6 (w1 (biggest diameter) 
xw2xw2). Once per week we will also perform live animal bioluminescence imaging 
using the IVIS Spectrum system (Caliper, Australia) to monitor tumour growth and 
metastasis. The weight of the mice will also be recorded. Upon the end of the study, 
the mice will be sacrificed and tumour and organ tissue harvested for 
immunohistochemical analysis using H&E, Ki-67 and tunnel stains. To assess the 
biodistribution and uptake of the BsAb tagged with GFP11, the tumour and organ 
tissue harvested will also be incubated with recombinant GFP1-10 protein, allowing 
for the spontaneous formation of functional GFP fused to the BsAb. The quantitation 
and localisation of the BsAb will be performed using fluorescence microscopy. 
 
An in vivo BsAb stability study will also be performed by injecting a single 
intravenous dose of 1 mg of BsAb. The subsequent levels of the BsAb will be 
measured in serum collected at 5 min, 30 mins, 2 h, 7 h, 24 h, 48 h and 72 h post 
injection as compared to serum collected prior to BsAb injection. The detection of 
intact BsAb in serum will be conducted using the split GFP tag.  
 
  
Chapter 8: Rational design of IGF-1R/αv integrin bi-specific antibodies 187 
8.2.17 Statistical analyses 
Quantitative assays will be performed in triplicates and will be presented as 
means ± standard error of the mean (SEM). To compare among treatments and 
controls, analysis of variance (ANOVA) with tukey post hoc test will be conducted. 
Significance will be accepted at ρ<0.05.  
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8.3 DISCUSSION 
Breast cancer is a burden in Australia, with an estimate of over 16,000 (150 
males and 15,934 females) newly diagnosed cases in 2016 (Australian Institute of 
Health and Welfare, 2014). Despite advances in both detection and treatment, 
metastatic breast cancer (MBC) remains problematic to treat, leading to a poor long-
term prognosis. MBC or stage IV breast cancer is characterised by the presence of 
secondary tumours that have disseminated from the primary tumour site (National 
Cancer Institute, 2011). Common areas in which distal metastases can be found are the 
bone, brain, liver and lungs (Kennecke et al., 2010), commonly causing interference 
with the functional integrity of these organs. Previous studies have demonstrated the 
relationship between the role of the extracellular matrix and the growth factor system 
in cancer metastatic process and tumour development (Clemmons & Maile, 2005; 
Doerr & Jones, 1996; Kim, et al., 2011; Weigelt & Bissell, 2008; White & Muller, 
2007; Zent & Pozzi, 2009). In particular, two systems which have been implicated are 
the Insulin-like growth factor axis and αv integrins (Hollier, et al., 2008; Kashyap, et 
al., 2011; Van Lonkhuyzen, et al., 2007). It has been demonstrated by these studies 
that the co-activation of IGF-1R and αv integrin stimulates tumour cell growth and 
migration, through the synergistic activation of both pathways. Currently, therapeutic 
candidates in clinical trials target either the IGF or the integrin system individually, 
with none currently targeting both systems simultaneously (Crudden, et al., 2015; Ley, 
Rivera-Nieves, Sandborn, & Shattil, 2016). Given that both pathways are 
synergistically linked, a single molecule able to inhibit both IGF and integrin systems 
may offer a novel MBC therapy and potential improvements in prognosis.  
 
One method of dual pathway inhibition is through the use of a bispecific 
antibody (BsAb). Unlike naturally occurring antibodies, BsAb molecules are 
synthetically generated and designed to bind two pre-determined targets (Kontermann, 
2012). In the preceding chapters of this dissertation, the proposed BsAb described 
would comprise of α-IGF-1R and α-αv integrin single-chain variable fragment (ScFv) 
domains joined by a peptide linker. To obtain the coding sequences (CDS) encoding 
the ScFv molecules making up the two arms of the BsAb, they were to be generated 
individually through the phage display selection process with immobilised IGF-1R or 
αv integrin. Once the selection process was complete, as determined by the successful 
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characterisation of candidates in biophysical and cell-based functional assays, clones 
can then be sequenced and a BsAb generated. In respect to the IGF-1R ScFv isolated 
as part of this process, it has been demonstrated to bind with high affinity to IGF-1R, 
which translates to the functional inhibition of both the migration and metabolic 
activity of tumour cells. However, unlike the promising result shown by the α-IGF-1R 
ScFv candidate, the αv integrin process yielded clones that did not bind to αv integrin 
and did not show functionality in cell-based assays. Given the lack of functional ScFv 
targeting the αv integrin, it was therefore not possible to generate the original BsAb 
incorporating both α-IGF-1R and α-αv integrin domains to fulfil the original objective 
of this project.  
 
In spite of the difficulties experienced in this project, the results obtained with 
the IGF-1R targeting ScFv demonstrate the rationale is sound and the ultimate aim of 
generating a function blocking BsAb would be possible with further investigation. In 
order to fulfil the original aims of this project, a total of four new BsAb constructs 
were proposed for future study by incorporating a promising αv integrin antibody 
sequence derived from the literature. The proposed constructs were: A) α-IGF-1R:α-
αv, B) α-IGF-1R:α-BSA, C) α-αv:α-BSA and D) α-BSA:α-BSA. Of the four new 
BsAb constructs proposed, three were designed to function as control antibodies. 
Additional variations of BsAb could be constructed from a combination of the three 
binding ScFv domains, such as swapping the order from α-IGF-1R:α-αv to α-αv:α-
IGF-1R. In addition, the variable heavy and the light chains of each ScFv-based 
domain can also be rearranged internally. Despite the possibility in additional 
configurations, the proposed BsAb constructs should be characterised prior to further 
optimisation experiments. In order to obtain the αv integrin antibody sequence, a 
literature search was performed. Abituzumab was chosen as the αv integrin antibody, 
based on availability of its sequence information via patent information (US patent 
US8562986), in addition to having human pharmacokinetic and toxicology data as a 
result of phase I clinical trials (Uhl, et al., 2014; Wirth, et al., 2014). Having clinical 
data available for the αv integrin arm of newly generated BsAb would likely strengthen 
its support for further clinical trial progression. It should be noted that since the α-αv 
sequence was derived from a commercial source, the commercial value of the BsAb 
may be limited. Potentially, given the format conversion of Abituzumab into a BsAb 
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arm along with partnering to α-IGF-1R domains, such steps may be considered 
sufficiently inventive and classified as a novel product. With the procurement of 
sequence information for the α-αv arm of the BsAb, 4 new codon optimised for E. coli 
expression constructs were proposed (Figure 8-1).  
 
Currently, there is no consensus on the correct usage of a BsAb negative control 
in functional and clinical experiments (Choi et al., 2013). It has been commonly 
accepted that in experiments conducted using an intact full-length antibody, that an 
isotype match control is included as part of the study (Hulspas, O'Gorman, Wood, 
Gratama, & Sutherland, 2009). The rationale of including a negative control is to 
assess if there are any non-specific reactions due to non-CDR elements, or problems 
generated during the antibody production process. Commonly, this is due to the Fc 
receptor-mediated interactions (Datta-Mannan et al., 2015). However, in studies 
involving the use of antibody fragments, such as ScFv or BsAb, due to their synthetic 
nature, the generation of an isotype matched control is problematic and their usage is 
not consistent in the literature. In one report, an antibody-based negative control was 
not included at all as part of their study with the excipient (commonly PBS) of the 
ScFv used instead as a negative control (Taki et al., 2015). In an attempt to generate a 
more biologically relevant negative control for the BsAb, three of the four proposed 
BsAb constructs contain α-BSA ScFv domains. The α-BSA ScFv have been 
incorporated as negative control domains, having shown in a previous study that phage 
displaying anti-BSA ScFv were biologically inert in a mouse model (Dong et al., 
2016). The proposed negative BsAb controls would validate the tandem BsAb format, 
and also allow for the robust interrogation of the constructs biological activities.   
 
Protein heterogeneity is a concern for the characterisation and validation of 
human protein therapeutic candidates (Dorai & Ganguly, 2014). When the purified 
ScFv samples generated within this study were interrogated with SEC 
chromatography, a mixed population consisting of monomer and dimer species was 
revealed (Figure 5-2, Figure 5-4). Indeed, the detection and monitoring of protein 
aggregation is a major quality control step for any therapeutic protein production 
(Roberts, 2014). Previous studies addressed this mixed population by performing a 
SEC fractionation step to isolate the monomeric form of the ScFv (Persic et al., 1999; 
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Rouet, et al., 2012). Initial fractionation testing within the current study showed that 
the final eluate was low in concentration, due in part to the low concentration of the 
starting unfractionated sample. It is believed the detailed improvements outlined in 
this chapter would significantly increase the expected expression yield, thus achieving 
a higher concentration of starting material prior to fractionation. In addition to the SEC 
fractionation, to further monitor for protein heterogeneity, N-terminal protein 
sequencing of the purified BsAb molecule was also added to the newly proposed 
characterisation workflow. This is to ensure that the engineered PelB signal peptide 
has been correctly cleaved from the mature BsAb molecule, as differential cleavage of 
signal peptides has been previously observed in E. coli expression systems 
(Pechsrichuang et al., 2016).  
 
Another area of concern for any potential receptor targeting therapeutic is cross-
reactivity, caused by inhibition of an off-target pathway. In particular, due to the high 
degree of structural homology between the IGF-1R and IR (Ullrich, et al., 1986), 
antibodies designed to bind the IGF-1R potentially can also bind non-specifically to 
the IR. This non-specific inhibition of the IR pathway can cause adverse effects such 
as hyperglycaemia (Atzori et al., 2011; Haluska, et al., 2014). In studies involving the 
generation of an IGF-1R inhibitor, assays generally include measures to assess the 
potential cross-reactivity with the IR. Various methods can be employed to monitor 
this interaction, such as using a solid phase receptor binding assay (Burtrum, et al., 
2003) and Western blotting to assess IR activation (Girnita, et al., 2004). The pre-
existing BIAcore assays as described previously in this thesis can be modified to assess 
for IR cross-reactivity. In the new workflow described in this chapter, IR cross-
reactivity will be quantitatively assessed by immobilising IR alone on a BIAcore 
sensor, and BsAb will be subsequently injected onto the surface. This affinity of 
interaction will be compared to the affinity obtained from the BsAb injected over the 
surface with immobilised IGF-1R. The subsequent results will definitively show if 
cross-reactivity exists. Should cross-reactivity be demonstrated, additional rounds of 
development will be needed, such as repeating the phage display process, or 
alternatively, incorporating literature derived α-IGF-1R antibody sequences.  
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The ultimate goal of this project was to facilitate the development of an anti-
cancer therapeutic for use in humans. To achieve this aim, the BsAb candidates 
generated from this project have to be approved by regulatory bodies within each host 
country; such as the Food and Drug Administration (FDA) in the USA, European 
Medicines Agency (EMA) in the European Union and the Therapeutic Goods 
Administration (TGA) in Australia. To initiate this approval process in the USA, an 
Investigational New Drug (IND) application is needed to be submitted to the FDA, 
signalling that a pharmaceutical agent will be used in an experimental way (Holbein, 
2009). A similar process exists in Australia, requiring a submission via the Clinical 
Trial Notification (CTN) Scheme or the Clinical Trial Exemption (CTX) Scheme. The 
IND contains information in three broad areas, which are 1) Data demonstrating that 
the product is reasonably safe for testing in humans, which is most likely to be 
supported by animal pharmacokinetics data, 2) Information concerning the 
manufacturing process, and 3) Clinical Protocols and Investigator Information. To 
assess if sufficient data has been generated with the additional steps proposed within 
this chapter, the pathway to a clinical trial of a parental antibody to the BsAb 
abituzumab should be replicated as a guide to the approval process needed for the 
BsAb. In the key pre-clinical study published by Mitjans, et al. (1995), the antibody 
clone 17E6 (abituzumab, EMD 525797) was generated by mouse immunisation with 
αvβ3. The isolated antibody was characterised to determine αv integrin binding using 
in vitro methods such as enzyme-linked immunosorbent assay (ELISA), fluorescence 
activated cell sorting (FACS) and immunoprecipitation. In a similar manner, the 
BIAcore assays proposed in this chapter allow not only for the confirmation of binding 
between the two BsAb arms to either IGF-1R or αv integrin, but can also determine if 
the conversion from abituzumab IgG to ScFv/BsAb containing the abituzumab CDR 
has affected binding kinetics. Mitjans, et al. (1995) subsequently performed cell-based 
functional assays to determine tumour response to antibody treatment. One such 
experiment, the attachment assay, will be performed as proposed using a similar 
principle. Furthermore, in vivo mouse experiments will also be performed in a similar 
manner to preclinical studies for abituzumab. The safety profile of the BsAb can be 
extrapolated based on the parental abituzumab. A maximum dose of 1500 mg of 
abituzumab has been tested in clinical trial phase I, without inducing significant 
adverse reactions (Wirth, et al., 2014). Based on this information, it is reasonable that 
the same molar dose of the BsAb most similar to abituzumab (α-αv:α-BSA) can be 
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calculated. A 1500 mg dose of abituzumab (~150 kDa) is equivalent to 10 µmol. The 
equivalent molar dose of a BsAb (56 kDa) would be 560 mg, and this should be the 
initial upper limit for any clinical trials. Taken together, the assays proposed follow a 
similar trajectory of a drug currently under clinical trial phase II review. Therefore, it 
is highly likely that the modified assays in this chapter would increase the likelihood 
of success and facilitate further clinical progression.  
 
Should the BsAb demonstrate success in blocking IGF and integrin dependent 
tumour progression, alternative pathways that are synergistic should also be 
investigated. One potential combination pair is between IGF-1R and Epidermal growth 
factor receptor (EGFR). They are both examples of tyrosine kinase receptors, which 
play important roles in tumour development through their influence on cell 
proliferation and migration. It has also been demonstrated that cross-talk exists 
between both IGF and EGF signalling pathways, making the targeting with a BsAb 
inhibiting both pathways commercially and clinically attractive (Jin & Esteva, 2008). 
A recent study investigating an IgG-based BsAb targeting IGF-1R and EGFR 
demonstrated potent tumour inhibition activities in both in vitro and mouse models 
(Schanzer et al., 2016). Given promising results revealed by the IgG based BsAb, 
further investigations into ScFv based BsAb targeting both IGF-1R and EGFR should 
also be warranted.  
 
In conclusion, four novel BsAb were proposed using an in silico approach by 
incorporating the functionally active α-IGF-1R ScFv domains obtained from within 
this study and a promising α-αv integrin antibody currently under clinical trial. In 
addition to the new constructs, improved expression methodology was proposed with 
the aim of improving yield. Furthermore, the results from the additional quality control 
steps and improved functional assays would likely meet the requirements to warrant 
future pre-clinical and clinical studies. The newly proposed BsAb constructs and the 
additional methodologies contained within this chapter could be completed in 1 year, 
due to the optimisations of prior processes contained in this study. Such a development 
will enable new methods to treat and potentially mitigate breast cancer tumour growth 
and metastasis, thus improving the lives of breast cancer sufferers.  
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Appendix 1: Current IGF-1R targeting antibodies in development. Source: The 
therapeutic antibody database (http://tabs.craic.com/) 
 
Name Internal 
Name 
Antigen Company Trials 
▼ 
Patents Phase 
Cixutumumab IMC-A12, 
NSC742460 
IGF-1R ImClone 43 11 Phase 2 
Ganitumab AMG 479 IGF-1R Amgen, 
Millennium 
24 19 Phase 3 
Figitumumab CP-751871, 
CP-751, 871 
IGF-1R Amgen, Pfizer, 
Schering-
Plough 
11 34 Phase 3 
RG1507 R1507 IGF-1R Genmab, 
Roche 
10  Phase 2 
Dalotuzumab MK-0646, 
MK0646, 
h7C10 
IGF-1R Merck & Co 5 17 Phase 2 
Robatumumab SCH 
717454, 
19D12 
IGF-1R Merck & Co, 
Schering-
Plough 
4 19 Phase 2 
AVE1642 EM164 IGF-1R ImmunoGen 3 11 Phase 1 
BIIB022   == M14 IGF-1R Biogen 3 9 Phase 1 
Istiratumab MM-141 HER3, IGF-
1R 
Dyax, 
Merrimack 
2 8 Phase 2 
teprotumumab   
>> 
RO4858696-
000, 
RO4858696 
IGF-1R Roche  19 Preclinical 
Immunomedics 
patent anti-IGF-
1R 
hR1 IGF-1R Immunomedics  7 Preclinical 
GSK patent anti-
IGF-1R 
 IGF-1R GSK  4 Preclinical 
Biogen EI-04   == EI-04 EGFR, IGF-
1R 
Biogen   Preclinical 
Roche patent 
anti-IGF-
1R/ANGPT2 
 Angiopoietin 
2, IGF-1R 
Roche  5 Preclinical 
Xencor patent 
anti-IGF-1R 
 IGF-1R Xencor  2 Preclinical 
Genentech 
patent anti-IGF-
1R 
 IGF-1R Genentech  1 Preclinical 
U.Adelaide 
patent anti-IGF-
1R 
 IGF-1R U.Adelaide  1 Preclinical 
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Pierre Fabre 
patent anti-IGF-
1R 
12B1 IGF-1R Merck & Co, 
Pierre Fabre 
 17 Preclinical 
Roche Glycart 
patent anti-
EGFR/IGF-1R 
 EGFR, IGF-
1R 
Glycart  5 Preclinical 
BMS patent anti-
EGFR/IGF-1R 
 EGFR, IGF-
1R 
BMS  5 Preclinical 
U.Hong Kong 
patent anti-IGF-
1R   >> 
H10 IGF-1R U.Hong Kong  3 Preclinical 
NIH patent anti-
IGF-1R 
 IGF-1R NIH  4 Preclinical 
City of Hope 
patent anti-IGF-
1R 
 IGF-1R City of Hope  2 Preclinical 
Pharmacia 
patent anti-IGF-
1R 
 IGF-1R Pfizer  1 Preclinical 
Roche patent 
anti-IGF-1R   << 
IR18 IGF-1R Roche  1 Preclinical 
Sorrento patent 
anti-IGF-1R 
 IGF-1R Sorrento  2 Preclinical 
R-Pharm patent 
anti-IGF-1R 
 IGF-1R R-Pharm  1 Preclinical 
U.Hong Kong 
patent anti-IGF-
1R / Her2   << 
 HER2/neu, 
IGF-1R 
U.Hong Kong  1 Preclinical 
NRC Canada 
patent anti-IGF-
1R 
 IGF-1R NRC Canada  3 Preclinical 
 
 
  
  
Appendices 247 
Appendix 2: Current αv integrins targeting antibodies in development. Source: The 
therapeutic antibody database (http://tabs.craic.com/) 
 
Name Interna
l Name 
Antige
n 
Compa
ny 
Paten
ts 
Pape
rs 
Phase 
etaracizumab Abegri
n, 
MEDI-
522, 
hLM60
9, 
Vitaxin
, 
LM609 
Integri
n αVβ3 
AME, 
Medim
mune 
8 10 Phase 1/2 
abituzumab EMD52
5797, 
EMD 
525797
, DI-
17E6, 
DI17E6 
Integri
n αV 
Merck 
Serono 
8 4 Phase 2/3 
intetumumab   >> CNTO 
95 
Integri
n αV 
Centoc
or 
Ortho 
23 9 Phase 1/2 
STX-100 BG000
11 
Integri
n αvβ6 
Biogen
, Strom
edix 
11 1 Phase 2 
IMGN388   <<  Integri
n αV 
Immun
oGen 
1  Phase 1 
VPI-2690B  Integri
n αVβ3 
Janssen 
Biotech
, Vascu
lar 
1  Phase 2 
U.California patent anti-
Integrin αvβ5 
Integri
n αvβ5 
Biogen
, U.Cal
ifornia 
3  Preclinical 
264RAD  Integri
n αvβ6 
AstraZ
eneca, 
Medim
mune 
7 2 Preclinical 
Macrogenics 
patent anti-
Integrin Alpha V 
B 6 
mBLA
3 
Integri
n αvβ6 
Macro
Genics 
1  Preclinical 
U.California 
patent anti-
Integrin αvβ8 
37E1B
5 
Integri
n αvβ8 
U.Calif
ornia 
7  Preclinical 
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Seattle Genetics patent anti-
Integrin alpha V beta 6 
Integri
n αvβ6 
Seattle 
Genetic
s 
2  Preclinical 
U.North Carolina patent 
anti-Integrin alphaV beta3 
Integri
n αVβ3 
UNC 6  Preclinical 
MFEVP1  Integri
n αvβ6 
Cancer 
Resear
ch 
Techno
logy 
4  Preclinical 
U.California patent anti-
Integrin αvβ6 
Integri
n αvβ6 
U.Calif
ornia 
1  Preclinical 
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Appendix 3: Sequencing trace of αIGF-1R ScFv (WT) 
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Appendix 4: Blast search of IGF-1R ScFv 
 
 
anti-TNF alpha single chain Fv antibody [synthetic construct] 
Sequence ID: gb|AEX15593.1|Length: 245Number of Matches: 1 
Related Information 
Range 1: 1 to 245GenPeptGraphicsNext MatchPrevious Match 
Alignment statistics fo r match #1 
Score Expect Method Identities Positives Gaps 
426 bits(1094) 9e-150 Compositional matrix adjust. 229/245(93%) 232/245(94%) 0/245(0%) 
Query  2    MAEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSRISQEGDYT  61 
            MAEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVS IS  G  T 
Sbjct  1    MAEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSSISSTGAST  60 
 
Query  62   LYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGRGVFDYWGQGTLVTVSSGG  
121 
             YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKG   FDYWGQGTLVTVSSGG 
Sbjct  61   TYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGGAAFDYWGQGTLVTVSSGG  
120 
 
Query  122  GGSGGGGSGGGGSTDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKL  
181 
            GGSGGGGSGGGGSTDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKL 
Sbjct  121  GGSGGGGSGGGGSTDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKL  
180 
 
Query  182  LIYRASHLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSRKSPPTFGQGTKVEI  
241 
            LIY AS+LQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQ+  +P TFGQGTKVEI 
Sbjct  181  LIYSASYLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANNAPTTFGQGTKVEI  
240 
 
Query  242  KRAAA  246 
            KRAAA 
Sbjct  241  KRAAA  245 
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Appendix 5: Sequencing trace of α-αv A2 ScFv (WT) 
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Appendix 6: Sequencing trace of α-αv B1 ScFv (WT) 
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Appendix 7: Sequencing trace of α-αv F3 ScFv (WT) 
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Appendix 8: SDM reactions, gel extraction, and enzymatic treatments. 
 
Site-Directed Mutagenesis reaction.  
  Reaction Final con 
Q5 Hot Start High-Fidelity 2X Master Mix 12.5 μl 1X 
10 μM Forward Primer 1.25 μl 0.5 μM 
10 μM Reverse Primer 1.25 μl 0.5 μM 
Template DNA 1 μl 1-25 ng 
Nuclease-free water 9.0 μl   
 
Overview of Qiagen gel extraction kit 
Step Reagent name Buffer compositions Mechanism 
1 QG 5.5 M guanidine thiocyanate (GuSCN) 
20 mM Tris HCl pH 6.6 
Solubilisation of the 
DNA containing 
agarose 
2 Isopropanol Isopropanol  
3 DNA Binding  Binding of DNA to the 
silica column 
4 QG 5.5 M guanidine thiocyanate (GuSCN) 
20 mM Tris HCl pH 6.6 
Wash 
5 PE 10 mM Tris-HCl pH 7.5 
80% ethanol 
Removal of excess salts 
from column 
6 Elution Water Elution of pDNA from 
column 
 
Kinase, Ligase & Dpn1 (KLD) treatment. 
 
 
  10 μl RXN 
PCR Product 1 μl 
2X KLD Reaction Buffer 5 μl 
10X KLD Enzyme Mix 1 μl 
Nuclease-free water 3 μl 
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Appendix 9: Sequential optimisation conducted for the purification of ScFv using Ni-
NTA affinity chromatography.  
 
 Material Affinity 
system 
Conditions  Outcome 
Cultures 
expressing 
different 
ScFv 
clones  
Periplasmic 
extract 
Supernantant 
Ni-NTA Binding buffer: 
50 mM NaH2PO4 
300 mM NaCl 
pH 8.0 
 
Wash buffer: 
50 mM NaH2PO4 
300 mM NaCl 
20 mM imidazole 
pH 8.0 
Silver 
stained 
SDS-
PAGE, 
Western 
blotting 
The expressed ScFv 
was found in the flow-
through and the wash 
fractions, indicating 
poor binding of the 
ScFv to the resin.  
Cultures 
expressing 
different 
ScFv 
clones 
Periplasmic 
extract 
Supernantant 
Ni-NTA Binding buffer: 
50 mM NaH2PO4 
300 mM NaCl 
pH 8.0 
 
Wash buffer: 
50 mM NaH2PO4 
300 mM NaCl 
0 mM imidazole 
pH 8.0 
Silver 
stained 
SDS-
PAGE, 
Western 
blotting 
Elimination of 
imidazole in the wash 
step did not improve  
retention of ScFv 
ScFv clone Supernantant Ni-NTA Precipitation of ScFv 
using PEG6000 
followed by NI-NTA 
Western 
blotting 
The precipitation of 
ScFv was 
supernantant was 
sucessul. However, 
the resulting pellet 
was insoulable in Ni-
NTA buffer 
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Appendix 10: BIAcore response of αv antibody on immobilised αv with or with 
Mg/Mn 
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Appendix 11: Recombinant αv integrin datasheet 
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Appendix 12: Quality control on recombinant αv integrin. Sample of the recombinant 
αv integrin was centrifuged at 10,000 g for 10 mins. The supernatant and the insoluble 
fraction was separated and SDS-PAGE loading buffer was added to both. Each sample 
was further divided into two with one set heated at 72 °C for mins prior to separation 
on a SDS-PAGE. The same samples were also used in a Western blot and interrogated 
with an α-αv antibody. Recombinant αvβ3 was included as a positive control for the 
αv portion of the heterodimer.  
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Appendix 13: SDM removal of the amber stop codon. Each reaction sample post 
mutagenic PCR were separated on an agarose gel. The mutated (TAG to GAG) 
linearised vector of the correct size of ~5 kb (red arrow) was excised and the DNA 
contents isolated using a gel extraction kit.  
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Appendix 14 
 
Engineered anti-alpha V-integrin hybrid antibodies 
EMD 525797 
US Patent No 8,562,986 B2 
Date: 22.10.13 
 
Variable (underlined) and constant heavy chain sequences 
QVQLQQSGGELAKPGASVKVSCKASGYTFSSFWMHWVRQAPGQGLEWIGY
INPRSGYTEYNEIFRDKATMTTDTSTSTAYMELSSLRSEDTAVYYCASFLGRG
AMDYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPV
TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKP
SNTKVDKTVEPKSSDKTHTCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT
CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQAQSTFRVVSVLTVVH
QDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQ
VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
 
Variable (underlined) and constant light chain sequences 
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKAPKLLIYYTSK
IHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQGNTFPYTFGQGTKVEIK
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS
QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
GEC 
 
ScFv sequence generated from variable heavy and light chains with linker sequence 
QVQLQQSGGELAKPGASVKVSCKASGYTFSSFWMHWVRQAPGQGLEWIGY
INPRSGYTEYNEIFRDKATMTTDTSTSTAYMELSSLRSEDTAVYYCASFLGRG
AMDYWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTI
TCRASQDISNYLAWYQQKPGKAPKLLIYYTSKIHSGVPSRFSGSGSGTDYTFT
ISSLQPEDIATYYCQQGNTFPYTFGQGTKVEIK 
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Appendix 15 
 
α-IGF-1R+BSA BsAb 
 
Protein 
AMAEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEW
VSRISQEGDYTLYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK
GRGVFDYWGQGTLVTVSSGGGGSGGGGSGGGGSTDIQMTQSPSSLSASVGD
RVTITCRASQSISSYLNWYQQKPGKAPKLLIYRASHLQSGVPSRFSGSGSGTD
FTLTISSLQPEDFATYYCQQSRKSPPTFGQGTKVEIKRAAASTDGNTAMAEV
QLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSTIYY
AGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGYYVF
DYWGQGTLVTVSSGGGGSGGGGSGGGGSTDIQMTQSPSSLSASVGDRVTIT
CRASQSISSYLNWYQQKPGKAPKLLIYYASNLQSGVPSRFSGSGSGTDFTLTI
SSLQPEDFATYYCQQSDTSPTTFGQGTKVEIKRAAARDHMVLHEYVNAAGIT
HHHHHH 
 
DNA 
TAAGCAGCCATGGCCGAAGTTCAGCTGCTGGAAAGCGGTGGTGGTCTGG
TTCAGCCTGGTGGTAGCCTGCGTCTGAGCTGTGCAGCAAGCGGTTTTACC
TTTAGCAGCTATGCAATGAGCTGGGTTCGTCAGGCACCTGGTAAAGGTCT
GGAATGGGTTAGCCGTATTAGCCAAGAAGGTGATTACACCCTGTATGCA
GATAGCGTTAAAGGTCGTTTTACCATCAGCCGTGATAATAGCAAAAATAC
CCTGTACCTGCAGATGAATAGTCTGCGTGCAGAGGATACCGCAGTGTATT
ATTGTGCAAAAGGTCGTGGTGTGTTTGATTATTGGGGTCAGGGCACCCTG
GTTACCGTGAGCAGCGGTGGCGGTGGTAGTGGTGGTGGCGGTAGCGGAG
GTGGTGGTTCAACCGATATTCAGATGACCCAGAGTCCGAGCAGCCTGAG
CGCAAGCGTTGGTGATCGTGTTACCATTACCTGTCGTGCAAGCCAGAGCA
TTAGCAGTTATCTGAATTGGTATCAGCAGAAACCGGGTAAAGCACCGAA
ACTGCTGATTTATCGTGCCAGCCATCTGCAGAGCGGTGTTCCGAGCCGTT
TTAGCGGTAGTGGTAGCGGCACCGATTTTACCCTGACCATTAGCAGCCTG
CAGCCGGAAGATTTTGCAACCTATTATTGTCAGCAGAGCCGTAAAAGCCC
TCCGACCTTTGGCCAGGGCACCAAAGTTGAAATTAAACGTGCAGCAGCA
AGCACCGATGGTAATACCGCAATGGCAGAGGTGCAACTGCTGGAATCAG
GCGGTGGCCTGGTACAGCCAGGCGGTTCACTGCGTCTGTCATGCGCAGCA
TCAGGCTTTACCTTTTCAAGCTATGCCATGTCATGGGTGCGCCAGGCTCC
AGGCAAAGGCTTAGAATGGGTGAGCACCATCTATTATGCAGGTAGCAAT
ACCTATTATGCCGATTCAGTGAAAGGTCGCTTCACCATTTCACGCGATAA
TTCAAAAAACACGCTGTATTTACAGATGAACTCACTGCGTGCCGAAGATA
CAGCCGTTTATTATTGCGCCAAAGGCTATTATGTCTTTGACTACTGGGGA
CAGGGTACACTGGTGACAGTTAGCTCAGGTGGCGGAGGTTCAGGCGGAG
GCGGATCAGGTGGTGGTGGAAGCACAGATATCCAGATGACACAGTCACC
GAGCAGTCTGTCAGCATCAGTGGGTGATCGCGTGACAATTACATGCCGTG
CCAGTCAGAGTATTTCTAGCTACTTAAACTGGTATCAACAAAAGCCTGGC
AAAGCCCCTAAACTGTTAATTTACTATGCAAGCAACCTGCAGTCTGGTGT
TCCGTCACGTTTTTCAGGTAGCGGTTCAGGTACAGATTTCACACTGACAA
TTAGTTCACTGCAGCCAGAGGATTTCGCCACATACTATTGCCAGCAGTCA
GATACCAGTCCGACCACATTTGGTCAGGGAACAAAGGTGGAAATCAAGC
GTGCAGCCGCACGTGACCACATGGTCCTTCATGAGTACGTAAATGCTGCT
GGGATTacaCATCATCACCATCATCATTAAGCGGCCGCTAAGCA 
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Appendix 16 
 
α-αv+BSA BsAb 
 
Protein 
MQVQLQQSGGELAKPGASVKVSCKASGYTFSSFWMHWVRQAPGQGLEWI
GYINPRSGYTEYNEIFRDKATMTTDTSTSTAYMELSSLRSEDTAVYYCASFL
GRGAMDYWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGD
RVTITCRASQDISNYLAWYQQKPGKAPKLLIYYTSKIHSGVPSRFSGSGSGTD
YTFTISSLQPEDIATYYCQQGNTFPYTFGQGTKVEIKSTDGNTAMAEVQLLES
GGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSTIYYAGSNT
YYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGYYVFDYWGQ
GTLVTVSSGGGGSGGGGSGGGGSTDIQMTQSPSSLSASVGDRVTITCRASQSI
SSYLNWYQQKPGKAPKLLIYYASNLQSGVPSRFSGSGSGTDFTLTISSLQPED
FATYYCQQSDTSPTTFGQGTKVEIKRAAARDHMVLHEYVNAAGITHHHHHH 
 
DNA 
TAAGCACCATGGATGCAGGTTCAGCTGCAGCAGAGCGGTGGTGAACTGG
CAAAACCGGGTGCAAGCGTTAAAGTTAGCTGTAAAGCAAGCGGTTATAC
CTTTAGCAGCTTTTGGATGCATTGGGTTCGTCAGGCACCTGGTCAAGGTC
TGGAATGGATTGGTTATATCAATCCGCGTAGTGGCTATACCGAATATAAC
GAAATTTTTCGCGATAAGGCAACCATGACCACCGATACCAGCACCAGCA
CCGCATATATGGAACTGAGCAGCCTGCGTAGCGAAGATACCGCAGTGTA
TTATTGTGCAAGCTTTTTAGGTCGTGGCGCAATGGATTATTGGGGTCAGG
GCACCACCGTTACCGTTAGCTCAGGTGGTGGTGGTAGTGGTGGCGGTGGT
TCAGGCGGTGGCGGTAGCGATATTCAGATGACCCAGAGTCCGAGCAGTC
TGAGCGCAAGCGTTGGTGATCGTGTTACCATTACCTGTCGTGCAAGCCAG
GATATTAGCAATTATCTGGCATGGTATCAGCAGAAACCGGGTAAAGCAC
CGAAACTGCTGATCTATTATACCAGCAAAATTCATAGCGGTGTTCCGAGC
CGTTTTAGCGGTAGCGGTAGTGGCACCGATTATACATTTACCATTAGCAG
TCTGCAGCCGGAAGATATTGCAACCTATTATTGTCAGCAGGGTAACACCT
TTCCGTATACCTTTGGTCAGGGTACAAAAGTGGAAATCAAAAGTACCGAT
GGTAATACCGCAATGGCAGAAGTGCAGCTGCTGGAATCAGGTGGCGGTC
TGGTGCAGCCTGGTGGTAGCCTGCGTCTGAGCTGTGCAGCCAGTGGTTTT
ACCTTTTCAAGCTATGCAATGAGCTGGGTGCGCCAGGCACCAGGCAAAG
GTTTAGAATGGGTTAGCACCATCTATTATGCAGGCAGCAATACCTATTAT
GCCGATAGCGTGAAAGGTCGCTTTACCATTTCACGTGATAATAGCAAAAA
CACCCTGTACCTGCAGATGAATAGTCTGCGTGCAGAGGATACAGCCGTCT
ATTATTGCGCAAAAGGCTATTATGTGTTCGATTACTGGGGACAGGGTACA
CTGGTTACCGTGAGCAGCGGAGGTGGTGGATCTGGTGGCGGAGGTAGCG
GAGGCGGAGGCAGCACCGATATCCAAATGACACAGAGCCCGTCAAGCCT
GAGCGCCTCAGTGGGTGATCGCGTGACAATTACATGCCGTGCCAGCCAG
AGCATTAGCAGCTATCTGAATTGGTATCAACAAAAACCTGGCAAGGCTCC
CAAACTGTTAATTTACTATGCAAGCAATCTGCAGAGTGGTGTTCCGTCAC
GTTTTTCAGGTAGCGGTTCAGGTACAGATTTTACCCTGACAATTAGCTCA
CTGCAGCCTGAGGATTTCGCCACATATTATTGCCAACAGAGCGATACCAG
TCCGACCACATTTGGCCAGGGCACGAAAGTTGAGATTAAACGTGCAGCA
GCACGTGACCACATGGTCCTTCATGAGTACGTAAATGCTGCTGGGATTaca
CATCATCACCATCATCATTAAGCGGCCGCTAAGCA 
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α-IGF-1R+αv BsAb 
 
Protein 
AMAEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEW
VSRISQEGDYTLYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK
GRGVFDYWGQGTLVTVSSGGGGSGGGGSGGGGSTDIQMTQSPSSLSASVGD
RVTITCRASQSISSYLNWYQQKPGKAPKLLIYRASHLQSGVPSRFSGSGSGTD
FTLTISSLQPEDFATYYCQQSRKSPPTFGQGTKVEIKRAAASTDGNTMQVQL
QQSGGELAKPGASVKVSCKASGYTFSSFWMHWVRQAPGQGLEWIGYINPRS
GYTEYNEIFRDKATMTTDTSTSTAYMELSSLRSEDTAVYYCASFLGRGAMD
YWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCR
ASQDISNYLAWYQQKPGKAPKLLIYYTSKIHSGVPSRFSGSGSGTDYTFTISSL
QPEDIATYYCQQGNTFPYTFGQGTKVEIKRDHMVLHEYVNAAGITHHHHHH 
 
DNA 
TAAGCAGCCATGGCCGAAGTTCAGCTGCTGGAAAGCGGTGGTGGTCTGG
TTCAGCCTGGTGGTAGCCTGCGTCTGAGCTGTGCAGCAAGCGGTTTTACC
TTTAGCAGCTATGCAATGAGCTGGGTTCGTCAGGCACCTGGTAAAGGTCT
GGAATGGGTTAGCCGTATTAGCCAAGAAGGTGATTACACCCTGTATGCA
GATAGCGTTAAAGGTCGTTTTACCATCAGCCGTGATAATAGCAAAAATAC
CCTGTACCTGCAGATGAATAGTCTGCGTGCAGAGGATACCGCAGTGTATT
ATTGTGCAAAAGGTCGTGGTGTGTTTGATTATTGGGGTCAGGGCACCCTG
GTTACCGTGAGCAGCGGTGGCGGTGGTAGTGGTGGTGGCGGTAGCGGAG
GTGGTGGTTCAACCGATATTCAGATGACCCAGAGTCCGAGCAGCCTGAG
CGCAAGCGTTGGTGATCGTGTTACCATTACCTGTCGTGCAAGCCAGAGCA
TTAGCAGTTATCTGAATTGGTATCAGCAGAAACCGGGTAAAGCACCGAA
ACTGCTGATTTATCGTGCCAGCCATCTGCAGAGCGGTGTTCCGAGCCGTT
TTAGCGGTAGTGGTAGCGGCACCGATTTTACCCTGACCATTAGCAGCCTG
CAGCCGGAAGATTTTGCAACCTATTATTGTCAGCAGAGCCGTAAAAGCCC
TCCGACCTTTGGCCAGGGCACCAAAGTTGAAATTAAACGTGCAGCAGCA
AGCACCGATGGTAATACCATGCAGGTCCAGCTGCAGCAGTCAGGTGGTG
AACTGGCAAAACCGGGTGCAAGCGTGAAAGTTAGCTGTAAAGCCAGTGG
TTATACCTTTTCAAGCTTTTGGATGCATTGGGTGCGCCAGGCACCAGGTC
AGGGTTTAGAATGGATTGGTTATATCAATCCGCGTAGCGGTTATACCGAA
TATAACGAAATTTTTCGCGACAAAGCAACCATGACCACCGATACCAGCA
CCAGCACCGCATATATGGAACTGAGCAGTCTGCGTAGTGAAGATACAGC
AGTTTATTACTGCGCAAGCTTTTTAGGTCGCGGTGCAATGGATTACTGGG
GACAGGGTACAACCGTTACCGTTAGCTCAGGTGGCGGAGGTTCAGGCGG
AGGCGGATCAGGTGGTGGTGGGAGCGATATCCAAATGACACAGAGCCCG
TCAAGCCTGTCAGCATCAGTGGGTGATCGCGTGACAATTACATGCCGTGC
CAGTCAGGATATTAGTAATTATCTGGCATGGTATCAACAAAAGCCTGGCA
AAGCCCCTAAACTTCTGATCTATTATACCAGCAAAATCCATAGCGGTGTG
CCGTCACGTTTTTCAGGTAGCGGTTCAGGTACAGATTATACGTTTACCATT
AGTTCACTGCAGCCAGAGGATATCGCCACATATTATTGCCAACAGGGTAA
TACCTTTCCGTATACATTTGGTCAGGGAACGAAGGTGGAAATCAAACGTG
ACCACATGGTCCTTCATGAGTACGTAAATGCTGCTGGGATTacaCATCATC
ACCACCATCACTAAGCGGCCGCTAAGCA 
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α-BSA+BSA BsAb 
 
Protein 
AMAEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEW
VSTIYYAGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK
GYYVFDYWGQGTLVTVSSGGGGSGGGGSGGGGSTDIQMTQSPSSLSASVGD
RVTITCRASQSISSYLNWYQQKPGKAPKLLIYYASNLQSGVPSRFSGSGSGTD
FTLTISSLQPEDFATYYCQQSDTSPTTFGQGTKVEIKRAAASTDGNTAMAEV
QLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSTIYY
AGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGYYVF
DYWGQGTLVTVSSGGGGSGGGGSGGGGSTDIQMTQSPSSLSASVGDRVTIT
CRASQSISSYLNWYQQKPGKAPKLLIYYASNLQSGVPSRFSGSGSGTDFTLTI
SSLQPEDFATYYCQQSDTSPTTFGQGTKVEIKRAAARDHMVLHEYVNAAGIT
HHHHHH 
 
DNA 
TAAGCAGCCATGGCCGAAGTTCAGCTGCTGGAAAGCGGTGGTGGTCTGG
TTCAGCCTGGTGGTAGCCTGCGTCTGAGCTGTGCAGCAAGCGGTTTTACC
TTTAGCAGCTATGCAATGAGCTGGGTTCGTCAGGCACCTGGTAAAGGTCT
GGAATGGGTTAGCACCATCTATTATGCAGGTAGCAATACCTATTATGCCG
ATAGCGTTAAAGGTCGCTTTACCATTAGCCGTGATAATAGCAAAAATACC
CTGTACCTGCAGATGAATAGTCTGCGTGCAGAGGATACCGCAGTGTATTA
TTGTGCAAAAGGCTATTATGTGTTCGACTATTGGGGTCAGGGCACCCTGG
TTACCGTGAGCAGCGGTGGCGGTGGTAGTGGTGGTGGCGGTAGCGGAGG
TGGTGGTTCAACCGATATTCAGATGACCCAGAGTCCGAGCAGCCTGAGC
GCAAGCGTTGGTGATCGTGTTACCATTACCTGTCGTGCAAGCCAGAGCAT
TAGCAGTTATCTGAATTGGTATCAGCAGAAACCGGGTAAAGCACCGAAA
CTGCTGATTTATTACGCAAGCAATCTGCAGAGCGGTGTTCCGAGCCGTTT
TAGCGGTAGTGGTAGCGGCACCGATTTTACCCTGACCATTAGCAGCCTGC
AGCCGGAAGATTTTGCAACCTATTATTGTCAGCAGAGCGATACCAGTCCG
ACCACCTTTGGCCAGGGCACCAAAGTTGAAATTAAACGTGCAGCAGCAA
GCACCGATGGTAATACCGCAATGGCAGAGGTGCAACTGCTGGAATCAGG
CGGTGGCCTGGTACAGCCAGGCGGTTCACTGCGTCTGTCATGCGCAGCAT
CAGGCTTTACCTTTTCAAGCTATGCCATGTCATGGGTGCGCCAGGCTCCA
GGCAAAGGCTTAGAATGGGTGAGTACAATTTATTATGCCGGTTCCAACAC
GTATTATGCAGATTCAGTGAAAGGCCGTTTTACCATCTCACGCGATAATT
CAAAAAACACGCTGTATTTACAGATGAACTCACTGCGTGCCGAAGATAC
AGCCGTTTATTATTGCGCCAAAGGTTACTACGTCTTTGATTATTGGGGAC
AAGGTACACTGGTGACCGTTAGCTCAGGTGGCGGAGGTTCAGGCGGAGG
CGGATCAGGTGGTGGTGGAAGCACAGATATCCAGATGACACAGTCACCG
AGCAGTCTGTCAGCATCAGTGGGTGATCGCGTGACAATTACATGCCGTGC
CAGCCAGTCAATTAGCTCATACTTAAACTGGTATCAACAAAAGCCTGGCA
AAGCCCCTAAACTGTTAATTTACTATGCATCAAACCTGCAGTCTGGTGTT
CCGTCACGTTTTTCAGGTAGCGGTTCAGGTACAGATTTCACACTGACAAT
TAGTTCACTGCAGCCAGAGGATTTCGCCACATACTATTGCCAGCAGTCAG
ATACCTCACCGACAACATTTGGTCAAGGTACAAAAGTGGAAATCAAGAG
AGCAGCAGCACGTGACCACATGGTCCTTCATGAGTACGTAAATGCTGCTG
GGATTacaCATCATCACCATCACCACTAAGCGGCCGCTAAGCA  
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